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ABSTRACT 
 
PPARs: Potential Mechanisms Regulating Blood Lipid and Lipoprotein Concentrations 
at Rest and Following Exercise in the Obese.  (August 2010) 
Nicholas Perry Greene, B.S., University of South Carolina;  
M.S., University of South Carolina 
Chair of Advisory Committee: Dr. Stephen F. Crouse 
 
Obesity is associated with greater rates of cardiovascular disease, dyslipidemia and 
dysfunctional lipid metabolism.  Exercise may provide an effective therapeutic tool to 
ameliorate dyslipidemia.  However, how exercise attenuates dyslipidemia with obesity is 
not fully understood.  Additionally, whether acute exercise or exercise training is the 
primary driver of such changes in this population is unknown.  Furthermore, 
mechanisms mediating these exercise responses are not elucidated.  The peroxisome 
proliferator-activated receptors (PPARs) provide a likely mechanism through enhanced 
expression of oxidative metabolism and cholesterol transport proteins augmenting fatty 
acid oxidation and cholesterol transport. 
Study one describes blood lipid and lipoprotein responses to acute aerobic exercise 
and exercise training in obese men and women.  The primary measured effects include: 
increased HDL-C in men following 12 wks exercise training, and a shift from HDL3-C 
to HDL2-C, with concomitantly reduced HDL-C mean density and LDL3-C in women.  
Acute exercise of 400 kcal duration performed before and after training, yielded a 
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decreased TC: HDL-C ratio in men, which was unaffected by training.  Thus, the 
primary exercise-based treatment for dyslipidemia with obesity appears to be exercise 
training. 
In study two, PPARδ and PGC-1α content were significantly enhanced after acute 
exercise, whereas PPARα and AMPKα content were augmented only after training.  
These effects were seen with concomitantly increased content of target proteins involved 
in oxidative and lipoprotein metabolism including lipoprotein lipase, CPT-I, COX-IV, 
and FAT/CD36.  PPARδ expression was correlated with total and LDL-cholesterol 
concentrations.  AMPKα expression was correlated with the concentration of HDL-C 
and its subfractions, suggesting regulation of blood cholesterols by PPARδ and AMPKα. 
Study three demonstrates comparative responses to high volume resistance exercise 
(RE) in lean and obese Zucker rats.  RE enhanced PPARδ expression regardless of 
phenotype, but PGC-1α in obese only.  Mitochondrial biogenesis was enhanced in lean 
animals only, indicating PPARδ and PGC-1α content is disconnected from 
mitochondrial biogenesis with obesity. 
These studies enhance our understanding of exercise as a therapeutic tool in treating 
dyslipidemia and dysregulated lipid metabolism often associated with obesity.  They 
further demonstrate the necessity for exercise training to attenuate dyslipidemia, while 
illustrating PPAR-mediated augmentations in oxidative and lipoprotein metabolism 
following exercise with obesity. 
  
v 
 
DEDICATION 
 
To my lovely wife and our beautiful daughter, Liz and Amelia Greene.   
Liz, you have been everything to me since the moment we met.  I know it sounds 
cliché but I fall in love with you more by the day.  Thank you for supporting me over 
these last few years.  Without you I don‘t know if I could have done it!  You have been 
the one dealing with me when I was most frustrated and have been and always will be 
the one by my side through thick and thin.   
Amelia, you are much too young to understand now, but you and your mother have 
been the two best things to ever happen to me.   
  
vi 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my dissertation committee chair, Dr. Stephen F. Crouse.  Your 
guidance, patience, and willingness to let me explore new questions and methodologies 
for your laboratory have been invaluable.  I would also like to thank my dissertation 
committee: Dr. Jim Fluckey, Dr. Steve Riechman, and Dr. Steve Smith.  Dr. Fluckey, 
thank you for opening the doors of your laboratory to me; this has allowed me great 
opportunity to expand on my research experience and guidance at A&M.  I would like to 
thank Drs. Crouse, Riechman, and Fluckey for standing by me through both the good 
and bad times; you will not know what this has meant to me. 
I would also like to thank the members of both the Applied Exercise Science and 
Muscle Biology Laboratories.  Particularly, from the AESL, I would like to thank Aaron 
Carbuhn, Brad Lambert, Dr. Steve Martin, and Dr. John Green without whom the human 
studies would not have been possible, especially Aaron.  I would also like to thank Brad 
for many beers and burgers shared at Koppe Bridge coping with the stresses of being 
Ph.D. students.  From the MBL I would like to give special thanks to Mats Nilsson, 
Mike Wiggs, Justin Dobson, Kevin Shimkus and Amanda Davis.  Mats, thank you for 
allowing me the opportunity to work with you on the rat studies.  To all of the MBL and 
the Bone Biology Laboratory, the many conversations of science, sports, movies, etc 
shared over coffee were, at the least, a great stress relief. 
I would like to take this opportunity to thank my friends and mentors from the 
University of South Carolina and Columbia, SC.  Some of those people include, but 
vii 
 
definitely are not limited to: Dr. and Mrs. J. Larry Durstine, Dr. Teresa Moore, Dr. Greg 
Hand, Dr. J. Mark Davis, Dr. Jim Carson, Tommy and Melanie Waltz, Toinette Reed, 
James Christensen, Stephen Chen, Chris Kline, Chris Campbell, Tyrone Washington, 
Chris and Melissa Bopp, and Dave Beeson. 
Finally, I would like to give a special thanks to my and Liz‘s parents: Ted and 
Connie Greene, and Dave and Hilary Johnson, and the rest of our families.  Thank you 
all for the examples you have provided us and for the never ending support.  I speak for 
Liz, Amelia, and myself when I say we love you. 
 
Everywhere you look in science, the harder it becomes to understand the universe 
without God 
-Robert Herrmann 
 
 
  
viii 
 
TABLE OF CONTENTS 
  Page 
ABSTRACT .......................................................................................................... iii 
DEDICATION....................................................................................................... v 
ACKNOWLEDGEMENTS ................................................................................... vi 
TABLE OF CONTENTS ....................................................................................... viii 
LIST OF FIGURES ............................................................................................... xi 
LIST OF TABLES ................................................................................................. xiii 
CHAPTER 
 I INTRODUCTION AND REVIEW OF LITERATURE ..................... 1 
 
   Dysregulation of Lipid Metabolism with Obesity ......................... 2 
   Classic Exercise Training, General Physiologic Adaptations ........ 2 
   Cholesterol Transport and Metabolism ......................................... 5 
   Dyslipidemia................................................................................ 14 
   Exercise as a Therapeutic Agent in the Treatment of  
   Dyslipidemia................................................................................ 15 
   Skeletal Muscle in the Regulation of Lipids and Lipoproteins ...... 22 
   Peroxisome Proliferator-Activated Receptors ............................... 23 
   PPAR and Exercise ...................................................................... 39 
   Summary ..................................................................................... 42 
   Aims of the Experiments .............................................................. 43 
 
 II ACUTE EXERCISE AND AQUATIC TRAINING AFFECT  
  BLOOD LIPID-LIPOPROTEIN CONCENTRATIONS,  
  PARTICLE NUMBERS AND DENSITY, AND hsCRP IN 
OVERWEIGHT/OBESE MEN AND WOMEN ................................ 45 
   
   Introduction ................................................................................. 45 
   Methods ....................................................................................... 49 
   Results ......................................................................................... 57 
   Discussion ................................................................................... 67 
 
  
  
ix 
 
CHAPTER  Page 
 III PPARδ AND AMPKα PROTEIN CONTENT ARE ENHANCED 
FOLLOWING EXERCISE AND CORRELATED WITH BLOOD  
  LIPID AND LIPOPROTEIN CONCENTRATIONS IN THE  
  OBESE .............................................................................................. 76 
 
   Introduction ................................................................................. 76 
   Methods ....................................................................................... 80 
   Results ......................................................................................... 90 
   Discussion ................................................................................... 97 
 
 IV HIGH VOLUME RESISTANCE EXERCISE ENHANCES  
  PPARδ AND PGC-1α PROTEIN EXPRESSION, BUT NOT  
  MARKERS OF MITOCHONDRIAL BIOGENESIS IN THE  
  OBESE ZUCKER RAT ..................................................................... 107 
 
   Introduction ................................................................................. 107 
   Methods ....................................................................................... 110 
   Results ......................................................................................... 120 
   Discussion ................................................................................... 128 
 
 V CONCLUSIONS ............................................................................... 136 
    
   Exercise and Blood Lipids and Lipoproteins with Obesity ........... 136 
   Exercise and PPARs with Obesity ................................................ 137 
   Exercise and PPAR in the Lean and Obese Zucker Rat ................ 139 
   Comprehensive Conclusions ........................................................ 141 
   Significance ................................................................................. 143 
   Limitations and Delimitations ...................................................... 144 
   Summary ..................................................................................... 145 
REFERENCES ...................................................................................................... 147 
APPENDIX A ....................................................................................................... 167 
APPENDIX B ........................................................................................................ 170 
APPENDIX C ........................................................................................................ 178 
APPENDIX D ....................................................................................................... 185 
APPENDIX E ........................................................................................................ 186 
x 
 
  Page 
APPENDIX F ........................................................................................................ 188 
APPENDIX G ....................................................................................................... 190 
APPENDIX H ....................................................................................................... 200 
APPENDIX I ......................................................................................................... 206 
APPENDIX J ......................................................................................................... 217 
VITA ..................................................................................................................... 223 
  
xi 
 
LIST OF FIGURES 
  Page 
Figure 1 Vascular transfer of cholesterol and TAG ....................................... 7 
 
Figure 2 Basic structure and mechanism of action of the PPARs ................... 25 
 
Figure 3 PPAR (-α and -δ) and cholesterol metabolism ................................. 29 
 
Figure 4 PPARδ and fatty acid oxidation in skeletal muscle .......................... 34 
 
Figure 5 Activation of PPARδ, AMPK and PGC-1α with exercise and  
 downstream effects ......................................................................... 38 
 
Figure 6 Effect of exercise training on HDL-C and HDL2b-C in                
overweight and obese men and women ........................................... 62 
 
Figure 7 Effect of exercise training on HDL2a-C, HDL3-C and HDL-C             
mean density in overweight and obese men and women .................. 63 
 
Figure 8 Effect of exercise training on LDL3-C in overweight and obese             
men and women .............................................................................. 64 
 
Figure 9 Effect of acute exercise and exercise training on serum NEFA 
concentrations in overweight and obese men and women ................ 64 
 
Figure 10 Effect of acute exercise on the ratio of total cholesterol to HDL-C            
in overweight and obese men and women ....................................... 65 
 
Figure 11 Effect of acute exercise on high sensitivity C-reactive protein in 
overweight and obese men and women ........................................... 66 
 
Figure 12 Influence of exercise and exercise training on PPARα and PPARδ 
expression in overweight and obese men and women ...................... 91 
 
Figure 13 Influence of exercise and exercise training on AMPKα and PGC-1α 
expression in overweight and obese men and women. ..................... 92 
 
Figure 14 Influence of exercise and exercise training on CD36/FAT, CPT-I  
 and COX-IV expression in overweight and obese men and women.  94 
 
Figure 15 Influence of exercise and exercise training on LPL expression in 
overweight and obese men and women. .......................................... 95 
xii 
 
 
  Page 
 
Figure 16 Expression of PPARδ and PGC-1α in lean and obese Zucker                 
rats in SED or RE treatments .......................................................... 122 
 
Figure 17 Phosphorylation of LKB1 and AMPKα at Thr172 in lean and            
obese Zucker rats in SED or RE treatments ..................................... 123 
 
Figure 18 Expression of CD36/FAT in lean and obese Zucker rats in.                    
No effect of exercise treatment was seen ......................................... 124 
 
Figure 19 Expression of PPARδ and PGC-1α target proteins in lean and            
obese Zucker rats in SED or RE treatments ..................................... 125 
 
Figure 20 Mitochondrial protein synthesis in lean and obese Zucker rats                  
in SED or RE conditions ................................................................. 126 
 
  
xiii 
 
LIST OF TABLES 
 Page 
Table 1 Physical characteristics, and physical activity and dietary         
information before and after training in all subjects, women,                 
and men .......................................................................................... 50 
 
Table 2 Lipid and lipoprotein concentrations in overweight and obese              
men and women .............................................................................. 60 
 
Table 3 Lipid and lipoprotein particle numbers and densities in              
overweight and obese men and women ........................................... 61 
 
Table 4 Physiological variables, and activity and dietary habits before  
 and after training in all subjects, women, and men .......................... 81 
 
Table 5 Correlation of PPARα , PPARδ, AMPKα, and PGC-1α 
to blood lipids and lipoproteins and target proteins.......................... 96 
 
Table 6 Body weight and composition of lean and obese Zucker rats in            
SED or RE treatment groups ........................................................... 111 
 
Table 7 Serum lipids and lipoproteins of lean and obese Zucker rats ............ 120 
 
Table 8 Pearson‘s product-moment correlation matrix of PPARδ,                    
PGC-1α, and AMPKα to serum lipids and lipoproteins and other     
skeletal muscle proteins measured................................................... 127 
  
1 
 
 
CHAPTER I 
INTRODUCTION AND REVIEW OF LITERATURE 
 
This dissertation adheres to the journal article format method for dissertations.  This 
document is organized into five chapters (Chapters II-IV are intended to serve as 
standalone manuscripts to be submitted for publication in peer-reviewed journals).  In 
accordance with these guidelines, this chapter provides a review of pertinent literature 
and presents the questions to be addressed in Chapters II-IV.  Chapter V presents general 
conclusions to the dissertation as a whole. 
Rates of obesity and diabetes have risen to epidemic proportions in the United States 
(27)  These disease states, along with other metabolic diseases, are characterized by 
impairments in energy metabolism including insulin resistance and debilitated lipid 
metabolism.  Dysregulated oxidative metabolism is evident in reduced content and 
activity of oxidative enzymes within skeletal muscle.  Due to impairments in cellular 
metabolic function, individuals suffering from these disease states often exhibit elevated 
blood glucose and dyslipidemia including elevated total cholesterol (TC), LDL-
cholesterol (LDL-C), and triacylglycerols (TAG, also known as triglycerides), as well as 
depressed HDL-cholesterol (HDL-C).   
 
____________ 
This dissertation follows the style of the American Journal of Physiology- 
Endocrinology and Metabolism. 
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Dysregulation of Lipid Metabolism with Obesity 
Obesity is strongly associated with incidences of diabetes (57) and dyslipidemia (6).  
In addition, obesity is an established risk factor for cardiovascular disease (CVD) (2) and 
has been associated with increased risk for several types of cancer (10).  Obesity can 
induce metabolic disruptions by multiple mechanisms, potentially leading to 
development of disease.  For example, Koves et al. (35) described increased serum 
nonesterified fatty acids (NEFA) and plasma oleate, linoleate, stearate and palmitate 
concentrations in high fat feeding-induced obesity in mice compared to standard chow 
fed controls.  In that study high fat fed animals exhibited increased concentrations of 
several acylcarnitine species within the gastrocnemius muscle and an impaired ability to 
switch to carbohydrate fuel supplies, concomitant with increased rates of incomplete 
mitochondrial β-oxidation.  In contrast, Holloway et al. (30) suggested that the primary 
cause of impaired energy metabolism in obesity is reduced mitochondrial content.  
Regardless, it appears a major problem with the development of obesity is the inability 
to properly utilize fuel stores which can lead to an accumulation of lipid and lipid 
intermediates both in the tissue and in the blood compartments which may cause further 
disease. 
Classic Exercise Training, General Physiologic Adaptations 
Exercise training has the potential to ameliorate many of these obesity-related issues, 
and is classically defined as either endurance or resistance, each with its own general 
training adaptations.  Classic endurance training (ET; e.g., running, cycling) results in 
elevated maximal aerobic capacity (VO2max), and decreased body weight and fat, with 
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little or no change in lean mass (5, 229).  In comparison, classic resistance training (RT; 
e.g., weight training) is most commonly known for yielding increases in lean mass and 
muscular strength.  However, similar to ET, RT can produce improvements in muscle 
oxidative capacity (203) and fat metabolism (161), particularly if the exercise mode is of 
relatively high volume (e.g., circuit training).  This is reflected in the shift toward type 
IIA muscle fibers with RT (121).  However, studies examining mitochondrial aspects of 
skeletal muscle following high volume RT observed either no change or even reduced 
mitochondrial density (volume mitochondria to volume total muscle).  Thus, while 
mitochondrial proliferation after higher volume RT may be similar to that which occurs 
with ET, changes in mitochondrial content may be diluted by concomitant increases in 
myofibrillar growth.   
In our laboratory, we have recently investigated the comparative effects of a classic 
ET model (land treadmill, LTM) to a novel form of ET, aquatic treadmill (ATM) (82).  
ATM training incorporates a motor-driven treadmill placed in the floor of a pool with 
frontal water resistance jets and water depths generally at the 4
th
 intercostal space.  Data 
from these comparisons show that ATM training is equally capable of producing 
improved VO2max and reduced body weight and fat as LTM training.  However, we 
demonstrated that ATM training produces greater improvements in leg lean mass than 
LTM and potential improvements in total body lean mass (P=0.059).  These data suggest 
that ATM training may act similarly to circuit training methods in which RT is 
performed at a high pace with little rest and produces both gains in lean mass and 
VO2max (92). 
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Due to potential lean mass gains accompanying enhanced oxidative function with the 
ATM type exercise, for the study presented in Chapter IV of this dissertation the model 
of high volume (relatively low intensity with a higher number of repetitions) resistance 
exercise (RE) has been chosen because it may better mimic the concentric overload 
which is apparent during the ATM training utilized for the studies presented in Chapters 
II and III.  Due to the potential gains in lean body mass with ATM training (82), a 
response not seen for LTM training; a treadmill analogue for the study presented in 
Chapter IV would not resemble adaptations seen with ATM training.  However, the RE 
model presented here has been shown to elicit increases in muscle mass and protein 
synthesis in muscles of the hindlimb (64).   
Guillet et al. (84) have demonstrated elevated mitochondrial protein synthesis rates 
(mtFSR) following high volume RE.  Therefore, high volume RE may be similarly 
capable of eliciting mitochondrial biogenesis and enhanced oxidative function as some 
forms of aerobic exercise.  We propose that mitochondrial biogenesis with RE has been 
masked in previous literature due to the limitations of assessing this phenomenon by 
mitochondrial density.  If muscular hypertrophy is occurring, specifically of the 
myofibrillar compartment, mitochondrial growth may occur but be hidden by the growth 
of other cellular compartments when mitochondrial density is the chosen marker.  
Together, increases in lean mass and mitochondrial growth, which is associated with 
enhanced oxidative potential and aerobic capacity, suggest the viability of high volume 
RE as an analogue for the ATM training in Chapters II and III. 
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Cholesterol Transport and Metabolism 
One of the hallmark conditions associated with obesity is dyslipidemia.  This 
dissertation explores the use of exercise as a therapeutic agent for dyslipidemia with 
obesity.  Furthermore, mechanisms by which skeletal muscle may influence lipid and 
lipoprotein concentrations are explored.  To better understand the underlying 
mechanisms let us first review what is known about cholesterol and fatty acid (FA) 
transport and metabolism.   
Lipoproteins 
Lipoproteins are customarily classified based on hydrated density (g·cm
-2
), which is 
commonly determined by gradient ultracentrifugation and electrophoresis (103).  Classes 
of lipoproteins have since come to be further described by the lipid and protein 
composition of the particle and the particle diameter.  The largest, most buoyant 
lipoproteins contain a greater relative amount of lipid in their core with reduced protein 
mass.  With decreasing hydrated density the particle is characterized by reduced lipid 
content and a relatively greater protein mass (85).  In order of lowest to highest density 
the generally accepted lipoprotein fractions are: chylomicrons, very low density 
lipoprotein-cholesterol (VLDL-C), intermediate density lipoprotein-cholesterol (IDL-C), 
LDL-C, and HDL-C. 
Apolipoproteins.  Each class of lipoprotein is associated with a characteristic 
composition of apolipoproteins (Apo).  The Apos both enable the solubilization and 
stabilization of the lipoprotein complex within the circulation, and serve a vital role in 
the lipoprotein complex‘s interaction with tissue receptors and lipolytic enzymes (141).  
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The accepted nomenclature for the different types of apolipoproteins was developed 
based on the lipoprotein fraction they were first identified with.  Based on this 
nomenclature those designated ApoA are primarily associated with HDL-C, those 
designated ApoB are primarily associated with LDL-C, and ApoC associated with 
VLDL-C.  However, some overlap in Apo constituents does occur where ApoB is also 
associated with VLDL-C and ApoC represents a minor portion of the HDL-C associated 
Apo (103).  Other types of Apo include Apos D and E.  ApoE is associated with 
chylomicrons and VLDL-C (141).  ApoB represents two proteins from one gene, where 
ApoB48 is a smaller protein associated with chylomicron and ApoB100 is associated 
with VLDL-C and LDL-C. 
Subfractions.  Beyond these standard lipoprotein fractions HDL-C and LDL-C can 
be further divided into subfractions based on electrophoretic mobility.  Using SDS-
PAGE electrophoresis combined with Gaussian summation techniques, Verdery et al. 
(215) were able to identify six HDL-C class subfractions.  The six subfractions were 
designated based on their mobility during gel electrophoresis relative to albumin and 
particle size (nm).  The smallest HDL-C subfraction was HDL3c-C with a radius of 3.9 
nm and the largest was HDL1-C with a radius of 6.0 nm.  Of these subfractions the most 
commonly measured are HDL3-C and HDL2(a and b)-C. 
Though less well described than HDL-C subfractions, LDL-C can also be divided 
into several subfractions.  Using density gradient ultracentrifugation, Krauss and Burke 
(125) identified six total subclasses of LDL-C.  Currently, four main subclasses of LDL-
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C are readily accepted, denoted LDL1-4, based on size and density, where the largest and 
most buoyant class is LDL1-C and the smallest, most dense is LDL4-C (124).   
 Transport 
Cholesterol transport and metabolism has been previously reviewed by Ikonen (100).  
Cholesterol transport is broken into two main pathways: exogenous and endogenous, 
depicted in Figure 1.  The exogenous pathway involves lipid and cholesterol absorption 
by the gut and packaging into chylomicrons for release into the lymphatics to be placed  
 
 into the circulation.  The endogenous pathway includes hepatic packaging and release of 
very low density lipoprotein (VLDL) and the return of excess cholesterol ester (CE) by 
way of the reverse cholesterol transport system.   
Figure 1.  Vascular transfer of cholesterol and TAG.  Transfer is depicted at cell membranes of the small 
intestine, liver, and skeletal muscle (peripheral tissue).  CE, cholesterol ester; TAG, triacylglycerols; 
Chylo, chylomicron; VLDL, very low density lipoprotein; LDL, low density lipoprotein; HDL, high density 
lipoprotein; 2-MAG, 2-monoacylglycerol; NEFA, nonesterified fatty acid; LPL, lipoprotein lipase; LDLR, 
LDL receptor; ABCA1/G1, ATP-binding cassette A1/G1; LRP, LDLR like protein; Apo, apolipoprotein; 
SR-B1, scavenger receptor-B1; LCAT, lecithin: cholesterol acyltransferase 
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Exogenous pathway.  The exogenous pathway begins with the uptake of dietary lipid 
and cholesterol via enterocytes by the NPC1L1 receptor into the brush border of the gut 
(100).  Upon absorption by the enterocytes, cholesterol is esterified by Acyl CoA: 
Cholesterol Acyltransferase (ACAT) (100).  Cholesterol and TAG can then either be 
packaged into chylomicrons or re-released into the gut via the ABCG5 and -G8 
transporters (100).  For incorporation into chylomicrons, lipid is packaged with ApoB48 
and then released into the lymphatic system.  From the lymphatics, the chylomicrons can 
be released into the circulation, generally within 40 minutes of a meal.  
Chylomicrons are hydrolyzed in the circulation primarily by two mechanisms: 
lipoprotein lipase (LPL) and LDL-receptor like protein (LRP) (28).  LPL is a lipase 
produced by most tissues including skeletal muscle and adipose tissue (85).  The 
translated LPL is released to the vascular endothelium and located in the membrane of 
neighboring endothelial cells.  From here LPL can hydrolyze TAG from chylomicrons 
and other cholesterol carrying species, including VLDL-C, IDL-C, LDL-C, and free 
TAG.  This hydrolysis, like that of most lipases, yields 2-monoacylglycerol (2-MAG) 
and two nonesterified fatty acids (NEFA, also known as free fatty acids, FFA) (85).  
LRP is a specific cell receptor for chylomicron which recognizes ApoB48 on the surface 
of the chylomicron (214).  As the chylomicron is degraded, the remnant is absorbed by 
the liver.   
Endogenous pathway.  The endogenous pathway begins with the packaging and 
release of VLDL-C from the liver.  VLDL-C is packaged with a large portion of TAG in 
the core of the lipoprotein and contains ApoB100 and ApoE as primary Apo constituents 
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(85).  Once released into circulation, the ApoB100 and ApoE are recognized as substrate 
for the LDL-receptor (LDLR) originally discovered by Brown and Goldstein (20, 76).  
VLDL-C is an ideal substrate for this receptor, as the receptor‘s highest affinity is for 
ApoE.  As the CE and TAG are hydrolyzed from VLDL-C, the particle becomes more 
dense, and is eventually known as IDL-C (85).  IDL-C is generally removed from the 
circulation within about 2-6 hours due to the high affinity of ApoE for the LDLR.  
During this process, however, about half of the ApoE dissociates from IDL-C in 
circulation.  This dissociation carries two consequences: the half-life of IDL-C in the 
circulation extends to approximately 2 or 3 days, and IDL-C becomes known as LDL-C 
as CE and TAG are removed, creating an increasingly dense particle (85).   
Reverse cholesterol transport.  The process of reverse cholesterol transport involves 
the removal of excess cholesterol from peripheral tissues and blood and packaging into 
HDL-C for return to the liver, where cholesterol can either be repackaged into VLDL-C 
or used to make bile acids (100).  HDL-C is originally formed as little more than ApoAI, 
which is synthesized in the liver and sent into the circulation.  The peripheral tissues 
have a receptor known as ATP-binding cassette A1 (ABCA1) (100).  This receptor 
packages CE with ApoAI, forming a nascent HDL-C.  CE from the circulation can be 
added to this nascent HDL-C, producing HDL3-C, a process mediated by the enzyme 
lecithin: cholesterol acyltransferase (LCAT) in addition to ABCA1.  HDL3-C 
incorporates additional CE either by recognition by the ABC transporters (A1 and G1) of 
peripheral tissues or by further incorporation by the LCAT mechanism.  With this 
further addition of CE, the HDL3-C particle becomes a larger and more buoyant form of 
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HDL-C known as HDL2-C (177, 215).  Due to the nature of the accumulation of CE, 
HDL3 is generally the smaller, more dense species, whereas HDL2 is the larger, less 
dense species of HDL (177, 201).  HDL2-C then directs the return of CE and TAG to the 
liver where scavenger receptor B1 (SR-B1) binds the HDL2-C and facilitates the 
absorption of CE and any associated TAG or NEFA into the liver (100).  The HDL-C 
itself then remains in the circulation where it can release from SR-B1 and repeat its 
cycle.  HDL-C can also transfer its cholesterol to chylomicron and VLDL-C remnants, 
IDL-C and LDL-C by way of the cholesterol ester transfer protein (CETP). 
Metabolism 
Primary metabolism of cholesterol and FA in peripheral tissues (outside of the liver) 
in humans is the oxidation of FA and the use of cholesterol as a membrane constituent 
and substrate for hormone production.  The liver is the principal site for cholesterol and 
FA synthesis.  Generally, both cholesterol and FA synthesis begin with the substrate 
acetyl-CoA (85).  Acetyl-CoA in the cytoplasm can be derived from citrate released by 
the tricarboxylic acid (TCA) cycle.  When the NADH+H
+
 concentration is high in the 
mitochondria, isocitrate dehydrogenase (ICDH) is inhibited.  This inhibition causes an 
accumulation of mitochondrial citrate, which can be transported to the cytosol (85).  
Once in the cytosol, the citrate is split by the enzyme ATP-citrate lyase yielding 
oxaloacetate (OAA) and acetyl-CoA.  OAA can be used to form malate, which will 
inhibit the entry of pyruvate into the mitochondria, thus slowing flux through the TCA 
cycle.  The acetyl-CoA, however, can then be used as substrate for either cholesterol or 
FA synthesis (85). 
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Cholesterol synthesis.  Cholesterol synthesis begins with the joining of two acetyl-
CoAs by thiolase, yielding acetoacetyl-CoA (85).  Acetoacetyl-CoA and a third acetyl-
CoA now can form HMG-CoA via HMG-CoA synthase.  HMG-CoA is a substrate for 
HMG-CoA reductase (HMG-CoAR), a rate limiting and committed step in the synthesis 
of cholesterol (85).  Cholesterol can then be formed following a series of reactions which 
have not yet been completely elucidated.  After synthesis the CE can be packaged with 
TAG, NEFA and Apos B and E to form VLDL-C and released to the circulation.  
Cholesterol homeostasis further depends on regulation by the sterol regulatory element–
binding proteins (SREBPs), transcription factors which stimulate the transcription of 
HMG-CoAR and LDLR (100).   
Fatty acid synthesis.  De novo FA synthesis begins with the temporary fixation of 
CO2 with acetyl-CoA by acetyl-CoA carboxylase (ACC) (85).  This reaction forms 
malonyl-CoA, which is a primary substrate for fatty acid synthase (FAS).  FAS can 
systematically add acetyl-CoA to malonyl-CoA one at a time to a growing FA chain.  
The affinity of FAS is reduced as the carbon chain becomes longer (85).  In most tissues, 
FAS will release the newly synthesized FA when it reaches 16 carbons in length.  
Beyond 16C, the new FA can undergo further elongation to long chain and very long 
chain FAs using a series of enzymes known as elongases (85).  The cell can also modify 
the FA by use of desaturases.  In most animals, three desaturases are present including n-
5, n-6, and n-9 (85).  FAs must also be esterified to avoid cellular damage.  This process 
is mediated by acyl-CoA synthase (ACS), which forms a fatty acyl-CoA using NEFA 
and CoASH as substrates.   
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Fatty acid oxidation.  The first step of fatty acid oxidation (FAO) is the uptake of 
FA.  Primary mechanisms for FA incorporation by the tissue include fatty acid 
transporters such as fatty acid transport protein (FATP) and fatty acid translocase 
(FAT/CD36), LPL, and LDLR mediated endocytosis of LDL (85).  With the LDLR 
mechanism, LDL is taken to the lysosome, where LDLR can be re-sent to the membrane 
and LDL can be hydrolyzed, releasing TAG and CE (106).  The TAG can then be 
hydrolyzed by hormone sensitive lipase (HSL) to yield 2-monoacylglycerol (2-MAG) 
and 2 NEFA (85).  2-MAG can be further hydrolyzed by a MAG lipase to yield NEFA 
plus glycerol.  In this process the regulation of HSL is very important.  As the name 
suggests, the lipase is susceptible to regulation by blood hormones such as insulin and 
epinephrine (EPI)/norepinephrine (NE).   In the skeletal muscle, insulin will ultimately 
inhibit HSL, while NE/EPI will stimulate HSL (222).  Adrenergic stimulation by EPI 
promotes the activation of adenylate cyclase and cAMP.  cAMP then stimulates cAMP-
dependent protein kinase A (PKA) which can then promote HSL activity by 
phosphorylation of HSL at three stimulatory sites (200).  Previous evidence 
demonstrates that this EPI dependent stimulation of HSL is an important aspect to the 
enhanced activity of HSL at the onset of exercise (200).  Insulin, however, stimulates 
phosphodiesterase (PDE) which causes the degradation of cAMP to AMP.  This causes 
the deactivation of PKA, and thus removes PKA mediated stimulation of HSL (222). 
As previously stated, to prevent cellular damage, NEFA must be esterified by ACS.  
This yields FA-CoA, which can be used as substrate for carnitine: palmitoyl 
acyltransferase-I (CPTI, also known as CATI) (85).  This is necessary as long chain 
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NEFA and FA-CoA cannot cross the mitochondrial membrane without the aid of 
facilitated transport mechanisms.  Of note, a mitochondrial pool of FAT/CD36 can also 
facilitate FA transport into the mitochondria (96).  CPTI exchanges the CoA from the 
FA-CoA for carnitine, allowing the FA to traverse the mitochondrial membrane.  Once 
at the inner membrane, CPTII can re-exchange the carnitine, reforming the FA-CoA and 
sending carnitine back to the outer membrane to pick up another FA (85).  CPTI is 
considered the primary rate limiting step of FAO, and is inhibited by malonyl-CoA, the 
product of ACC.  Thus when energy supply is high, NADH+H
+
 inhibits isocitrate 
dehydrogenase (ICDH) increasing citrate which leaks out of the mitochondria and is 
split to form acetyl-CoA and OAA, providing substrate for ACC forming malonyl-CoA 
and inhibiting CPTI (85).   
Once in the mitochondria, FA-CoA undergoes β-oxidation, which for every turn 
through the cycle will split off two carbons in the form of acetyl-CoA, NADH+H
+
, and 
FADH2.  The acetyl-CoA can then be used as substrate for the TCA cycle yielding GTP, 
3 NADH+H
+
, and FADH2 (85).  NADH and FADH2 then provide substrate for the 
electron transport system (ETS).  ETS will use these molecules as reducing agents 
thereby pumping H
+
 into the inner-membrane space.  H
+
 is the substrate for ATP 
synthase (85).   
In times of energy surplus, the uncoupling proteins (UCPs) will uncouple ETS from 
ATP synthase allowing H+ to go back into the mitochondria.  In excess this may cause 
the formation of H2O2 (a form of reactive oxygen species, ROS).  Furthermore, during 
energy surplus, lipids will accumulate in the cell.  Both the free radical formation and 
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lipid accumulation may activate a series of serine kinases which phosphorylate and 
thereby inhibit the insulin receptor substrate (IRS) (13, 120).  This serves an important 
mechanism in maintaining the cell‘s energy homeostasis, but with chronic elevated lipid 
and ROS driving inhibition of IRS, glucose will not be taken up by the cell.  The 
pancreatic β cells may then fatigue trying to overcome the cell‘s inhibition of IRS.  This 
process will yield insulin resistance and eventually type 2 diabetes mellitus. 
Dyslipidemia 
Perhaps the most well known association of dyslipidemia with the risk of CVD and 
atherogenesis comes from the Framingham Heart Study.  This study began in 1948 in an 
effort to identify characteristics which are associated with the onset and development of 
CVD and now includes data from multiple generations of the residents of the town of 
Framingham, Mass.  The first report from the study to associate risk of coronary heart 
disease with elevated serum cholesterol was published in 1961 (108).  Results from the 
study indicate the relationship of blood lipids and lipoproteins to general CVD risk (45), 
coronary heart disease risk (44, 230), and risk for intermittent claudication (153).  In 
addition, Drexel et al. (54) have demonstrated that LDL-C, HDL2-C, HDL3-C, and TAG 
are each independently predictive of the extent of coronary atherosclerosis in a sample of 
patients undergoing angiography for evaluation of suspected or established coronary 
artery disease. 
Due to these associations, abnormal blood lipid and lipoprotein concentrations are a 
recognized risk factor for the development of CVD by the American College of Sports 
Medicine (ACSM) and American Heart Association (AHA) (2, 156).  Therefore, the 
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potential to relieve dyslipidemia using exercise-based therapy is of great interest.  
Dyslipidemia is characterized by elevated TC (>200 mg·dL
-1
), LDL-C (>130 mg·dL
-1
) 
and TAG (>200 mg·dL
-1
), and low HDL-C (< 40 mg·dL
-1
) (2, 156).  In addition to total 
concentration of the lipoprotein fractions, subfractions of HDL-C and LDL-C represent 
differential atherogenic risk.  Increased blood concentrations of HDL2-C signals the 
acquisition of cholesterol by HDL, thus a shift from HDL3-C to HDL2-C and 
concomitantly enhanced reverse-cholesterol transport is consistent with reduced 
atherogenic risk (177, 201).  Such a shift toward enhanced HDL2-C concentration yields 
a decrease in HDL mean density, a factor also associated with reduced atherogenic risk 
(91).  Smaller LDL-C subfractions (LDL3-C and LDL4-C) are considered to represent 
greater atherogenic risk because they are more susceptible to oxidation and greater 
binding to the arterial wall (124) and thus are correlated with coronary artery disease 
(37).  Therefore, the understanding of cholesterol based therapies must be expanded 
beyond the assessment of total HDL and LDL related cholesterol and evaluate the 
influence of therapies on the lipoprotein subfractions.   
Exercise as a Therapeutic Agent in the Treatment of Dyslipidemia 
The potential for exercise to act as a therapeutic agent in the treatment of 
dyslipidemia has long been known.  As far back as 1964, Holloszy et al. (94) reported a 
decrease in the blood concentration of TAG in subjects who performed exercise 3 
days·wk
-1
 for 6 months.  To properly understand the influence of exercise on blood 
lipids and lipoproteins, we must understand the factors which may influence the efficacy 
of the protocol including: 1) the comparative influence of type of exercise (endurance vs. 
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resistance), 2) exercise training compared to acute exercise, 3) differences among 
varying populations (i.e., men vs. women, hypercholesterolemic vs. exercise trained, 
lean vs. obese, etc.), and 4) the aspects of exercise itself which determine an effective 
exercise regimen (i.e., intensity, duration, and frequency).  Research in the 
understanding of exercise-mediated alterations in blood lipids and lipoproteins has been 
carried out in both cross-sectional and longitudinal study designs.  Here we provide a 
brief review of some of the more influential findings.  
Cross-sectional studies.   
Cross-sectional studies have contributed much of the basis for the concept that 
exercise training produces beneficial effects on blood lipids and lipoproteins.  Two such 
studies by Williams et al. (226-227) have included data from more than 7,000 subjects.  
In one study, they examined the relationship of heart disease risk to exercise quantity 
and intensity and found that both quantity and intensity of habitual exercise were 
associated with reduced risk, including greater HDL-C and lower LDL-C and TAG 
concentrations (227).  In the National Runners‘ Health Study (226), they reported that 
run distance per week was associated with reduced TAG and increased HDL-C.  In 
addition, Halle et al. (86) have previously observed that increasing levels of habitual 
physical activity are correlated with reduced concentrations of TAG and small, dense 
LDL-C (presumably LDL3-C and LDL4-C) in hypercholesterolemic men.   
Exercise training.   
Exercise training can beneficially alter blood lipids and lipoproteins.  In general, 
plasma TAG are reduced following exercise training, with the greatest effects often seen 
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in subjects who were previously inactive and with higher baseline TAG (115, 207).  In 
contrast, TC is normally unchanged by exercise training (143, 233) unless accompanied 
by reductions in body fat (111).  Similarly, total LDL-C is often unaffected by exercise 
training (115, 207).  HDL-C appears to increase following exercise training in a dose 
dependent manner with energy expenditure.  Changes in HDL-C are more likely with 
training protocols lasting greater than 12 weeks (179, 196).  Absolute increases in HDL-
C with training are generally seen to approximate 2-8 mg·dL
-1
.  For example, Thompson 
et al. (206-207) have previously measured increases in HDL-C of 3 mg·dL
-1 
(206) and 8 
mg·dL
-1 
(207) when subjects‘ diets were manipulated to maintain constant body weight 
and body fat for the duration of the study.  Our laboratory (42) has demonstrated the 
potential of exercise training to reduce CVD risk by causing a shift in HDL-C 
subfractions including increased HDL2-C and decreased HDL3-C concentrations in 
hypercholesterolemic men. 
To understand the effect of exercise training intensity, our laboratory (41) performed 
a study in which subjects were trained for an equal frequency and duration (assessed by 
caloric expenditure), but assigned into training groups for high (80% VO2max) or low 
intensity (50% VO2max).  Decreased TC and HDL3-C, and increased HDL2-C 
concentrations were reported with no observed effect of training intensity.  These 
findings indicate that intensity of exercise training does not appear to be a primary 
determining factor in exercise training induced changes in blood lipid and lipoprotein 
concentrations.  However, a previous review of pertinent literature by Durstine et al. (59) 
suggests the importance of a caloric threshold, which is suggested to occur at 
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approximately 1200-1500 kcal·wk
-1
, for exercise training mediated changes in lipids and 
lipoproteins.  Thus it appears that training volume, rather than intensity, is the key to 
exercise training induced changes in blood lipids and lipoproteins.  Based on these data, 
the exercise training protocol presented in Chapters II and III of this dissertation was 
designed to elicit 1500 kcal·wk
-1
 in exercise training-based caloric expenditure. 
Acute exercise.   
In addition to the adaptive influence of exercise training, acute exercise presents 
transient effects on blood lipids and lipoproteins which often peak 24 h after exercise 
and are no longer seen by 72 h (42-43, 65, 223, 234).  Like exercise training, the primary 
effect of acute exercise on blood lipids and lipoproteins appears to involve a reduction in 
TAG and an increase in HDL-C.  Though TC can change following acute exercise, it 
generally requires a very large caloric expenditure.  Previous work from our laboratory 
(43) examining lipid and lipoprotein responses to high compared to low intensity acute 
exercise in hypercholesterolemia shows increased HDL-C and LDL-C, and decreased 
TAG 24 and 48 h post-exercise, following a single exercise session of 350 kcal 
expenditure, regardless of intensity (80% vs. 50% VO2max).  Similar to exercise 
training, these findings indicate that exercise intensity may not be a major determining 
factor in eliciting changes in blood lipids and lipoproteins.   
However, findings regarding the influence of exercise duration, frequently defined 
by caloric expenditure, have provided information detailing population based caloric 
thresholds.  Ferguson, et al. (65) investigated the effect of exercise duration on blood 
lipid responses in trained male runners performing exercise sessions of 800, 1100, 1300, 
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and 1500 kcal, showing that 1100 kcal was required to elicit changes in lipids and 
lipoproteins.  Our laboratory demonstrated that an energy expenditure of approximately 
350 kcal is sufficient to elicit changes in blood lipids and lipoproteins in previously 
untrained, hypercholesterolemic men (43, 81).  In physically active postmenopausal 
women, Weise et al. (223) have shown that 400 kcal was sufficient to reduce TAG at 24 
h post exercise, regardless of prior cholesterol concentrations.  By contrast, Wooten et al. 
(234) demonstrated no significant change in blood lipids and lipoproteins following 
exercise of 500 kcal in duration in physically inactive postmenopausal women.  These 
data indicate that they may have failed to reach caloric threshold for their sample of 
physically inactive women.  Together previous data suggest that exercise duration (as 
defined by caloric expenditure) is the key to blood lipid and lipoproteins responses seen 
with acute exercise, and that the population studied influences the effective duration, 
whereby gender, cholesterol status, previous exercise training, and obesity may all have 
an effect.   
Influence of exercise training on the transient response to acute exercise. 
Only one known published study has compared and contrasted the influence of acute 
exercise and exercise training on blood lipids and lipoproteins (42), demonstrating 
changes in lipids and lipoproteins consistent with reduced atherogenic risk following 
both acute exercise and exercise training in hypercholesterolemic men.  Interestingly, in 
the untrained state, acute exercise yielded an increase in LDL-C concentration which 
was no longer seen after 16 wks of training, suggesting that training may alter the acute 
response to exercise.  However, the influence of training on the transient response to 
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acute exercise requires further examination to elucidate the nature of such an interaction.  
To better discern the nature of exercise-induced changes in lipids and lipoproteins, 
Chapter II of this dissertation examines the possibility of such an interaction in 
overweight and obese individuals. 
Resistance exercise.   
Relatively little is known about the effect of RE on blood lipids and lipoproteins.  
Many of the previous studies investigating RT have suffered design flaws, including low 
caloric expenditure, and inadequate quantification of the exercise training.  However, the 
limited findings include no change in TAG and no change in TC when body weight, lean 
body mass, and percent body fat are unchanged (18, 187, 210).  When lean body mass is 
increased and percent body fat decreased with RT, both TC and LDL-C have been seen 
to decrease (18, 210).  These findings indicate the importance for a reduction in body fat 
to elicit changes in these cholesterol concentrations with RT.  Results for changes in 
HDL-C have been mixed demonstrating either unchanged (116) or increased (210) 
HDL-C concentration following an RT regimen. 
Acute RE has the potential to produce beneficial changes to the blood lipid and 
lipoprotein profile.  Wallace et al. (218) have previously shown that a high volume, but 
not low volume, bout of RE can elicit increases in HDL-C and HDL3-C concentration, 
with concomitant decreases in TAG content and LCAT activity.  These findings indicate 
that RE may be able to improve blood lipid and lipoprotein concentrations, but only 
when a volume-based threshold, similar to aerobic exercise, is attained.   
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Obesity, exercise, and blood lipids and lipoproteins. 
Despite known therapeutic benefits of exercise for the obese, the effects of exercise 
on blood lipids and lipoproteins in this population are incompletely described.  The bulk 
of published studies examining interventions to reduce blood lipids and lipoproteins in 
this population have used methods designed to induce weight loss either by diet or by 
combination of diet and exercise (61, 180, 212, 232).  Such weight loss interventions can 
be effective in producing beneficial changes in blood lipids and lipoproteins.  In fact, 
Williams et al. (228) have previously demonstrated increased HDL2b-C in men following 
a 12 month weight loss program by either diet (-7.2 kg) or exercise (-4.0 kg).  However, 
weight loss may not be necessary to elicit the therapeutic benefits of exercise in the 
obese (33, 126).  Studies examining the effects of exercise training alone on lipids and 
lipoproteins in the obese have often focused solely on men and included blood sampling 
within 24 h of the cessation of exercise training (157, 228).  Such timing of blood 
sampling may be confounded by the transient response to the last exercise session which 
may last up to 72 h following exercise (42-43, 65, 223, 234); therefore, the interpretation 
of these studies should be taken with caution.  Also, the influence of acute exercise has 
rarely been considered in this population.   
Exercise training with obesity.  Nicklas et al. (157) have previously demonstrated an 
increase in HDL-C and HDL2-C in lean and overweight men following 9 months of 
exercise training, however, no such effect was observed in obese men.  Slentz et al. 
(183) have demonstrated increased HDL-C and ―large‖ HDL-C, presumably HDL2-C, in 
overweight and mildly obese men in high volume exercisers (1700 kcal·wk
-1
), but not 
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with lower volume (approximately 1100 kcal·wk
-1
).  Their findings were seen 24 h 
following the last exercise session, and lasted through 15 days following the cessation of 
exercise training.  They further showed that any exercise was sufficient to prevent 
increased LDL-C concentration and particle number and reduced LDL size observed in 
sedentary controls over the course of their study.  Their findings suggest the efficacy of 
an exercise regimen alone to yield beneficial changes in HDL-C so long as a minimum 
duration is achieved.  These data are suggestive of the benefits of exercise training on 
these cardiovascular risk markers but do not provide information regarding any influence 
of acute exercise or understanding of potential gender interactions in the overweight and 
obese population. 
Skeletal Muscle in the Regulation of Lipids and Lipoproteins 
Particularly with regards to physical exercise, skeletal muscle is the primary tissue 
involved in energy catabolism.  Skeletal muscle may account for as much as 56-65% of 
total body weight (190) and as such contributes 20-30% of total energy expenditure at 
rest, a figure which increases greatly during exercise.  Of total energy expenditure, lipid 
catabolism may account for 70% of skeletal muscle energy expenditure during rest 
(185), the rate of which only increases during prolonged exercise.  Therefore, skeletal 
muscle must rely on mobilization of lipid stores from other tissues to supply its energetic 
demands.  Considering that changes in serum lipids and lipoproteins during exercise 
appear dependent upon caloric expenditure, skeletal muscle must be considered as a 
primary source for the mediation of serum lipids and lipoproteins following exercise. 
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Previous studies have been conducted to directly understand the influence of skeletal 
muscle on exercise-derived changes in blood lipids and lipoproteins by assessing 
alterations in these factors across the vascular beds of skeletal muscle.  Kiens and Lithell 
(113) reported the effects of one-leg exercise on the arterial-venous difference in blood 
lipids and lipoproteins.  They demonstrated significantly greater HDL-C and HDL2-C in 
the venous compared to arterial blood of the exercised leg.  Furthermore, they 
demonstrated significant clearance of VLDL-TAG from arterial to venous compartments 
in the exercised leg, but not in the non-exercised leg.  They additionally observed 
enhanced muscle LPL activity in the exercised leg.  Together these data suggest a vital 
role of skeletal muscle in the regulation of blood lipids and lipoproteins, particularly 
during and following exercise.  Therefore, the studies presented in this dissertation 
explore the role of skeletal muscle in the regulation of blood lipids and lipoproteins with 
and without exercise in overweight and obese individuals. 
Peroxisome Proliferator Activated Receptors 
To understand the ability of obese individuals to respond and adapt to the metabolic 
challenges of exercise and to exhibit normal metabolic function, it is necessary to 
understand the mechanisms by which metabolic capabilities are regulated and how these 
mechanisms may be altered in obesity.  Furthermore, since little is understood about the 
mechanisms behind changes in blood lipids and lipoproteins with exercise, it is also 
necessary to elucidate such mechanisms.  By doing so practitioners will better be able to 
treat both the obese and other populations to yield antiatherogenic changes in blood lipid 
and lipoprotein concentrations.  The peroxisome proliferator-activated receptors 
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(PPARs) are transcription factors which may prove essential for these metabolic 
functions. 
Issemann and Green (102) first discovered PPAR in 1990, when they identified 
PPARα, the first of three known PPAR isoforms (-α, -γ and -β/δ).  The PPARs are a 
family of transcription factors with the ability to increase or decrease the rate of 
transcription of genes generally corresponding to metabolic enzymes and FA transport 
proteins.  The PPARs have been found to have roles in glucose and lipid metabolism, 
endothelial function, and in dictating muscle fiber type.  Previous work has related 
enhanced PPAR expression to improved insulin sensitivity (238) and beneficial changes 
in blood lipid and lipoprotein concentrations (160), providing a direct link to the 
treatment of metabolic diseases by enhancing PPAR expression and activity.  Therefore, 
PPARs have been implicated as potential therapeutic targets for the treatment of several 
metabolic diseases including obesity, diabetes mellitus, dyslipidemia and the metabolic 
syndrome.   
Tissue distribution.   
The PPAR isomers show tissue specific expression.  PPARs -α and -δ are expressed 
at the greatest levels in tissues with high metabolic activity, including liver and muscle.  
PPARα is primarily expressed in liver, kidneys, heart and skeletal muscle (15).  
However, PPARδ is ubiquitously expressed throughout the body (15).  Though PPARδ 
expression is relatively low in the liver and kidneys, it is the most abundant isoform in 
skeletal muscle (152) and is believed to be the primary isoform in this tissue.  Due to its 
importance in skeletal muscle, PPARδ will be the primary focal point for metabolic 
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regulation in this dissertation.  PPARγ is primarily expressed in both the brown and 
white adipose tissue, and to a lesser degree in immune cells such as macrophages (15).  
Due to its lack of expression in skeletal muscle, PPARγ will not be discussed further in 
this review.   
Structure.   
The generic structure of PPAR is seen in Figure 2.  The PPARs exhibit a domain 
structure that is similar to other nuclear receptors such as thyroid and steroid hormone 
receptors.  The NH2-terminal region of PPAR consists of a ligand-independent binding 
domain, followed by a DNA binding domain consisting of two zinc fingers, a ligand 
binding and dimerization domain and a ligand-dependent activation domain at the 
carboxy-terminus (49).   
Mechanism of action.   
The mechanism of action is depicted in Figure 2.  PPAR can be activated by 
phosphorylation and/or ligand binding; upon activation PPAR forms a heterodimer with 
the retinoid X receptor (RXR) (49).  Binding with the RXR in the cytoplasm allows 
Figure 2:  Basic structure and mechanism of action of the 
PPARs.  RXR, Retinoid X Receptor; FA, Fatty Acids; 
GW501516, synthetic PPARδ specific pharmaceutical agonist; 
PPRE, Peroxisome Proliferator Response Element 
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PPAR to enter the nucleus where it can bind DNA.  Once in the nucleus, PPAR 
recognizes and binds specific promoter regions of target genes, termed peroxisome 
proliferator response elements (PPRE) (49).  This mechanism allows the PPARs to 
stimulate transcription of target genes, primarily those involved in lipid and glucose 
metabolism.  The PPARs are also capable of repressing transcription of specific genes 
by a DNA binding independent manner, relying on protein-protein interactions and 
cofactor competition. 
Regulation and activation.   
PPAR activity can be regulated by a variety of methods.  Primary means of 
activation include ligand binding and phosphorylation (23, 49).   
Ligand-binding.  PPARs are activated by a variety of natural and synthetic ligands.  
Primary natural ligands for the PPAR family are FA and their derivatives (8).  These 
ligands are capable of recruiting specific cofactors which can either enhance or diminish 
the ligand‘s ability to bind PPAR (49).   
All three isoforms of PPAR are activated by saturated FAs, such as palmitic acid, 
and polyunsaturated fatty acids (PUFAs) such as arachidonic and linoleic acids.  PPARs 
appear to be more responsive to n-3 and n-6 PUFAs as ligands than to saturated FAs or 
monounsaturated FAs (49, 112).  In addition, other natural substances, primarily FA 
derivatives from arachidonic acid metabolism, can selectively bind and activate each 
individual isoform.  For example, PPARα is activated by 8S-HETE and leukotriene B4, 
among others (49, 112).   
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Synthetic ligands have also been developed as a means of potential pharmacological 
treatments for metabolic disease.  These synthetic ligands include the fibrates (e.g., 
fenofibrate) which stimulate PPARα, the thiazolidinediones (TZDs; e.g., rosiglitazone) 
which stimulate PPARγ, and experimental ligands including GW501516 which stimulate 
PPARδ (112, 160).  Other synthetic ligands have also been developed, such as 
ragaglitazar, which act on all three isoforms (10). 
Phosphorylation.  In addition to ligand dependent activation, the PPARs are 
phosphoproteins, and are targets of several phosphorylation cascades involved in energy 
metabolism.  PPAR was first recognized as a phosphoprotein in 1996, when it was 
discovered that PPARα was a target of insulin signaling via the ERK-MAPK pathway 
(181).  In general, phosphorylation of PPARs -α and -δ yields enhanced basal and ligand 
mediated activity.  Phosphorylation and activation of PPARα occurs via several kinase 
cascades, including the mitogen-activated protein kinases (MAPKs) ERK-MAPK and 
p38 MAPK, PKA, AMP-activated protein kinase (AMPK), and calcium-dependent 
protein kinase (PKC) (9, 24, 52, 181).  Much less is known about the phosphorylation of 
PPARδ, but PKA, cyclic AMP dependent protein kinase (cAMP), and likely p38 MAPK 
are capable of phosphorylating PPARδ, thus increasing both basal and ligand-stimulated 
activity of PPARδ (15, 24, 52).  Furthermore, AMPK appears essential for maximal 
activation of PPARδ (122); though a direct phosphorylation of PPARδ by AMPK has yet 
to be described.   
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PPARα.   
The primary functions of PPARα involve the influx and efflux of cholesterol by the 
liver, delivery of FAs to peripheral cells and their metabolism therein.  In fact, this 
isoform has proven to have a primary role in lipid metabolism, atherosclerosis and 
inflammation (238).  Expression of PPARα is enhanced during fasting, a time in which 
FAs become more prevalent as an energy source, aiding in the switch from primary 
carbohydrate metabolism to lipid metabolism.   
Lipid and lipoprotein metabolism.  The role of PPARs -α and -δ in lipoprotein and 
cholesterol transport and metabolism is depicted in Figure 3.  PPARα functions to aid in 
the delivery of FAs to peripheral tissues and their subsequent processing and metabolism 
within the cell.  PPARα expression and activity thus yields increased transcription of 
genes for enzymes such as FAT/CD36 and FATP which mediate FA transport into the 
cell (144).  This is followed by increased expression of ACS, which activates the FA by 
adding an acyl group, thereby trapping the FA within the cell, since activated FAs are 
incapable of transport out of the cell (144).  Within the mitochondria, PPARα is capable 
of upregulating the expression of genes for enzymes such as carnitine-palmitoyl 
transferase-I (CPT-I), which transports FAs into the mitochondria for β-oxidation (145).  
Expression of PPARα also increases expression of acetyl-CoA synthase, a mitochondrial 
enzyme necessary for β-oxidation. 
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The second role of PPARα in lipid and lipoprotein metabolism is the stimulation of 
lipolysis and cholesterol metabolism.  PPARα directly increases LPL expression, which 
functions in lipolysis and serves to enhance clearance of TAG rich lipoproteins (178).  
PPARα also inhibits expression of apolipoprotein CIII (ApoCIII) (149), a protein which 
inhibits the TAG hydrolysis activity of LPL, contributing to the lipid lowering effects of 
fibrates. 
Lipid metabolism involves not only the delivery of lipids and lipoproteins to the 
periphery and use within the peripheral cells, but also the ability to transport back to the 
liver.  As discussed, the method by which this occurs is termed reverse cholesterol 
transport.  Reverse cholesterol transport involves three major steps:  (1) transport of 
lipids out of the peripheral cells, (2) delivery back to the liver via the blood, and (3) 
uptake by the liver. 
Figure 3:  PPAR (-α and -δ) and cholesterol metabolism. Depiction of proteins whose 
transcription is stimulated by PPARs -α and -δ in liver and peripheral tissue.  Proteins depicted 
are transcriptionally upregulated by PPAR unless otherwise indicated.  LDL-R, LDL-Receptor; 
LPL, Lipoprotein Lipase; ABCA-1, ATP-Binding Cassette A-1; SR-B1, Scavenger Receptor-B1; 
FA, Fatty Acids; TAG, Triacylglycerol; CE, Cholesterol Ester; Apo, Apolipoprotein; VLDL, Very 
Low Density Lipoprotein; HDL, High Density Lipoprotein  
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ABCA1 is a primary mediator of the delivery of CE to HDL particles, whereas SR-
B1 is a receptor protein on the liver which binds HDL and stimulates the absorption of 
CE from HDL.  Both SR-B1 (29) and ABCA1 (30) transcription are enhanced by 
PPARα activators.  In addition, PPARα expression has been shown to increase 
transcription of HDL-associated apolipoproteins including ApoAI and ApoAII (216).  
Interestingly, the opposite effect occurs in the rat model; HDL concentrations in the 
circulation are decreased corresponding to decreased ApoAI and ApoAII levels.  This is 
likely due to PPARα inducing the expression of Rev-erbα, an orphan nuclear receptor 
which inhibits the transcription of ApoAI in the rat (216).   
Integrative metabolism.  A primary role of the PPARs is to facilitate a shift in energy 
metabolism from carbohydrate (CHO) to predominantly FAO, by promoting both 
enhanced FAO and reduced glucose metabolism.  One pertinent observation regarding 
the role of PPARα in glucose metabolism is that PPARα-null mice exhibit extreme 
hypoglycemia, characterized by a 50% decrease in blood glucose following a 24 hour 
fast (114).  The primary influences of PPARα on blood glucose likely occur in the liver.  
PPARα appears to modulate glycerol metabolism and gluconeogenesis in the liver (163).  
The likely cause of this shift is a PPARα transcriptional dependency for the production 
of glyceraldehyde 3 phosphate dehydrogenase, glycerol kinase, and glycerol transporters 
(aquaporins 3 and 9) (163).  PPARα overexpression may impair glucose metabolism.  
Finck et al. (66) have reported reduced insulin-stimulated glucose uptake in transgenic 
mice overexpressing PPARα.  In that study, they showed PPARα overexpression 
resulted in depressed mRNA content of the glucose transporter GLUT4, and 
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phosphofructokinase, a glycolytic rate-limiting enzyme, as well as enhanced expression 
of the glycolysis inhibitor pyruvate dehydrogenase kinase 4 (66). 
One focus of research of the PPARs has been their relationship to insulin 
concentrations and sensitivity.  Results of various studies have suggested seemingly 
contradictory roles of PPARα in insulin sensitivity.  Knauf et al. (114) found that whole 
body insulin sensitivity is increased 15% in PPARα-null mice compared to wild type 
controls.  However, several other published reports suggest that activation of PPARα 
enhances insulin sensitivity.  In these studies, researchers have used nutritional, genetic 
(Zucker rat), and lipoatrophic models for insulin resistance and found improved insulin 
sensitivity following treatment with pharmaceutical agonists of PPARα (32, 83, 237). 
PPARα may also have some influence on protein synthesis through the 
insulin/mTOR pathway.    In addition to influencing insulin sensitivity, PPARα exhibits 
control over the expression of the protein TRB3.  Koo et al. (118) demonstrated that 
PPARα knockout mice exhibit greatly reduced TRB3 mRNA content.  TRB3 influences 
the insulin/mTOR pathway by inhibition of Akt, such that greater PPARα content and 
activity will yield increased TRB3 concentration and therefore potentially inhibit Akt.   
PPARδ.   
Perhaps the least studied of the three isoforms, PPARδ is the most abundantly 
expressed isoform.  PPARδ‘s importance in FA metabolism was identified by the use of 
knockout animals.  Animals lacking endogenous expression of PPARδ often die during 
embryogenesis, and those that do survive tend to present decreased fat mass (7, 155).  
Muoio et al. (152) performed the first known study documenting the function of PPARδ.  
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Their research showed evidence for what appeared to be compensatory regulation of 
lipid metabolism by PPARδ in skeletal muscle of PPARα knockout mice.  Since this 
study it has become generally accepted that the primary isoform of skeletal muscle is 
PPARδ.  With the use of synthetic agonists it was discovered that PPARδ increases FAO 
in both human and rodent myocytes (129, 139, 170).   
With respect to its function in lipid metabolism, PPARδ activation in genetically 
obese mice enhances skeletal muscle β-oxidation and protects against diet-induced 
obesity (202, 219).  Wang et al. (220) demonstrated the importance of PPARδ on 
oxidative phosphorylation by showing that transgenic mice over-expressing skeletal 
muscle PPARδ display a switch in muscle fiber type to favor type I (slow-oxidative) 
muscle fibers.   PPARδ transgenic mice only gained a third as much weight after 
prolonged high fat feeding compared to wild type (220).  PPARδ over-expression, 
independent of exercise, also facilitates an increase in muscle oxidative properties 
similar to that observed with endurance exercise training (199).  Therefore, PPARδ is 
best known for regulating transcription of genes involved in FA transport, β-oxidation, 
and mitochondrial respiration (119).   
Lipid and lipoprotein metabolism.  Fatty acid transport inside of the cell is 
modulated by PPARδ through enhanced transcription of several key genes.  With 
activation of PPARδ, LPL expression is increased, resulting in greater breakdown of 
VLDL cholesterol yielding NEFAs.  This prepares the FAs for transport into the cell 
where FATP and FAT/CD36 are upregulated resulting in the accumulation of 
intracellular NEFA (192, 199).  The trapping of the FA into the cell is then modulated by 
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increased expression of ACS.  PPARδ upregulates the expression of CPT-I enhancing 
FA transport into the mitochondria.  Within the mitochondria, PPARδ enhances the 
expression of genes for several enzymes involved in β-oxidation including long-chain 
acyl CoA dehydrogenase, and acetyl-CoA acyl transferase 2.  This yields enhanced 
catabolism of FAs to acetyl-CoA for use in the TCA cycle (199).  See Figure 4 for 
influence of PPARδ on intracellular lipid metabolism. 
The seminal study to show an effect of PPARδ activation on blood lipids and 
lipoproteins was conducted by Oliver, et al. (160).  They observed that treating obese 
rhesus monkeys with the PPARδ agonist GW501516 resulted in decreased TAG, LDL-C 
and LDL particle number, and increased HDL-C concentration (160).  In fact, genetic 
studies have linked PPARδ to cholesterol metabolism and transport in man (93, 182).  
Unfortunately, studies in humans using PPARδ agonists are currently few and restricted 
to hospitalization protocols.  A bedrest study in humans has demonstrated that subjects 
receiving a PPARδ agonist maintained HDL-C concentration while those on placebo 
displayed reduced HDL-C.  In addition, although not significant (P = 0.08), subjects 
receiving the PPARδ agonist showed decreased TAG (192).  In moderately obese men, 
treatment with the PPARδ agonist reduces TAG, LDL-C and insulin, with a concomitant 
increase in expression of skeletal muscle CPT-I (170).   
Treatment with pharmacological PPARδ agonists has been shown to promote reverse 
cholesterol transport (159, 211), an effect attributed to PPARδ dependent enhanced 
expression of ABCA1.  This suggests that the role of PPARδ goes beyond that of 
increasing the cell‘s use of FA for an energy source, and indicates a major role for 
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PPARδ in lipoprotein metabolism.  In fact, the findings of Oliver, et al. (160) compare 
favorably to the changes in blood lipids and lipoproteins seen with aerobic exercise (41, 
81, 223).   
Integrative metabolism.  In addition to influencing lipid and lipoprotein transport and 
metabolism, PPARδ affects genes inhibiting glucose metabolism.  By upregulating the 
expression of pyruvate dehydrogenase kinase 4 (PDK4), PPARδ is able to indirectly 
inhibit pyruvate dehydrogenase (Figure 4) (202).  This prevents the conversion of 
pyruvate to acetyl-CoA, creating an abundance of pyruvate, and inhibiting  
 
 
 
 
glycolysis by product inhibition.  This mechanism ultimately results in sparing glucose 
stores.  However, though no effect is seen on lactate concentrations at rest, PPARδ 
agonists given at high doses (100 mg·kg
-1
 body mass) resulted in significant 
Figure 4: PPARδ and fatty acid oxidation in skeletal muscle.  Skeletal muscle expressed proteins 
which are transcriptional targets of PPARδ.  FATP, Fatty Acid Transport Protein; FAT/CD36, Fatty 
Acid Translocase; LDL-R, LDL-Receptor; HSL, Hormone Sensitive Lipase; ACS, Acyl CoA 
Synthase; CPT-I, Carnitine Palmitoyl Transferase; PDK4, Pyruvate Dehydrogenase Kinase; 
UCP2,3, Uncoupling Proteins 2 and 3. 
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accumulation of muscle lactate (35-36).  By an apparent contrast, Burkart et al. (23) have 
reported increased mRNA content of GLUT4 and PFK in mouse cardiomyocytes in 
cardiac-specific PPARδ transgenic mice, which corresponded with increased glucose 
oxidation and glycogen stores in this tissue.  Kramer et al. (123) demonstrated enhanced 
glucose uptake following treatment with GW501516 and insulin compared to an equal 
treatment of insulin alone.  This effect occurred despite no effect on GLUT4 mRNA 
content; however, content and phosphorylation of p38 MAPK, AMPK, and ERK1/2 
MAPK were enhanced in GW501516 treated cells (123).  These findings further 
illustrate the importance of PPARδ in glucose uptake by the cell. 
PPARδ also shows a potential effect on insulin sensitivity, similar to that seen with 
PPARα.  Lee et al. (128) have reported improved insulin sensitivity following treatment 
with GW501516 in db/db mice (a model for type II diabetes).  Tanaka et al. (202) 
reported similar findings in dietarily induced obese mice, with glucose tolerance and 
insulin sensitivity enhanced by treatment with GW501516.  However, studies using both 
rat and human myocyte cultures have shown no effect of PPARδ on insulin sensitivity 
(47, 51, 205).  Therefore, the role of PPARδ with regards to insulin sensitivity is not 
fully understood. 
PGC-1α.   
The actions of PPARs are heavily reliant upon PPARγ coactivator-1α (PGC-1α).  
Though first identified for its role in the coactivation of PPARγ (167), PGC-1α serves as 
a coactivator for all PPARs and a variety of other nuclear factors including nuclear 
respiratory factors 1 and 2 (NRF-1, and NRF-2) (151, 166).  Through the coactivation of 
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various transcription factors, PGC-1α serves to regulate several biological functions 
including mitochondrial proliferation, fatty acid catabolism, angiogenesis, fiber type 
shifts, and antioxidant defense (134).  The most well known of these functions of PGC-
1α is to serve as a ‖master regulator‖ of mitochondrial biogenesis (147).  Perhaps due to 
its role in mitochondrial biogenesis, PGC-1α is believed to be tightly coupled with FAO; 
however, Holloway et al. (97) observed that though this is true in lean women, FAO 
appears uncoupled from PGC-1α expression in obese women.  These data suggest a 
disconnect between PGC-1α and its normal functions with obesity. 
PGC-1α may itself be a suitable target for treatment of metabolic diseases, especially 
type II diabetes, as PGC-1α has been linked to insulin sensitivity (147).  However, the 
precise role of PGC-1α in insulin resistance remains controversial.  Similar to findings 
linking PPARs -α and -δ to insulin sensitivity, attempts to link PGC-1α have produced 
mixed results.  Studies have shown reduced PGC-1α mRNA content in human diabetics, 
suggesting a potential role in insulin resistance (188).  At least one specific 
polymorphism of the PGC-1α gene, Gly482Ser, has been directly linked to reduced 
insulin sensitivity (62, 90).  Such single nucleotide polymorphisms of PGC-1α are 
prevalent in obese and diabetic individuals (62, 90).  Interestingly, transgenic mice 
overexpressing PGC-1α are insulin resistant (150), while PGC-1α-null mice show 
improved glucose tolerance and insulin sensitivity (133).  Targeted skeletal muscle-
specific overexpression of PGC-1α has been seen to induce muscle specific insulin 
resistance (31).  Animals with whole body overexpression of PGC-1α show hepatic 
insulin resistance.  However, contrary to findings with muscle specific overexpression, 
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these animals show enhanced muscle insulin sensitivity.  Thus the role of PGC-1α in 
insulin sensitivity is unquestioned, but the nature of that role is complex and may vary 
based on the tissue studied. 
PGC-1α activation is largely regulated by phosphorylation.  Two primary proteins 
involved in the activation of PGC-1α by phosphorylation are AMPK (104) and p38γ 
MAPK (1, 164) (Figure 5).  At least two AMPK phosphorylation sites have been 
identified on PGC-1α (137).  Work by Irrcher and Hood (101) shows that AMPK not 
only activates PGC-1α, but appears necessary for the transcription of PGC-1α itself.  
Therefore, AMPK may control PGC-1α both as a regulator of PGC-1α content and 
activity.  Akimoto et al. (1) first demonstrated the importance of p38 MAPK in the 
activation of PGC-1α.  They further showed the importance of p38 MAPK activation in 
the exercise-induced increase in PGC-1α expression.  This group has since demonstrated 
that this activity of p38 MAPK is specific to the -γ isoform (164), proposing that the -α 
and -β isoforms of p38 MAPK are primarily involved in autophagy (148). 
AMP-activated protein kinase.   
The importance of AMPK in the stimulation of PPAR and PGC-1α should be 
acknowledged.  Kramer et al. (122) have shown that PPARδ-stimulated increases in 
FAO are abolished when AMPKα has been silenced.  Further evidence also shows that 
phosphorylation of AMPKα is a potent stimulator of PGC-1α transcription (101).  
AMPK has been referred to as a ―master metabolic switch,‖ which is not only necessary 
for the immediate regulation of energy metabolism, but aids in the induction of exercise 
training adaptations.  To examine the influence of AMPK the structure of this protein 
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must be considered.  AMPK is a heterotrimer with subunits -α, -β, and -γ; of these the -α 
subunit is the catalytic and primary subunit (154).  Primary means of activation of 
AMPK include an increase in AMP: ATP and creatine: phosphocreatine ratios, 
phosphorylation at Thr172 of the -α subunit, and allosteric modification (154).   
AMPK is most known for its ability to stimulate ATP production pathways under 
conditions of energy depletion, however, AMPK is also capable of regulating long-term 
adaptive responses (154).  For example, AMPK can induce expression of GLUT4 and 
mitochondrial genes, actions that may work through PGC-1α (137), and appears 
important in exercise training-mediated muscle fiber type shifts (172).  AMPK is further 
capable of regulating FAO by influencing FA transport at the cell membrane, within the 
cytosol and at the mitochondrial membrane, and mediating content and activity of 
mitochondrial enzymes (208).  To mediate these effects, AMPK has been demonstrated 
to induce enhanced content of FAT/CD36 at the cellular and mitochondrial membranes 
Figure 5: Activation of PPARδ, AMPK and PGC-1α with exercise and downstream effects. 
AMPK, AMP-activated protein kinase; p38 MAPK, p38 mitogen-activated protein kinase; 
NEFA, nonesterified fatty acids; FA, fatty acids; LKB1, serine/threonine kinase 11; CAMKK, 
calcium/calmodulin dependent protein kinase kinase.  
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(208), an effect also ascribed to PPARδ (151).  Considering that PPARδ stimulated 
increases in FAO are not seen when AMPK is silenced, AMPK likely serves to direct the 
activity of PPARδ (122), even though a direct action of AMPK on PPARδ remains only 
postulated.  
PPAR and Exercise   
Exercise mediated activation of PPAR.   
Exercise mediated mechanisms for activation of PPARs -α and -δ, PGC-1α, and 
AMPK can be seen in Figure 5.  As previously stated, the major natural ligands for 
PPARs are FA and their derivatives (8).  Both fasting and exercise states create an 
increase in serum FA concentration and FA uptake (81, 217).  Furthermore, endurance 
exercise trained individuals display greater concentrations of intramuscular fat than 
untrained individuals (77).  Therefore, an increase in FA availability created by exercise 
and exercise training provides ligand for PPAR, potentially increasing activity and 
signaling the need for an increase in PPAR expression.   
Also, as mentioned, PPARs are phosphoproteins which can be acted upon by 
multiple kinases (24, 52).  Among those kinases several have been shown to be activated 
by exercise including: ERK-MAPK, p38 MAPK, JNK-MAPK, and AMPK (16, 79, 
174), creating a second mechanism for exercise based stimulation of PPAR. Increased 
PPAR activity may then mediate enhanced expression of genes involved in lipid and 
lipoprotein metabolism, yielding enhanced FAO, glucose sparing, mitochondrial 
biogenesis, and improved cholesterol metabolism and transport.  Although this 
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dissertation does not test ligand binding or phosphorylation of PPAR, these processes 
provide a link by which exercise may stimulate enhanced PPAR expression and activity.   
PPAR and acute exercise.   
To the author‘s knowledge, two previous studies have examined the effect of acute 
endurance exercise on PPAR mRNA content in humans.  Mahoney et al. (142) and Watt 
et al. (221) have each previously considered the effect of an acute bout of fatiguing cycle 
exercise on PPAR mRNA expression in humans.  In both studies, PPARs -α and -δ 
exhibited increased mRNA expression at 3 h post exercise.  Mahoney et al. (20) further 
demonstrated that at 48 h post exercise, mRNA levels had returned to baseline values.  
Watt et al. (221) also demonstrated enhanced PGC-1α mRNA and protein content 3 h 
post exercise.   
PPAR and exercise training.   
Several studies have investigated the effect of exercise training on the expression of 
PPARs -α and -δ.  In 2000, Horowitz et al. (98) published one of the first studies 
evaluating the role of PPARα in the metabolic adaptations to exercise training.  Their 
findings indicated an increase in PPARα content in the muscle, along with enhanced 
muscular oxidative capacity after exercise training.  Kannisto et al. (109) revealed a 
differential response of the PPARs to exercise training.  Their study demonstrated the 
greatest increase in expression of either PPAR isoform, compared to sedentary control 
condition, was with high fat feeding, but PPARδ expression was increased with exercise 
training regardless of diet.  In addition, the exercise training effect on PPARδ was 
accompanied by a decrease in intramuscular fat content.  Fritz et al. (24) explored the 
41 
 
 
effect of a low-intensity 4 month endurance exercise program on PPARδ in type 2 
diabetics, and showed a significant increase in PPARδ protein expression and a tendency 
toward an increase in PPARδ mRNA expression.  In contrast, following six weeks of 
endurance training, Russell et al. (175) measured elevated skeletal muscle mRNA 
content of PPARα and PGC-1α, with no change in PPARδ mRNA content.   
PGC-1α and exercise.   
In contrast with PPARδ, a relative wealth of data has been published to document the 
effect of exercise and exercise training on PGC-1α expression.  From that work, a 
relative consensus exists that PGC-1α mRNA and protein expression are enhanced with 
both acute exercise and exercise training (4, 71, 146, 172).  Sriwijitkamol, et al. (194) 
have previously shown that seven weeks of exercise training induced greater PGC-1α 
protein expression in obese Zucker rats.  Given a potential uncoupling of PGC-1α from 
FAO in the obese (97) it is of extreme interest to understand how exercise in the obese 
affects the relationship of PGC-1α to responses such as enhanced FAO and 
mitochondrial proliferation.  In addition to aerobic exercise effects, Deldicque et al. (48) 
showed that a single bout of RE yields an increase in PGC-1α mRNA content 
immediately post-exercise.  However, the effects of acute exercise and exercise training 
on PPARδ and PGC-1α have not previously been compared and contrasted (Chapter III 
of this dissertation).  
AMPK and exercise.   
The response of AMPK to exercise must be considered on both the acute exercise 
and exercise training levels.  The influence of acute exercise on AMPK appears to be 
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driven primarily by an increase in activity, as measured by phosphorylation at Thr172, 
seen immediately post-exercise, which returns to baseline by 2 h following exercise 
(131).  Interestingly, an attenuation of AMPK phosphorylation at Thr172 has been 
observed following moderate intensity exercise in obese and type 2 diabetic humans 
compared to lean controls (193).     
Exercise training is associated with an increase in expression of AMPKα.  As 
previously stated, AMPK protein can be divided into several subunits; these subunits 
may be differentially affected by exercise training.  Exercise trained individuals have 
been shown to express greater content of AMPKα1 but similar expression of the other 
AMPK subunits as compared to sedentary individuals (158).  Sriwijitkamol et al. (194) 
have shown an increase in AMPKα1 with exercise training in the obese Zucker rat, 
which is consistent with exercise training in humans (34).  In contrast, Leick et al. (131) 
demonstrate no influence of either acute exercise or exercise training on AMPKα protein 
content in PGC-1α knockout mice. 
Summary 
In summary, obesity is associated with increased rates of mortality and CVD 
concurrent with potentially severe metabolic perturbations.  Among the risks involved in 
obesity is dyslipidemia, characterized by elevated blood concentrations of TC, LDL-C, 
and TAG and reduced HDL-C concentrations.  Properly prescribed exercise can be a 
powerful therapeutic tool to combat such dyslipidemia; however, little is currently 
known about the mechanism by which this occurs.  The PPARs are a family of proteins 
which mediate adaptive responses congruent with those seen with exercise training and 
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appear to mediate changes in blood lipids and lipoproteins consistent with reduced 
atherogenic risk.  These studies were conducted to evaluate the efficacy of acute exercise 
and exercise training to elicit changes in blood lipids and lipoproteins consistent with 
reduced atherogenic risk and to explore the possibility that such responses are mediated 
by PPAR. 
Aims of the Experiments 
The primary purpose of these investigations is to explore the influence of exercise 
on lipids and lipoproteins and the regulation of lipid metabolism in obesity.  These 
studies were designed to explore the response of blood lipids and lipoproteins to acute 
exercise (Chapters II and IV) and exercise training (Chapter II), the influence of obesity 
(Chapter IV) and exercise (Chapters III and IV) on the regulation of lipid metabolism in 
skeletal muscle, and how skeletal muscle PPAR relates to blood lipid and lipoprotein 
concentrations (Chapters III and IV).  Therefore, this dissertation addresses the 
following aims: 
 
Specific Aim 1 (Chapter II).  Determine the response of traditional and nontraditional 
CHD risk markers in previously untrained, overweight and obese men and women to 
acute exercise and exercise training before and after exercise training implementing 
ATM or LTM exercise.   
 
Specific Aim 2 (Chapter III).  Determine if PPAR expression is altered following acute 
exercise and exercise training and if PPAR expression is associated with increases in 
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expression of PPAR target proteins including those of lipid metabolism and markers of 
mitochondrial growth, and blood lipids and lipoproteins in previously untrained 
overweight and obese men and women.   
 
Specific Aim 3 (Chapter IV).  Determine if PPAR protein expression is altered following 
a short term, high volume resistance exercise protocol in lean compared to obese Zucker 
rats, and if PPAR expression is associated with expression of PPAR target proteins, 
including those involved in lipid metabolism and markers of mitochondrial growth, and 
blood lipids and lipoproteins.   
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CHAPTER II 
ACUTE EXERCISE AND AQUATIC TRAINING AFFECT BLOOD 
LIPID-LIPOPROTEIN CONCENTRATIONS, PARTICLE 
NUMBERS AND DENSITY, AND hsCRP IN OVERWEIGHT/OBESE 
MEN AND WOMEN 
 
Introduction 
Rates of obesity have steadily risen to epidemic proportions (27).  Obesity is 
associated with greater incidence of diabetes (213) and dyslipidemia (6), and is an 
established independent risk factor for cardiovascular disease (CVD) (156).  With regard 
to dyslipidemia, both acute exercise and exercise training have been demonstrated in 
other populations to elicit changes in blood lipid and lipoprotein concentrations 
consistent with reduced risk for CVD (40-43, 46, 58, 60, 80, 94).  Furthermore, few have 
reported the influence of an exercise intervention on lipoprotein particle numbers in any 
population, though LDL particle number is considered a strong indicator of CVD (39), 
and reduced HDL particle numbers may facilitate development of atherosclerosis (117).  
In addition, inflammatory markers such as high sensitivity C-reactive protein (hsCRP) 
are related to obesity (162), and are independent predictors of CVD (169).  Despite these 
findings, the response of blood lipid and lipoprotein concentrations and particle numbers 
to exercise and exercise training in the obese remains inadequately described.  
Additionally, few have compared and contrasted such responses between men and 
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women or described the influence of exercise training on the transient response to acute 
exercise. 
Exercise training has been reported to induce changes in blood lipids and 
lipoproteins, including reductions in total cholesterol (TC), LDL-cholesterol (LDL-C) 
and triacylglycerols (TAG), and increased HDL-cholesterol (HDL-C) (59).  Our 
laboratory (41) has reported decreased TC and HDL3-C, and increased HDL2-C 
concentrations in hypercholesterolemic men following 24 weeks of exercise training 
(1050 kcal·wk
-1
).  Conversely, our laboratory demonstrated no influence of exercise 
training of similar frequency and duration in women (80).  While increased HDL-C 
concentrations have been commonly reported in men, women often exhibit unchanged 
(136) or reduced HDL-C concentration following training (14).  Furthermore, the 
influence of exercise on lipoprotein particle numbers has rarely been reported, primarily 
demonstrating reduced LDL particle number with training (183).  In addition to the 
influence of exercise training on lipids and lipoproteins, cardiorespiratory fitness is 
inversely related to hsCRP (127).   
Although the influence of exercise training on blood lipids and lipoproteins has been 
reported in a relatively large number of studies, results vary considerably, and often 
there was no control for the transient effects of the most recent session of exercise.  
Therefore, the interpretation of these studies must be taken with caution as the transient 
effects of acute exercise reportedly include increased HDL-C and decreased LDL-C and 
TAG, which last up to 72 h following exercise (43, 65, 223).  However, the exercise 
duration required to elicit such transient changes varies with the population studied, 
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ranging from 350 kcal in hypercholesterolemic men (43) to 1100 kcal in endurance 
trained runners (65).  By contrast, our laboratory has failed to measure such changes in 
women following exercise of 350 kcal (165, 223).  Wooten et al. (234) explored the 
influence of a greater volume of exercise  (500 kcal) in premenopausal, sedentary 
women, observing reductions in TC and HDL-C.  Acute exercise has previously been 
reported to increase serum hsCRP 24 h after exercise (176).  Given the varied nature of 
lipid and lipoprotein responses to both acute exercise and exercise training, 
understanding how a given population will respond to these stimuli is imperative.  In 
addition, despite apparent differences in lipid and lipoprotein responses to exercise and 
exercise training, researchers have rarely compared and contrasted these responses in 
men and women in the same study.   
Although of practical importance, only one study has been published to date to 
compare acute exercise and training effects on blood lipids and lipoprotein-lipids (42).  
In that study, changes in lipids and lipoproteins consistent with reduced atherogenic risk 
were demonstrated after both acute exercise and exercise training in 
hypercholesterolemic men.  Interestingly, in the untrained state, acute exercise yielded 
an increase in LDL-C concentration which was no longer measured after 16 wks of 
training, suggesting that training may alter the acute response to exercise.  To our 
knowledge, no single study has been published to characterize the independent and 
interactive effects of acute exercise and exercise training in obese men and women.  
Such information would be of benefit to practitioners in designing appropriate exercise 
intervention strategies to reduce CVD risk. 
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Despite known therapeutic benefits of exercise for the obese, the effects of exercise 
on blood lipids and lipoproteins in this population are incompletely described.  The bulk 
of published studies have used interventions designed to induce weight loss either by 
diet or by combination of diet and exercise (61, 180, 212, 232).  However, weight loss 
may not be necessary to elicit the therapeutic benefits of exercise in the obese (33, 126).  
Studies examining the effects of exercise training alone on lipids and lipoproteins in the 
obese have often focused solely on men and included blood sampling within 24 h of the 
cessation of exercise training (157, 228).  As previously discussed, such timing of blood 
sampling may be confounded by the transient response to the last exercise session; 
therefore, the interpretation of these studies should be taken with caution.  Also, the 
influence of acute exercise has rarely been considered in this population.  Thus, while 
previous results appear promising, the blood lipid and lipoprotein responses to a single 
session of exercise and exercise training in overweight and obese individuals are not 
fully understood, particularly in women.   
In addition, we have previously demonstrated the efficacy of aquatic treadmill 
(ATM) exercise to increase aerobic fitness and reduce weight and body fat percentage in 
the obese (82).  In that previous report we further revealed the potential of ATM exercise 
to elicit enhanced lean body mass, providing a potential advantage to ATM training.  
However, the efficacy of ATM training to elicit reductions in cardiovascular risk has not 
yet been examined. 
The purpose of our present study was to test the hypothesis that both acute exercise 
and exercise training will elicit changes in blood lipid and lipoprotein concentration and 
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particle numbers consistent with reduced atherogenic risk in overweight and obese men 
and women.  We hypothesized that exercise training would not affect the acute response 
to exercise.  In addition, we report the efficacy of ATM training compared with 
traditional land treadmill (LTM) training to induce changes in blood lipids and 
lipoproteins.  Thus, our study sheds new light on the effects of exercise and exercise 
training on lipid and lipoprotein concentrations and particle numbers in overweight and 
obese men and women.   
Methods 
Physically inactive, overweight and obese men (n = 10) and women (n = 8) were 
recruited from the Texas A&M University and College Station, TX communities to 
participate in the study.  The mean (SEM) age of subjects was 41 ± 2 years and 52 ± 2 
years for men and women, respectively.  Subjects were part of a larger cohort whose 
physiologic adaptations to the exercise training paradigm have previously been reported 
(82).  Potential volunteers were recruited through informational flyers, email 
announcements, and by word of mouth.  Volunteers were screened to ensure that they 
had not participated in regular aerobic activity for the previous 3 months (physically 
inactive), and were classified as overweight or obese initially by BMI and subsequently 
by percent body fat as measured by dual-energy x-ray absorptiometry (DEXA, Lunar 
Prodigy, GE Healthcare, Madison, WI).  Subjects were stratified according to ACSM 
standards for risk of CVD, and those for whom it was required underwent a physical 
examination by a cardiologist before participation in the experiment (2).  Preliminary 
physiological characteristics of the 18 subjects are presented in Table 1.   
50 
 
 
Table 1: Physical characteristics, and physical activity and dietary information before and after training in 
all subjects, women, and men.   
 All Subjects (n = 18) Women (n = 8) Men (n = 10) 
 Pre-Tr Post-Tr Pre-Tr Post-Tr Pre-Tr Post-Tr 
Physical Characteristics 
Body Mass (kg) 101.50 ± 
5.47 
98.81 ± 
5.08* 
98.01 ± 
8.16 
94.53 ± 
7.58 
104.99 ± 
7.30 
103.09 ± 
6.76 
Body Mass Index 
(kg·m
-2
) 
31.94 ± 
1.41 
31.18 ± 
1.28* 
32.03 ± 
2.26 
30.94 ± 
2.06 
31.86 ± 
1.68 
31.42 ± 
1.54 
Body Fat % † 41.14 ± 
1.52 
39.94 ± 
1.60 
44.26 ± 
2.44 
43.96 ± 
2.57 
38.02 ± 
1.82 
35.92 ± 
1.91 
Lean Body Mass (kg) † 52.70 ± 
2.18 
51.87 ± 
2.08 
45.53 ± 
3.49 
44.49 ± 
3.34 
59.88 ± 
2.60 
52.26 ± 
2.49 
Fat Mass (kg) 36.91 ± 
3.15 
35.73 ± 
3.15 
36.82 ± 
5.05 
35.37 ± 
5.04 
36.99 ± 
3.77 
36.09 ± 
3.76 
VO2max (L•min
-1) † 2.49 ± 
0.08 
2.74 ± 
0.10* 
2.04 ± 
0.11 
2.27 ± 
0.15 
2.95 ± 
0.10 
3.22 ± 
0.12 
VO2max (mL•kg
-1•min-
1) † 
25.15 ± 
1.30 
28.82 ± 
1.44* 
21.97 ± 
1.94 
25.35 ± 
2.20 
28.33 ± 
1.73 
32.29 ± 
1.86 
       
Activity and Nutritional Intake 
Caloric Expenditure 
(kcal•day-1) † 
3005 ± 
133 
2971 ± 
98 
2595 ± 
213 
2582 ± 
160 
3414 ± 
159 
3360 ± 
119 
Caloric Intake (kcal•day-
1) † 
2362 ± 
167 
2137 ± 
221 
2019 ± 
267 
1780 ± 
355 
2705 ± 
199 
2495 ± 
265 
Carbohydrate (g•day-1) † 293 ± 21 261 ± 33 235 ± 
34 
207 ± 
53 
350 ± 26 316 ± 39 
Total Fat (g•day-1) 91.4 ± 
8.5 
87.4 ± 
10.6 
84.0 ± 
13.7 
79.2 ± 
17.0 
98.9 ± 
10.2 
95.6 ± 
12.7 
Monounsaturated Fat 
(g•day-1) 
19.2 ± 
2.8 
17.6 ± 
3.5 
13.0 ± 
4.5 
17.6 ± 
5.6 
25.3 ± 
3.3 
17.7 ± 
4.2 
Polyunsaturated Fat 
(g•day-1) 
8.0 ± 1.1 10.1 ± 
2.6 
5.8 ± 
1.7 
11.0 ± 
4.1 
10.1 ± 
1.3 
9.2 ± 3.1 
Saturated Fat (g•day-1) 31.9 ± 
2.8 
27.9 ± 
3.1 
29.8 ± 
4.5 
27.0 ± 
4.9 
34.0 ± 
3.3 
28.8 ± 
3.7 
Protein (g) 91.6 ± 
8.0 
76.1 ± 
7.4 
81.0 ± 
12.8 
67.8 ± 
11.9 
102.1 ± 
9.5 
84.4 ± 
8.9 
*P<0.05 significant main effect of exercise training.  †P<0.05 significant main effect of gender.  Data are 
means collapsed across mode of exercise training factor; error, SEM. 
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General protocol 
All methods and procedures were approved by the Texas A&M University 
Institutional Review Board for Human Subjects in Research.  On the first visit to the 
laboratory, subjects were informed of the study procedures and read and signed an 
institutionally approved informed consent.  At this time, instructions were provided for 
completing physical activity and diet records.  Physiological and demographic 
assessments were completed on the second visit to the laboratory (methods to follow).  
The following week, the first of two acute exercise sessions was performed on a standard 
motor-driven land treadmill (methods to follow).  Fasting blood samples were obtained 
immediately prior to exercise and repeated 24 h following exercise.  Within two weeks 
of physiological testing, subjects were matched for age, gender, and BMI, and then 
randomly assigned to 12-weeks of either LTM or ATM training (methods to follow). All 
physiological and demographic testing procedures were repeated 72-96 h after the final 
exercise training session.  The acute exercise session was repeated approximately 7 days 
following post-training physiologic assessments, and blood sampling was again 
performed immediately prior to and 24 h following exercise. 
Diet and activity logs 
To study subjects in a free-living state, no attempt was made to modify diet or 
physical activity outside of the exercise training protocol.  To this end, subjects were 
instructed to maintain their accustomed dietary and physical activity habits throughout 
the course of the study.  To verify compliance with these instructions, dietary and 
activity habits were assessed on two occasions coinciding with the beginning and end of 
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exercise training.  Subjects were instructed to complete dietary and physical activity 
records on days which would best represent their normal daily habits.  On both occasions 
dietary logs were recorded for 3 consecutive days, including 1 weekend day.  The 3-day 
dietary records were analyzed for total caloric intake and for carbohydrate, fat, and 
protein composition using commercially available computer software (Food Processor
®
 
8.4, ESHA Research, Salem, OR).  The physical activity records used were an 
adaptation of a previously described protocol for physical activity recall (12).  Activity 
records were recorded for seven consecutive days and were analyzed for total energy 
expenditure.  In addition, upon completion of the study all subjects were required to read 
and sign dietary and activity compliance forms. 
Physiological assessments 
These procedures have been previously published (82).  In brief, body composition, 
including whole body percent fat, fat mass and lean body mass, were assessed using 
DEXA.  An incremental maximal graded exercise test (GXT) was conducted on a motor-
driven treadmill according to the Bruce protocol (21).  Oxygen consumption during 
exercise was assessed using an automated metabolic gas-analysis system (CPX/D 
Exercise Stress Testing System, Medical Graphics, Minneapolis, MN or Oxycon Pro, 
Erich JAEGER, Hoechberg, Germany) calibrated with gasses of known concentration 
before and after each exercise test.  VO2max was taken as the highest 15 s average 
oxygen uptake achieved during the exercise test.  Heart rate (HR) and rhythm were 
monitored continuously from
 
a 12-lead electrocardiogram.  Ratings of perceived exertion 
(RPE) using a Borg 15-point scale ranging from 6-20 (17) and
 
manual blood pressures 
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(BP) were obtained during the last 30 s of
 
each treadmill stage and at maximal exercise.  
At least two of the following criteria were required for the maximal exercise test to be 
considered valid: 1) achievement of maximum heart rate within 10 bpm of the age-
predicted maximum; 2) rating of perceived exertion ≥ 18; 3) respiratory exchange ratio 
>1.1 at maximal exertion; or 4) O2 uptake plateau despite further increases in workload.  
The same skilled laboratory personnel consistently performed all physiological 
measurements.    
Acute exercise sessions 
All non-study exercise was prohibited for 72 h prior to the experimental acute 
exercise sessions.  The experimental acute exercise sessions were performed on a 
motorized land treadmill approximately seven days after completion of maximal 
exercise testing at pre- and post-training timepoints.  The exercise protocol began with a 
3 min warm-up period at 53.6 m·min
-1
 at a 0% grade.  The duration of each acute 
exercise session was defined as the time required to expend 400 kcal at an intensity of 
70% of VO2max, based on the most recently acquired VO2max.  The necessary duration 
was estimated by dividing 400 kcal by the rate of energy expenditure at the required 
exercise intensity based on the respiratory exchange ratio energy-oxygen equivalent 
(kcal·LO2
-1
).  Initial treadmill velocity and grade were estimated using published 
metabolic equations for LTM exercise (2).  Heart rate, RPE and VO2 were measured 
every 5 min at the beginning of exercise to adjust treadmill velocity and grade until the 
required VO2 was achieved; thereafter VO2 measurements were taken every 10 min until 
the cessation of exercise, and minor adjustments were made as necessary to the treadmill 
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velocity and grade to maintain the required VO2, as well as, exercise time to ensure the 
expenditure of 400 kcal.  Subjects were asked to avoid any physical exertion outside of 
that required by their work until after all blood collection procedures were completed. 
Exercise training 
The exercise prescription and training progression for this study have previously 
been reported (82).  ATM training was conducted using a HydroWorx 1000 series 
treadmill  (HydroWorx International, Inc., Middletown, PA) as previously described 
(82).  LTM training was conducted on a standard motor-driven treadmill.  Subjects 
exercised three times per week for a 12-week period.  Training sessions were performed 
by all subjects at an equivalent caloric expenditure and relative intensity progressively 
increased from 250 kcal·session
-1
, 60% VO2max during the first week to 500 
kcal·session
-1
, 85% VO2max during weeks 6-12.  The prescribed exercise progression 
was such that by week 6 subjects expended approximately 1500 kcal·wk
-1
 in exercise 
training.  Exercise duration and intensity were calculated as described above for acute 
exercise sessions.  For ATM training treadmill velocity and jet resistance were estimated 
using a previously developed metabolic equation for ATM (Greene et al., manuscript 
accepted for publication in Research Quarterly for Exercise and Sport).  Treadmill 
velocity and grade/jet resistance were adjusted as necessary during the training session 
to attain the HR and RPE which matched the prescribed intensity.  Each individual‘s 
exercise prescription was adjusted for increases in VO2max during week 6 such that the 
prescribed intensity and duration were maintained throughout the study.   
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Blood sampling 
Blood samples were obtained on four occasions.  Before training, blood sample one 
was obtained with the subject at rest immediately preceding the acute exercise session 
and a second resting blood sample was drawn 24 h after a single aerobic exercise 
session.  After training, blood samples three and four were obtained before and after an 
acute exercise session in an identical manner to the pre-training procedures.  Resting 
samples were taken following at least 72 h without strenuous physical activity.  For all 
blood sampling, each subject reported to the laboratory, time of day controlled, after a 12 
h fast (water allowed ad libitum).  Prior to each blood draw, the subjects completed a 
form reporting their physical activity (previous 72 h) and dietary (previous 24 h) 
adherence, and the time of their last meal.  Blood samples were drawn without stasis 
from an antecubital vein with the subject seated at quiet rest into vacutainer tubes 
containing 10.5 mg Na-EDTA for plasma collection and a serum clotting factor (Becton 
Dickinson and Company, Rutherford, NJ) for serum collection.  All blood sampling was 
performed by trained and experienced personnel according to well-accepted, sterile 
protocols.  Serum and plasma were immediately isolated by centrifugation at 1500 x g 
for 30 minutes at 4°C.  Aliquots of serum were stored at -80°C for later analysis.  All 
blood variables (not including HDL and LDL mean densities) were adjusted for plasma 
volume shifts that occurred as a result of acute exercise using hematocrit and 
hemoglobin measurements obtained from each plasma sample (50).   
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Blood analysis 
Frozen aliquots of serum were sent to SpectraCell Laboratories, Inc (Houston, TX) 
for complete LDL density and lipoprotein particle number analyses.  A complete 
―Lipoprotein Particle Profile™‖ test was performed using the lipoprotein subgroup 
particle number analysis method.  The lipoprotein particle separation utilized a patent 
pending (209) continuous gradient generated by analytical ultracentrifugation. The 
lipoprotein particles were stained on their surface with a fluorescent dye and then 
separated in the gradient over a range of d = 1.000 - 1.300 g·cm
-3
.  After separation, the 
contents of the centrifuge tube were extracted and the fluorescence of the lipoprotein 
particles was measured in an HPLC-type flow system.  For processing, the fluorescence 
response was normalized to a cholesterol scale with a proprietary algorithm.  Values for 
each lipoprotein subgroup at their specific densities were determined using a multiple 
Gaussian fit/integration routine (209).  The total number of VLDL (VLDL#), LDL 
(LDL#), remnant lipoprotein (RLP#), dense low-density lipoprotein3 (LDL3#), dense 
low-density lipoprotein4 (LDL4#), HDL (HDL#) and buoyant high-density lipoprotein2b 
(HDL2b#) particles were determined in addition to the lipoprotein density.  The 
coefficient of variation for this analysis using known standards has been reported as 2-
3%.  Analysis of serum nonesterified fatty acids (NEFA) was performed colorimetrically 
using a commercially available kit (Wako Diagnostics, Richmond, Va).   
Statistical analysis 
An acute exercise (Rest and + 24 h) by exercise training (pre-tr vs. post-tr) by 
exercise mode (ATM vs. LTM) by gender (men vs. women) ANOVA repeated across 
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acute exercise and exercise training was employed as the global analysis for each 
dependent variable of interest, except for VO2max, body composition, diet and activity 
measures, in which case the acute exercise factor was not included.  Dependent variables 
of interest included VO2max , body composition, body weight, serum lipid and 
lipoprotein concentrations including TC, TAG, HDL-C, HDL2b-C, HDL2a-C, HDL3-C, 
LDL-C, LDL3-C, LDL4-C, RLP, intermediate density lipoprotein (IDL-C), VLDL-C, 
lipoprotein (a) (Lp(a)), and NEFA, serum lipoprotein particle numbers for HDL#, 
HDL2b#, LDL#, LDL3#, LDL4#, and RLP, TC: HDL-C ratio and mean densities of HDL 
and LDL, and blood concentrations of glucose, insulin and hsCRP.  Mode of aerobic 
exercise training did not significantly affect the exercise response for any of the 
variables of interest in either gender (P>0.05); therefore, we elected to remove this factor 
for all subsequent analyses. The comparison-wise error rate, α, was set at 0.05 for all 
statistical tests.  When significant F ratios were found, a Fisher‘s LSD post hoc analysis 
was used to distinguish differences among means.  All data were analyzed using the 
Statistical Analysis System (SAS, version 9.2, Cary, NC) and expressed as mean ± SEM. 
Results 
Physical characteristics and nutritional intake before and after training.   
Physiologic characteristics of these subjects have been previously reported as part of 
a larger cohort (82).  For the subset of subjects included in this current study, body 
weight (-2.7 kg) and BMI (-0.8 kg·m
-2
) were significantly reduced following exercise 
training, and VO2max (+3.7 mL·kg
-1
·min
-1
) was significantly increased (Table 1).  No 
other body composition variables tested were significantly affected by exercise training 
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(Table 1).  Body fat %, lean body mass, VO2max, caloric expenditure, caloric intake, 
and carbohydrate intake were all different between men and women (Table 1).  No 
dietary or non-study physical activity changes were observed throughout the study 
(Table 1).   
Exercise training does not affect the lipid and lipoprotein response to acute exercise in 
overweight and obese men and women.  
Exercise training did not influence the acute exercise response at + 24 hr of any 
measured blood lipid and lipoprotein variables.  Lipid and lipoprotein concentrations at 
rest and + 24 h after a single session of aerobic exercise before and after exercise 
training are shown in Table 2, corresponding lipoprotein particle numbers and mean 
densities are reported in Table 3.   
Exercise training increases HDL-C in overweight and obese men and induces a shift in 
HDL-C subfractions in women.   
HDL-C concentration and particle number were significantly lower in men compared 
to women (-15 mg·dL
-1
 at baseline), but exercise training significantly enhanced HDL-C 
concentration (+4 mg·dL
-1
) and HDL particle number (+588 nmol·L
-1
) in men only 
(Figure 6A and B).  Although mean HDL-C concentration was increased in women 
following exercise training (+2 mg·dL
-1
) this change was not significant.  The HDL2b-C 
concentration (+2.4 mg·dL
-1
) and particle number (+206 nmol·L
-1
) were enhanced by 
exercise training in both men and women (Figure 6C and D).  In addition, despite 
already greater HDL2a-C concentrations in women compared to men (+2.7 mg·dL
-1
), 
exercise training enhanced HDL2a-C concentrations (+2.2 mg·dL
-1
) in women only 
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(Figure 7A).  This finding was paralleled by reductions in HDL3-C (-2.7 mg·dL
-1
) and 
HDL mean density (-0.0041 g·cm
-2
) in women following exercise training (Figure 7B 
and C).  Conversely, HDL3-C was significantly increased in men (+1.4 mg·dL
-1
) 
following exercise training (Figure 7B).  We also found that LDL3-C concentration (-1.6 
mg·dL
-1
) and particle number (-16 nmol·L
-1
) were significantly reduced in women 
following exercise training, but not in men.  This reduction led to significantly lower 
LDL3-C concentration (-5.5 mg·dL
-1
) and particle number (-53 nmol·L
-1
) in women 
compared to men following exercise training (Figure 8).  In addition to these effects on 
serum lipoprotein-cholesterol concentrations, exercise training proved equally 
efficacious at reducing serum NEFA concentrations (-0.26 umol·L
-1
) in overweight and 
obese men and women (Figure 9A).  Exercise training did not affect serum 
concentrations of TC, TAG, LDL-C, LDL4-C, IDL-C, RLP, VLDL-C, glucose, insulin, 
hsCRP and Lp(a), or corresponding lipoprotein particle numbers,  densities, and ratios 
(e.g., the TC: HDL-C ratio) (Tables 2 and 3).  
  
60 
 
 
Table 2:  Lipid and lipoprotein concentrations in overweight and obese men and women. 
 All Subjects (n = 18) Women (n = 8) Men (n = 10) 
 Pre-Training Post-
Training 
Pre-Training Post-
Training 
Pre-Training Post-
Training 
 Rest + 24 
h 
Rest + 24 
h 
Rest + 24 
h 
Rest + 24 
h 
Rest + 24 
h 
Rest + 24 
h 
TC 190 
± 11 
186 
± 10 
186 
± 9 
182 
± 8 
201 
± 10 
201 
± 9 
201 
± 12 
204 
± 10 
180 
± 20 
172 
± 16 
173 
± 9 
168 
± 9 
TAG 93 ± 
11 
96 ± 
12 
102 
± 12 
94 ± 
8 
82 ± 
10 
85 ± 
10 
108 
± 19 
97 ± 
12 
103 
± 18 
105 
± 22 
99 ± 
16 
92 ± 
11 
LDL-C 120 
± 9 
116 
± 7 
112 
± 7 
114 
± 9 
126 
± 8 
126 
± 8 
124 
± 11 
135 
± 14 
115 
± 15 
107 
± 12 
105 
± 9 
101 
± 10 
LDL3-C 20 ± 
2 
20 ± 
2 
19 ± 
2 
19 ± 
3 
17 ± 
2 
17 ± 
2 
16 ±  
1 
16 ± 
1 
22 ± 
4 
21 
±4 
21 ± 
4 
22 ± 
4 
LDL4-C 7.1 ± 
0.7 
6.7 ± 
0.5 
6.7 ± 
0.5 
6.8 ± 
0.7 
6.4 ± 
0.5 
6.3 ± 
0.5 
6.2 ± 
0.4 
6.2 ± 
0.5 
7.8 ± 
1.2 
7.0 ± 
0.9 
7.0 ± 
0.8 
7.2 ± 
1.0 
IDL-C† 29 ± 
3 
28 ± 
3 
27 ± 
3 
27 ± 
3 
32 ± 
5 
32 ± 
4 
36 ± 
7 
35 ± 
6 
26 ±  
4 
24 ± 
4 
22 ± 
2 
22 ± 
2 
RLP 33 ± 
4 
32 ± 
3 
32 ± 
3 
31 ± 
3 
36 ± 
5 
36 ± 
4 
40 ± 
7 
39 ± 
6 
30 ± 
5 
29 ± 
4 
26 ± 
2 
25 ± 
2 
VLDL-
C 
18 ± 
2 
18 ± 
3 
20 ± 
2 
18 ± 
2 
15 ± 
2 
16 ± 
2 
21 ± 
4 
19 ± 
3 
20 ± 
4 
21 ± 
4 
20 ± 
3 
18 ± 
2 
HDL-
C† 
52 ± 
3 
52 ± 
3 
54 ± 
3 
54 ± 
3 
60 ± 
3 
60 ± 
4 
62 ± 
5 
62 ± 
4 
45 ± 
3 
45 ± 
3 
49 ± 
4 
49 ± 
4 
HDL2b-
C† 
19 ± 
2 
20 ± 
2 
22 ± 
2 
22 ± 
2 
24 ± 
2 
24± 
3 
27 ± 
3 
28 ± 
3 
15 ± 
2 
16 ± 
2 
18 ± 
2  
18 ± 
2 
HDL2a-
C† 
7.1 ± 
0.6 
7.4 ± 
0.8 
8.0 ± 
1.1 
7.7 ± 
1.1 
8.8 ± 
0.8 
8.5 ± 
1.4 
11.0 
± 1.6 
10.7 
± 1.9 
5.6 ± 
0.6 
6.3 ± 
0.8 
6.1 ± 
0.9 
5.8 ± 
0.8 
HDL3-
C 
25 ± 
1 
25 ± 
1 
24 ± 
1 
24 ± 
1 
27 ± 
1 
27 ± 
1 
24 ± 
2 
23 ± 
1 
24 ± 
2 
23 ± 
1 
24 ± 
1 
25 ± 
1 
TC: 
HDL 
3.72 
± 
0.22 
3.65 
± 
0.20 
3.55 
± 
0.20 
3.46 
± 
0.19 
3.30 
± 
0.21 
3.38 
± 
0.22 
3.30 
± 
0.30 
3.31 
± 
0.31 
4.05 
± 
0.33 
3.87 
± 
0.31 
3.68 
± 
0.27 
3.54 
± 
0.25 
NEFA 0.60 
± 
0.05 
0.73 
± 
0.08 
0.40 
± 
0.03 
0.41 
± 
0.03 
0.51 
± 
0.06 
0.87 
± 
0.10 
0.36 
± 
0.05 
0.45 
± 
0.07 
0.69 
± 
0.07 
0.59 
± 
0.09 
0.42 
± 
0.04 
0.39 
± 
0.04 
Glucose 93 ± 
2 
93 ± 
2 
93 ± 
2 
95 ± 
2 
90 ± 
3 
93 ± 
2 
91 ± 
1 
90 ± 
2 
95 ± 
3 
93 ± 
3 
94 ± 
2 
98 ± 
3 
Insulin 13 ± 
2 
11 ± 
2 
11 ± 
2 
12 ± 
2 
11 ± 
3 
10 ± 
2 
11 ± 
2 
10 ± 
3 
15 ± 
2 
12 ± 
2 
14 ± 
3 
13 ± 
3 
hsCRP 0.22 
± 
0.04 
0.30 
± 
0.07 
0.20 
± 
0.06 
0.22 
v 
0.06 
0.18 
± 
0.06 
0.22 
± 
0.06 
0.10 
± 
0.02 
0.14 
± 
0.04 
0.25 
± 
0.06 
0.36 
± 
0.11 
0.25 
± 
0.08 
0.27 
± 
0.08 
Lp(a) 23 ± 
6 
22 ± 
5 
23 ± 
8 
23 ± 
8 
30 ± 
11 
27 ± 
10 
31 ± 
22 
31 ± 
22 
18 ± 
5 
18 ± 
5 
19 ± 
6 
19 ± 
7 
†P<0.05 significant main effect of gender.  All concentrations expressed as mg·dL-1 except for insulin 
(uIU·mL-1).  Data are means collapsed across mode of exercise training factor; error, SEM. 
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Table 3:  Lipid and lipoprotein particle numbers and densities in overweight and obese men and women. 
 All Subjects (n = 18) Women (n = 8) Men (n = 10) 
 Pre-Training Post-
Training 
Pre-Training Post-
Training 
Pre-Training Post-
Training 
 Rest + 24 
h 
Rest + 24 
h 
Rest + 24 
h 
Rest + 24 
h 
Rest + 24 
h 
Rest + 24 
h 
LDL#  822 
± 60 
793 
± 50 
769 
±46 
758 
± 50 
838 
± 47 
839 
± 49 
815 
± 60 
814 
± 52 
808 
± 
108 
751 
± 85 
739 
± 65 
723 
± 75 
LDL3#  189 
± 22 
185 
±  20 
178 
± 21 
185 
± 25 
164 
± 15 
166 
± 15 
149 
± 11 
149 
± 10 
210 
± 39 
203 
± 35 
197 
± 33 
207 
± 39 
LDL4#  87 ± 
8 
83 ± 
7 
81 ± 
6 
85 ± 
8 
78 ± 
5 
78 ± 
6 
76 ± 
5 
78 ± 
6 
95 ± 
15 
87 ± 
12 
84 ± 
9 
89 ± 
13 
LDL 
Densit
y† 
1.03
18 ± 
0.00
03 
1.03
20 ± 
0.00
03 
1.03
20 ± 
0.00
03 
1.03
20 ± 
0.00
04 
1.03
12 ± 
0.00
04 
1.03
13 ± 
0.00
03 
1.03
12 ± 
0.00
04 
1.03
12 ± 
0.00
04 
1.03
23 ± 
0.00
04 
1.03
24 ± 
0.00
04 
1.03
24 ± 
0.00
04 
1.03
26 ± 
0.00
04 
RLP#  140 
± 15 
136 
± 12 
134 
± 14 
131 
± 14 
154 
± 22 
153 
± 17 
171 
± 30 
166 
± 27 
128 
± 20 
122 
± 17 
112 
± 8 
108 
± 8 
VLDL
#  
68 ± 
9 
70 ± 
10 
78 ± 
9 
71 ± 
7 
58 ± 
9 
60 ± 
10 
80 ± 
16 
73 ± 
11 
77 ± 
14 
79 ± 
16 
76 ± 
12 
69 ± 
9 
HDL# 
† 
9676 
± 
450 
9524 
± 
395 
9698 
± 
469 
9720 
± 
400 
1084
1 ± 
457 
1065
7 ± 
474 
1064
3 ± 
703 
1051
2 ± 
523 
8640 
± 
563 
8516 
± 
381 
9108 
± 
553 
9225 
± 
507 
HDL2b
# † 
1733 
± 
139 
1795 
± 
163 
1949 
± 
197 
1944 
± 
201 
2131 
± 
149 
2193 
± 
234 
2451 
± 
261 
2499 
± 
245 
1378 
± 
150 
1442 
± 
158 
1635 
± 
216 
1598 
± 
216 
HDL 
Densit
y 
1.09
60 ± 
0.00
01 
1.09
46 ± 
0.00
01 
1.09
30 ± 
0.00
01 
1.09
40 ± 
0.00
02 
1.09
39 ± 
0.00
01 
1.09
33 ± 
0.00
02 
1.08
98 ± 
0.00
02 
1.08
92 ± 
0.00
02 
1.09
74 ± 
0.00
02 
1.09
58 ± 
0.00
02 
1.09
54 ± 
0.00
02 
1.09
65 ± 
0.00
02 
†P<0.05 significant main effect of gender.  Particle numbers expressed as nmol·L-1, densities expressed as 
g·cm-2.  Data are means collapsed across mode of exercise training factor; error, SEM. 
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Figure 6:  Effect of exercise training on HDL-C and HDL2b-C in overweight and obese men and women.  Data 
presented are collapsed across mode of exercise training and presented for all subjects combined (n = 18), 
women (n = 8) and men (n = 10) before and after exercise training.  A:  HDL-C concentration.  B:  HDL particle 
number.  C:  HDL2b-C concentration.  D:  HDL2b particle number.  *P<0.05 Compared to pre-training value.  
†P<0.05 Different between genders within exercise training timepoint.  Bars, means collapsed across mode of 
exercise training factor; error bars, SEM.  
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Figure 7:  Effect of exercise training on HDL2a-C, HDL3-C and 
HDL-C mean density in overweight and obese men and women.  
Data presented are collapsed across mode of exercise training 
and presented for all subjects combined (n = 18), women (n = 
8) and men (n = 10) before and after exercise training.  A:  
HDL2a-C concentration.  B:  HDL3-C concentration.  C:  HDL-C 
mean density.  *P<0.05 Compared to pre-training value.  
†P<0.05 Different between genders within exercise training 
timepoint.  Bars, means collapsed across mode of exercise 
training factor; error bars, SEM.  
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Figure 9:  Effect of acute exercise and exercise training on serum NEFA concentrations in overweight and obese 
men and women.  Data presented are collapsed across mode of exercise training and presented for all subjects 
combined (n = 18), women (n = 8) and men (n = 10).  A:  Serum NEFA concentration before and after exercise 
training.  B:  Serum NEFA concentration before and after acute exercise.  *P<0.05 Compared to pre value.  
†P<0.05 Different between genders within exercise training timepoint.  Bars, means collapsed across mode of 
exercise training factor; error bars, SEM.  
Figure 8:  Effect of exercise training on LDL3-C in overweight and obese men and women.  Data presented are 
collapsed across mode of exercise training and presented for all subjects combined (n = 18), women (n = 8) and 
men (n = 10) before and after exercise training.  A:  LDL3-C concentration.  B:  LDL3 particle number.  *P<0.05 
Compared to pre-training value.  †P<0.05 Different between genders within exercise training timepoint.  Bars, 
means collapsed across mode of exercise training factor; error bars, SEM.  
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Acute exercise reduces the TC: HDL-C ratio in overweight and obese men, and raises 
serum hsCRP in both men and women.    
Acute aerobic exercise reduced the ratio of TC: HDL-C (-0.16) in men but not 
women regardless of training status (Figure 10).  Furthermore, whether our subjects 
were untrained or trained, serum concentrations of NEFA (+0.25 umol·L
-1
) in women 
(Figure 9B), as well as hsCRP (+0.06 mg·dL
-1
) in men and women (Figure 11) were 
significantly higher 24 h after a single session of 400 kcal of aerobic exercise.  Acute 
exercise did not affect serum concentrations of TC, TAG, LDL-C, LDL3-C, LDL4-C, 
IDL-C, RLP, VLDL-C, HDL-C, HDL2b-C, HDL2a-C, HDL3-C, glucose, insulin, and 
Lp(a), or corresponding lipoprotein particle numbers and densities (Tables 2 and 3). 
 
Figure 10:  Effect of acute exercise on the ratio of 
total cholesterol to HDL-C in overweight and obese 
men and women.  Data presented are collapsed 
across mode of exercise training and presented for all 
subjects combined (n = 18), women (n = 8) and men 
(n = 10) before and after acute exercise.  *P<0.05 
Compared to pre-exercise value.  Bars, means 
collapsed across mode of exercise training factor; 
error bars, SEM.  
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Figure 11:  Effect of acute exercise on high sensitivity 
C-reactive protein in overweight and obese men and 
women.  Data presented are collapsed across mode of 
exercise training and presented for all subjects 
combined (n = 18), women (n = 8) and men (n = 10) 
before and after acute exercise.  *P<0.05 Compared 
to pre-exercise value.  Bars, means collapsed across 
mode of exercise training factor; error bars, SEM.  
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Discussion 
In the current study we have compared the effects of acute aerobic exercise and 
exercise training on blood lipids, lipoproteins, and hsCRP in overweight and obese men 
and women.  We are among the first to report the influence of an exercise regimen on 
lipoprotein particle numbers and to compare and contrast acute exercise responses with 
the adaptations observed following exercise training.  Our findings demonstrate that 
exercise training did not affect the lipid and lipoprotein-lipid response to a single session 
of aerobic exercise in our sample of subjects.  Furthermore, we have demonstrated the 
efficacy of either ATM or LTM exercise training of 1500 kcal·wk
-1
 to elicit changes in 
blood lipid and lipoprotein concentrations consistent with reduced atherogenic risk in 
overweight and obese men and women, with only minimal weight loss.  In addition, 
acute exercise of 400 kcal·session
-1
 was insufficient to elicit significant effects on blood 
cholesterol concentrations, however a significant reduction in the ratio of TC: HDL-C 
was observed in men. 
The influence of exercise training on the acute response to exercise has been reported 
in only one previously published paper (42).  In that study by our laboratory and using 
hypercholesterolemic men as subjects, exercise training nullified an acute exercise 
induced increase in LDL-C concentration.  By contrast, in our current study we found no 
influence of exercise training on the acute response to exercise of blood lipids and 
lipoproteins.  While the lack of such an interaction may be due to the fact that we 
observed only limited changes in lipids and lipoproteins following acute exercise, some 
differences between our current study and our previous study may at least partially 
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explain our divergent findings.  First, we did not measure a transient increase in LDL-C 
concentrations after an acute exercise session regardless of training status in the men and 
women in our current study.  As this was the primary effect of acute exercise influenced 
by training in our previous study (14) we are unlikely to detect a similar effect without 
this acute increase in LDL-C concentration.  Second, our previous study was carried out 
across 24 wks with acute exercise sessions every 8 wks; the effect of exercise training on 
this transient response to acute exercise was not observed until 16 wks into exercise 
training, whereas our current study was included only 12 wks of training.  Finally, in our 
current study we examined the influence of acute exercise and exercise training on blood 
lipids and lipoproteins in obese men and women, whereas hypercholesterolemic men 
served as subjects in our previous study.   
An important finding of our current study is that exercise training elicited a reduction 
in atherogenic risk by HDL-C mediated mechanisms in both men and women; however, 
the nature of this effect was different between genders.  More specifically, we have 
shown that exercise training induced a significant increase in both HDL-C concentration 
and HDL particle number in overweight and obese men, but not in women (Figure 6).  
Similar to previous findings (240), this effect was mediated in large part by a 
concomitant increase in HDL2b-C concentration, and in our study increased HDL2b 
particle number.  Our finding that exercise training enhanced HDL-C concentrations in 
obese men is comparable to previously published reports in other populations including 
older and hypercholesterolemic individuals (43, 87, 207).  We expand on previous 
studies by showing that the increase in HDL-C and HDL2b-C concentrations in men is 
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driven by an increase in particle number of this lipoprotein fraction, rather than changes 
in particle size or density.   
Nicklas et al. (157) have previously demonstrated an increase in HDL-C and HDL2-
C in lean and overweight men following 9 months of exercise training.  In contrast to our 
findings, however, beneficial HDL-C changes did not occur in their obese men.  Nicklas 
et al. (157) sampled blood lipids 24 hr after the last session of exercise.  We (42-43, 223) 
and others (65, 234) have previously shown that the transient response to the last 
exercise session often peaks at 24 h and can last 48-72 h following exercise.  Therefore, 
while training induced alterations in lipids and lipoproteins cannot be ruled out as a 
contributing factor for the observations by Nicklas et al. (157), it is likely that at least 
part of their findings reflect a transient response to the final exercise session.  By 
contrast, in our present study we eliminated this possibility by restricting vigorous 
activity for 72 h prior to blood sampling.  Williams et al. (228) have previously 
demonstrated increased HDL2b-C in men following a 12 month weight loss program by 
either diet (-7.2 kg) or exercise (-4.0 kg), however, in their study blood samples were 
obtained after 12-16 hours without vigorous activity.  In our study, we accomplished 
similar changes with less weight loss (-1.9 kg in men), and after controlling for the 
transient effects of the last exercise session.  Our study may better compare to that by 
Slentz et al. (183) who showed similar increases in HDL-C and ―large‖ HDL-C, 
presumably HDL2-C, in overweight and mildly obese men in high volume exercisers 
(1700 kcal·wk
-1
), but not with lower volume (approximately 1100 kcal·wk
-1
).  Their 
findings were seen 24 h following the last exercise session, and lasted through 15 days 
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following the cessation of exercise training.  Combined with our results, this suggests the 
efficacy of exercise training of 1500 kcal·wk
-1
 to increase blood HDL-C in overweight 
and obese men.  
By contrast, the mean HDL-C concentration was not significantly elevated following 
exercise training in the overweight and obese women in our study.  These results in 
women corroborate those published by others after acute exercise (223) and exercise 
training (136).  Conversely, in some published studies a decrease in HDL-C in women 
following exercise training has been reported (14, 80).  We note that the mean HDL-C 
concentration of our women was 60 mg·dL
-1 
prior to training; this already elevated 
HDL-C concentration may reduce the likelihood of inducing an increase in the 
concentration of this fraction (132).   
Despite the lack of a significant change in total HDL-C in our sample of women, we 
measured a shift in HDL-C subfractions from HDL3-C to the HDL2-C (both HDL2b-C 
and HDL2a-C, Figures 6 and 7) subfractions, similar to that previously observed in 
hypercholesterolemic men (41).  This change in HDL subfractions could reduce 
atherogenic risk, since increased blood concentrations of HDL2-C signals acquisition of 
cholesterol by HDL, and thus an enhanced reverse-cholesterol transport process (177, 
201).  Consistent with this increase in HDL2-C at the expense of HDL3-C concentration,  
a decrease in HDL mean density was measured, a finding also associated with reduced 
atherogenic risk (91).  Thus, our results suggest that exercise training by overweight and 
obese women results in a reduction in atherogenic risk through a redistribution of 
cholesterol among the HDL subspecies, without a significant net change in total HDL-C 
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concentration.  Our data support the need for a more detailed assessment of HDL-
associated cholesterol and density beyond traditional approaches of simply measuring 
total HDL-C to assess the efficacy of an intervention aimed at improving the lipid profile 
and reducing atherogenic risk in women.  Furthermore, we demonstrate that overweight 
and obese men and women each display a reduction in atherogenic risk by HDL 
mechanisms but that this effect differs between genders. 
We show for the first time that exercise training induced a 9% decrease in LDL3-C 
concentration and a 10% decrease in LDL3 particle number in overweight and obese 
women, but not in men (Figure 8).  LDL-C categories include subfractions 1 through 4, 
defined based on size and density; the largest and most buoyant class is LDL1-C and the 
smallest, most dense is LDL4-C (124).  The smaller subfractions (LDL3-C and LDL4-C) 
are considered to represent greater risk because they are more susceptible to oxidation 
and greater binding to the arterial wall (124).  Therefore, a reduction in either of these 
subfractions, as observed in LDL3-C in our women subjects, is consistent with reduced 
atherogenic risk.  Although not significant, men displayed greater mean concentrations 
of these subfractions than did women (+4.5 mg·dL
-1 
for LDL3-C, and +1 mg·dL
-1 
for 
LDL4-C) at the onset of training, and no significant decrease in either of these 
subfractions was measured in men after training.  We note, however, that despite no 
significant effects on these subfractions men displayed a mean decrease in LDL3 and 
LDL4 particle numbers following exercise training. 
We cannot conclude that the reduction in LDL3-C in women was independent of the 
weight loss seen with our exercise training regimen, nevertheless, reduced LDL3-C in 
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endurance trained compared with sedentary individuals has been reported (239).  In 
addition, Halverstadt et al. (87) have previously shown exercise training induced 
reductions in ―small‖ LDL, along with modest changes in body weight, BMI and 
VO2max similar to those  measured in our current study.  Halverstadt et al. (87) also 
reported that these changes remained significant after adjusting for changes in body fat.  
We conclude that the reduction in LDL3-C concentration was the result of reduced LDL3 
particle number.  This finding is similar to our findings regarding HDL-C in men in that 
significantly altered lipoprotein-cholesterol concentrations appear to be mediated 
primarily by a change in lipoprotein particle number.   
In both overweight and obese men and women we observed a 38% reduction in 
serum NEFA concentration following training (Figure 9).  Our data corroborate 
previously published findings regarding exercise training in the obese (107). Elevated 
serum NEFA have previously been proposed to contribute to CVD by an oxidative stress 
mechanism (197).  Therefore, the observed reduction in serum NEFA with exercise 
training by our subjects may also serve to reduce atherogenic risk.  In contrast, we 
measured no significant effect of exercise training on hsCRP, confirming previous 
reports in overweight and obese men and women (99).  Based on our data, exercise 
training consisting of 1500 kcal·wk
-1
 is sufficient to induce changes in blood lipids and 
lipoproteins in overweight and obese men and women consistent with reduced 
atherogenic risk, although the nature of this adaptation appears to differ between 
genders. 
73 
 
 
In addition to our examination of exercise training induced changes in lipids and 
lipoproteins, we have further described the influence of a single session of exercise on 
these factors in our sample of overweight and obese men and women.  Considering that 
exercise duration, as measured by total caloric expenditure, appears to be the 
determining factor in eliciting transient changes in blood lipids and lipoproteins 
following acute exercise, it is likely that these transient responses are resultant of a 
differential ability to handle the energetic demands of the exercise.  In this study we 
have examined these transient responses in both the untrained state and after 12 wks of 
exercise training.  Based on previously published data from our laboratory (42-43, 81, 
223) describing the effects of acute exercise on lipids and lipoproteins in other 
populations we elected to perform these exercise sessions at an energy expenditure of 
400 kcal.  We have shown that acute exercise reduced the ratio of TC: HDL-C in obese 
men but had no such effect in women (Figure 10).  However, acute exercise also 
induced an increase in hsCRP in both men and women (27% increase, Figure 11) and 
NEFA (55% increase, Figure 9B) in women.  Such increases in hsCRP (110) and NEFA 
(81) have been previously reported.  Our finding that no cholesterol or TAG changes 
were significant in women corroborates previous findings in which 350 kcal of aerobic 
energy expenditure was insufficient to elicit such changes at 24 h post-exercise in both 
pre- and postmenopausal women (165).   
That we were unable to elicit significant increases in HDL-C or reductions in TAG 
concentrations, as noted in other studies of acute exercise (43, 65) suggests that we may 
have been below the necessary caloric threshold for this overweight and obese 
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population to elicit such responses.  That the necessary caloric threshold may be greater 
in the obese compared to other populations appears analogous to endurance trained 
individuals (65).  A greater caloric threshold in obese and endurance trained individuals, 
compared to other populations, may be due to the fact these populations have been 
reported to exhibit greater stores of intramuscular fat than lean controls (77-78).  If the 
transient blood lipid and lipoprotein response to exercise is driven by energetic need, as 
previously mentioned and evidenced by the apparent importance of a caloric threshold, 
an increase in intramuscular fat stores could blunt the need to mobilize fatty acids from 
other stores, therefore reducing the need for a change in blood lipids and lipoproteins.  
However, a greater caloric expenditure for acute exercise should be taken with caution 
as the acute exercise performed here induced increased serum hsCRP concentrations, 
and NEFA in women, and thus may be associated with a negative effect on these risk 
markers. 
In the current study, we found no significant changes in serum insulin, glucose, or 
Lp(a) following either acute exercise or exercise training in our sample of overweight 
and obese men and women.  Our findings regarding Lp(a) concentration corroborate 
previous work demonstrating no influence on this risk marker of acute exercise (57) or 
exercise training (140).  We also measured no effect of the exercise protocol on fasting 
serum glucose or insulin.  These findings are contrary to previous reports of exercise 
training in the overweight (184), in that we saw no significant change in fasting insulin.  
We should note, however, that our subjects, despite being overweight and obese, were 
not insulin resistant as defined by fasting glucose (mean fasting glucose at onset of study 
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93 mg·dL
-1
) (73).  Since fasting insulin and glucose levels were in normal range at the 
onset of the experiment, exercise and exercise training are less likely to cause significant 
reductions in these blood variables. 
In summary, we have shown that both acute exercise and exercise training by obese 
men and women generally produce changes in blood lipids and lipoprotein-lipids 
congruent with reduced cardiovascular risk without the use of dietary measures to aid in 
weight loss.  These data support the notion that exercise can have therapeutic benefits in 
the overweight and obese population without the need for dramatic weight loss.  We 
have also shown that aerobic exercise training using either ATM or LTM is equally 
efficacious for the reduction of cardiovascular risk markers so long as frequency, 
intensity, and duration of exercise are matched.  In addition, while acute exercise 
induced a reduction in the ratio of TC: HDL-C in overweight and obese men, acute 
exercise was also associated with an increase in serum hsCRP concentration in men and 
women, and NEFA in women.  In addition, exercise training did not appear to affect the 
transient response to acute exercise in this population.  Based on our present study, 
exercise training expending at least 1500 kcal·wk
-1
 is an effective course of action to 
reduce cardiovascular risk in the obese population. 
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CHAPTER III 
PPARδ AND AMPKα PROTEIN CONTENT ARE ENHANCED 
FOLLOWING EXERCISE AND CORRELATED WITH BLOOD 
LIPID AND LIPOPROTEIN CONCENTRATIONS IN THE OBESE 
 
Introduction 
Obesity and diabetes have become a major public health concern in the United States 
with prevalence of these diseases rising to epidemic levels (27).  In addition, obesity is 
an established independent risk factor for cardiovascular disease (156).  These disease 
states are characterized by impairments in energy metabolism including insulin 
resistance and dysregulation of lipid metabolism.  Dysregulated lipid metabolism is 
evident by reduced content and activity of oxidative enzymes within skeletal muscle.  As 
a result, individuals suffering from these disease states often exhibit elevated blood 
glucose and dyslipidemia including elevated total cholesterol (TC), LDL-cholesterol 
(LDL-C), and triacylglycerols (TAG), as well as depressed HDL-cholesterol (HDL-C).   
Our laboratory (41-42) and others (60, 94) have previously demonstrated that both 
acute exercise and exercise training are capable of eliciting beneficial changes in blood 
lipid and lipoprotein concentrations consistent with reduced risk for CVD, including 
reduced total cholesterol (TC), LDL-cholesterol (LDL-C) and triacylglycerol (TAG) 
concentrations, and elevated HDL-cholesterol (HDL-C) concentrations.  However, the 
mechanisms responsible for alterations in blood lipids and lipoproteins with exercise are 
currently poorly understood.  Both acute exercise and exercise training-induced changes 
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in blood lipids and lipoproteins appear to be dependent on the attainment of a necessary 
minimum caloric expenditure.  In fact, a review by Durstine et al. (59) has previously 
examined necessary caloric thresholds to elicit changes in the various cholesterol 
fractions and TAGs.  Considering that elevations in caloric expenditure with exercise are 
the result of enhanced skeletal muscle activity, we propose that skeletal muscle plays an 
essential function in mediating exercise-derived changes in blood lipids and lipoproteins, 
a concept which has recently been advanced by others (185).  Previous evidence 
suggests arterial-venous differences across vascular beds of exercising skeletal muscle, 
whereby HDL-C concentration is elevated and VLDL-TAG reduced in venous compared 
to arterial blood (113). 
Although there have been a plethora of therapeutic strategies for the treatment of 
metabolic dysregulation, pharmacological activation of the peroxisome proliferator-
activated receptors (PPARs; a family of nuclear receptors involved in the regulation of 
lipid metabolism and glucose homeostasis) has shown promise for the treatment of 
several metabolic diseases.  PPARδ, in particular, appears to play a critical role in 
metabolic adaptation in skeletal muscle.  In fact, pharmacological evidence suggests that 
the activation of PPARδ may improve insulin sensitivity (238) and induce beneficial 
changes in blood lipids and lipoproteins (160), providing a direct link to the treatment of 
these disease states by enhancing PPAR expression.   
The PPAR family members show tissue specific distribution.  PPARγ is primarily 
expressed in adipose tissue; while, PPARs -α and -δ are present in tissues with high 
metabolic activity, including liver and muscle.  The primary isoform in skeletal muscle 
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is PPARδ.  Animals bred to overexpress PPARδ exhibit increased oxidative myofiber 
content (220) and a general increase in muscle oxidative capacities analogous to that 
seen following exercise training (199).  In spite of such findings, the response to exercise 
of PPARδ remains inadequately described.  Acute fatiguing exercise has previously been 
demonstrated to induce increased mRNA content of PPARδ and PPARα (142, 221).  
However, it remains uncertain as to how PPARδ might respond to non-fatiguing exercise 
or whether previously observed increases in mRNA content yield elevated levels of this 
protein.  Exercise training has previously been demonstrated to enhance expression of 
PPARα protein (98), but less is known about PPARδ.  Studies involving PPARδ protein 
content and exercise training are few and present mixed findings showing either 
unchanged (175) or increased (70) content.  Further research is necessary to better 
understand how PPARδ responds to exercise and thereby mediates oxidative adaptations 
to exercise stress. 
Stimulation of PPARδ in obese rhesus monkeys using a synthetic pharmaceutical 
agonist has been shown to alter blood lipids and lipoproteins, including increased HDL-
C and decreased TAG and LDL-C concentrations, each congruent with reduced 
atherogenic risk (160).  Furthermore, a bedrest study in humans demonstrated that 
subjects receiving a PPARδ agonist maintained HDL-C concentration while those on 
placebo displayed reduced HDL-C.  In addition, although not significant (P = 0.08), 
subjects receiving the PPARδ agonist showed decreased TAG (192).  However, it is not 
currently known whether the exercise induced alteration in blood lipids and lipoproteins 
may be mediated by PPARδ.  In this study we specifically examined the role of skeletal 
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muscle PPARδ in the regulation of blood lipid and lipoprotein concentrations following 
exercise.   
AMP-activated protein kinase (AMPK) and PPARγ coactivator-1α (PGC-1α) are 
vital to the effects of PPARδ on skeletal muscle and whole body metabolism.  AMPK is 
considered to be a ‗master metabolic switch‘ most commonly associated with regulating 
the use of metabolic fuel supplies, but also involved in the stimulation of the 
transcription of oxidative genes (208).  PGC-1α, on the other hand, is believed to serve 
as a ‗master regulator of mitochondrial biogenesis‘ (147).  Both AMPK and PGC-1α 
appear necessary for the maximal activation of PPAR activity (122, 151).  Therefore, the 
role of these proteins cannot be overlooked in assessing the influence of exercise on 
skeletal muscle, and whole muscle metabolism in the obese. 
In addition, we have previously demonstrated the efficacy of aquatic treadmill 
(ATM) exercise to increase aerobic fitness and reduce weight and body fat percentage in 
the obese (82).  In that previous report we further revealed the potential of ATM exercise 
to elicit enhanced lean body mass, providing a potential advantage to ATM training.  
However, mechanisms mediating enhanced oxidative function with this form of exercise 
have yet to be described. 
Therefore, the purpose of this study was to test the hypotheses that: 1) both acute 
aerobic exercise and exercise training will elicit enhanced protein content of PPARδ and 
related proteins in the skeletal muscle of overweight and obese men and women, 2) 
enhanced PPARδ protein content will be associated with enhanced content of PPARδ 
target proteins involved in fatty acid and lipoprotein transport and metabolism, and 3) 
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PPARδ protein content will be correlated with the blood concentrations of lipids and 
lipoproteins at rest and following exercise in the obese.  In addressing these hypothesis, 
this study provides: 1) new understanding of the comparative adaptations of skeletal 
muscle proteins regulating oxidative function following either ATM or land treadmill 
(LTM) training; 2) novel evidence regarding the regulation of metabolism with obesity, 
as well as how obesity affects the individual‘s ability to adapt and respond to exercise; 
and 3) additional insight into the mechanisms involved in the regulation of blood lipids 
and lipoproteins in response to exercise and exercise training. 
Methods 
Physically inactive, overweight and obese men (n = 9) and women (n = 7) were 
recruited from the Texas A&M University and College Station, TX communities to 
participate in the study.  The mean (SEM) age of subjects was 41 ± 2 years and 52 ± 2 
years for men and women, respectively.  Subjects were part of a larger cohort whose 
physiologic adaptations to the exercise training paradigm have previously been reported 
(82).  Potential volunteers were recruited through informational flyers, email 
announcements, and by word of mouth.  Volunteers were screened to ensure that they 
had not participated in regular aerobic activity for the previous 3 months (physically 
inactive), and were classified as overweight or obese initially by BMI and subsequently 
by percent body fat as measured by dual-energy x-ray absorptiometry (DEXA, Lunar 
Prodigy, GE Healthcare, Madison, WI).  Subjects were stratified according to ACSM 
standards for risk of cardiovascular disease, and those for whom it was required 
underwent a physical examination by a cardiologist before participation in the 
81 
 
 
experiment (2).  Preliminary physiological characteristics of the 16 subjects who 
completed the study are presented in Table 4.   
 
 
 
Table 4: Physiological variables, and activity and dietary habits before and after training in all subjects, 
women, and men. 
 All Subjects (n = 16) Women (n = 7) Men (n = 9) 
 Pre-Tr Post-Tr Pre-Tr Post-Tr Pre-Tr Post-Tr 
Physical Characteristics 
Body Mass (kg)*  98.9 ± 
5.7 
96.4 ± 
5.3 
96.4 ± 
8.6 
93.1 ± 
8.0 
101.4 ± 
7.6 
99.8 ± 
7.0 
Body Mass Index (kg·m-2) 
* 
31.9 ± 
1.4 
31.2 ± 
1.3 
32.0 ± 
2.3 
30.9 ± 
2.1 
31.9 ± 1.7 31.4 ± 
1.5 
Body Fat % † 41.1 ± 
1.5 
39.9 ± 
1.6 
44.3 ± 
2.4 
44.0 ± 
2.6 
38.0 ± 1.8 35.9 ± 
1.9 
Lean Body Mass (kg) † 52.7 ± 
2.2 
51.9 ± 
2.1 
45.5 ± 
3.5 
44.5 ± 
3.3 
59.9 ± 2.6 59.3 ± 
2.5 
Fat Mass (kg) 36.9 ± 
3.2 
35.7 ± 
3.1 
36.8 ± 
5.1 
35.4 ± 
5.0 
37.0 ± 3.8 36.1 ± 
3.8 
VO2max (L•min
-1) * † 2.52 ± 
0.08 
2.77 ± 
0.10 
2.05 ± 
0.12 
2.28 ± 
0.15 
2.99 ± 
0.11 
3.26 ± 
0.13 
VO2max (mL•kg
-1•min-1) * 
† 
26.0 ± 
1.3 
29.6 ± 
1.4 
22.5 ± 
1.9 
25.8 ± 
2.2 
29.4 ± 1.7 33.3 ± 
1.8 
       
Activity and Nutritional Intake 
Caloric Expenditure 
(kcal•day-1) † 
3005 ± 
133 
2971 ± 
98 
2595 ± 
213 
2582 ± 
160 
3414 ± 
159 
3360 ± 
119 
Caloric Intake (kcal•day-1) 
† 
2362 ± 
167 
2137 ± 
221 
2019 ± 
267 
1780 ± 
355 
2705 ± 
199 
2495 ± 
265 
Carbohydrate (g•day-1) † 293 ± 21 261 ± 33 235 ± 34 207 ± 53 350 ± 26 316 ± 39 
Total Fat (g•day-1) 91.4 ± 
8.5 
87.4 ± 
10.6 
84.0 ± 
13.7 
79.2 ± 
17.0 
98.9 ± 
10.2 
95.6 ± 
12.7 
Monounsaturated Fat 
(g•day-1) 
19.2 ± 
2.8 
17.6 ± 
3.5 
13.0 ± 
4.5 
17.6 ± 
5.6 
25.3 ± 3.3 17.7 ± 
4.2 
Polyunsaturated Fat (g•day-
1) 
8.0 ± 1.1 10.1 ± 
2.6 
5.8 ± 1.7 11.0 ± 
4.1 
10.1 ± 1.3 9.2 ± 3.1 
Saturated Fat (g•day-1) 31.9 ± 
2.8 
27.9 ± 
3.1 
29.8 ± 
4.5 
27.0 ± 
4.9 
34.0 ± 3.3 28.8 ± 
3.7 
Protein (g) 91.6 ± 
8.0 
76.1 ± 
7.4 
81.0 ± 
12.8 
67.8 ± 
11.9 
102.1 ± 
9.5 
84.4 ± 
8.9 
*P<0.05 significant main effect of exercise training.  †P<0.05 significant main effect of gender.  Data are 
means collapsed across mode of exercise training factor; error, SEM. 
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General protocol 
All methods and procedures were approved by the Texas A&M University 
Institutional Review Board for Human Subjects in Research.  On the first visit to the 
laboratory, subjects were informed of the study procedures, and read and signed an 
institutionally approved informed consent.  At this time, instructions were provided for 
completing physical activity and diet records (methods to follow).  Briefly, physiological 
and demographic assessments were completed on the second visit to the laboratory.  
Approximately four days following physiological assessments, resting muscle biopsies 
were obtained from the vastus lateralis (resting/untrained state, methods to follow).  
Approximately three days later (seven days following physiological testing) the first of 
two acute exercise bouts was performed on a standard motor-driven land treadmill with 
pre-exercise blood samples obtained immediately prior to exercise (resting/untrained 
state, methods to follow).  Blood and muscle biopsy samples were obtained 24-h after 
the acute exercise session (exercised/untrained state).  Within two weeks of 
physiological testing, subjects were matched for age, gender, and BMI, and then 
randomly assigned to 12-weeks of exercise training using either LTM or ATM (methods 
to follow). All physiological and demographic testing procedures were repeated within 
72-96 h after the final exercise training session.  Blood samples and muscle biopsies 
were again obtained 24 hours after a single exercise session performed within 7 days of 
the end-of-study physiological assessments (exercised/trained state). 
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Diet and activity logs 
To study subjects in a free-living state, no attempt was made to modify diet or 
physical activity outside of the study protocol.  To this end, subjects were instructed to 
maintain their accustomed dietary and physical activity habits throughout the course of 
the study.  To verify compliance with these instructions, dietary and activity habits were 
assessed on two occasions coinciding with the beginning and end of exercise training.  
Subjects were instructed to complete dietary and physical activity records on days which 
would best represent their normal daily habits.  On both occasions dietary logs were 
recorded for 3 consecutive days, including 1 weekend day.  The 3-day dietary records 
were analyzed for total caloric intake and for carbohydrate, fat, and protein composition 
using commercially available computer software (Food Processor
®
 8.4, ESHA Research, 
Salem, OR).  The physical activity records used were an adaptation of a previously 
described protocol for physical activity recall (6).  Activity records were recorded for 
seven consecutive days and analyzed for total energy expenditure.  In addition, upon 
completion of the study all subjects were required to read and sign dietary and activity 
compliance forms. 
Physiological assessments 
These procedures have been previously published (82).  In brief, body composition, 
including whole body percent fat, fat mass and lean body mass, were assessed using 
DEXA.  An incremental maximal graded exercise test (GXT) was conducted on a motor-
driven treadmill according to the Bruce protocol (21).  Oxygen consumption during 
exercise was assessed using an automated metabolic gas-analysis system (CPX/D 
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Exercise Stress Testing System, Medical Graphics, Minneapolis, MN or Oxycon Pro, 
Erich Jaeger, Hoechberg, Germany) calibrated with gasses of known concentration 
before and after each exercise test.  VO2max was taken as the highest 15 s average 
oxygen uptake achieved during the exercise test.  Heart rate (HR) and rhythm were 
monitored continuously from
 
a 12-lead electrocardiogram.  Ratings of perceived exertion 
(RPE) using a Borg 15-point scale ranging from 6-20 (17) and
 
manual blood pressures 
(BP) were obtained during the last 30 s of
 
each treadmill stage and at maximal exercise.  
At least two of the following criteria were required for the maximal exercise test to be 
considered valid: 1) achievement of maximum heart rate within 10 bpm of the age-
predicted maximum; 2) rating of perceived exertion ≥ 18; 3) respiratory exchange ratio 
>1.1 at maximal exertion; or 4) O2 uptake plateau despite further increases in workload.  
The same skilled laboratory personnel consistently performed all physiological 
measurements.    
Acute exercise sessions 
All non-study exercise was prohibited for 72 h prior to the experimental acute 
exercise sessions.  The experimental acute exercise sessions were performed on a 
motorized land treadmill approximately seven days after completion of maximal 
exercise testing at pre- and post-training timepoints.  The exercise protocol began with a 
3 min warm-up period at 53.6 m·min
-1
 at a 0% grade.  The duration of each acute 
exercise session was defined as the time required to expend 400 kcal at an intensity of 
70% of VO2max, based on the most recently acquired VO2max.  The necessary duration 
was estimated by dividing 400 kcal by the rate of energy expenditure at the required 
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exercise intensity based on the respiratory exchange ratio energy-oxygen equivalent 
(kcal·LO2
-1
).  Initial treadmill velocity and grade were estimated using published 
metabolic equations for LTM exercise (2).  Heart rate, RPE and VO2 were measured 
every 5 min at the beginning of exercise to adjust treadmill velocity and grade until the 
required VO2 was achieved; thereafter VO2 measurements were taken every 10 min until 
the cessation of exercise, and minor adjustments were made as necessary to the treadmill 
velocity and grade to maintain the required VO2, as well as, exercise time to ensure the 
expenditure of 400 kcal.  Subjects were asked to avoid any physical exertion outside of 
that required by their work until after all blood and muscle collection procedures were 
completed. 
Exercise training 
 The exercise prescription and training progression for this study have previously 
been reported (82).  ATM training was conducted using a HydroWorx 1000 series 
treadmill  (HydroWorx International, Inc., Middletown, PA) as previously described 
(82).  LTM training was conducted on a standard motor-driven treadmill.  Subjects 
exercised three times per week for a 12-week period.  Training sessions were performed 
by all subjects at an equivalent caloric expenditure and relative intensity progressively 
increased from 250 kcal·session
-1
, 60% VO2max during the first week to 500 
kcal·session
-1
, 85% VO2max during weeks 6-12.  The prescribed exercise progression 
was such that by week 6 subjects expended approximately 1500 kcal·wk
-1
 in exercise 
training.  Exercise duration and intensity were calculated as described above for acute 
exercise sessions.  For ATM training treadmill velocity and jet resistance were estimated 
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using a previously developed metabolic equation for ATM (Greene et al., manuscript 
accepted for publication in Research Quarterly for Exercise and Sport).  Treadmill 
velocity and grade/jet resistance were adjusted as necessary during the training session 
to attain the HR and RPE which matched the prescribed intensity.  Each individual‘s 
exercise prescription was adjusted for increases in VO2max during week 6 such that the 
prescribed intensity and duration were maintained throughout the study.   
Blood and muscle sampling 
Blood and muscle samples were obtained on three occasions:  muscle sample one 
was obtained 3 days prior to acute exercise (resting/untrained state), blood sample one 
was obtained with the subject at rest immediately preceding the acute exercise session 
(resting/untrained state).  Blood and muscle sample two was obtained 24 h after a single 
aerobic exercise session (exercised/untrained state).  The third blood and muscle sample 
was obtained 24 h following acute exercise after 12 weeks of exercise training 
(exercised/trained state).  Resting samples were taken following at least 72 hours without 
strenuous activity.  For blood and muscle sampling each subject reported to the 
laboratory, time of day controlled, after a 12-hour fast (water allowed ad libitum).  Prior 
to sample collection, subjects completed a form reporting their physical activity and 
dietary adherence over the previous 24 hours and the time of their last meal.   
The same trained and experienced personnel consistently performed phlebotomy and 
biopsy procedures according to well-accepted, sterile protocols.  Blood samples were 
drawn without stasis from an antecubital vein with the subject seated at quiet rest into 
vacutainer tubes containing 10.5 mg Na-EDTA for plasma collection and a serum 
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clotting factor (Becton Dickinson and Company, Rutherford, NJ) for serum collection.  
Serum and plasma were immediately isolated by centrifugation at 1500 x g for 30 
minutes at 4°C.  Aliquots of serum were stored at -80°C for later analysis.  All blood 
variables (not including HDL and LDL mean densities) were adjusted for plasma 
volume shifts that occurred as a result of acute exercise using hematocrit and 
hemoglobin measurements obtained from each plasma sample (50).   
The muscle biopsy procedure used is a modification of Bergstrom‘s technique (11), 
as described by Evans et al. (63).  Muscle biopsies were taken from the vastus lateralis 
under local anesthetic (1% Xylocaine HCl) using a 5-mm needle.  All muscle samples 
were cleaned of visible fat, connective tissue, and blood.  Muscle samples were 
immediately frozen in liquid nitrogen (-190ºC), and then stored at -80ºC until analyzed.   
Blood analysis 
Frozen aliquots of serum were sent to SpectraCell Laboratories, Inc (Houston, TX) 
for complete LDL density and lipoprotein particle number analyses.  A complete 
―Lipoprotein Particle Profile™‖ test was performed using the lipoprotein subgroup 
particle number analysis method.  The lipoprotein particle separation utilized a patent 
pending (209) continuous gradient generated by analytical ultracentrifugation. The 
lipoprotein particles were stained on their surface with a fluorescent dye and then 
separated in the gradient over a range of d = 1.000 - 1.300 g·cm
-3
.  After separation, the 
contents of the centrifuge tube were extracted and the fluorescence of the lipoprotein 
particles was measured in an HPLC-type flow system.  For processing, the fluorescence 
response was normalized to a cholesterol scale with a proprietary algorithm.  Values for 
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each lipoprotein subgroup at their specific densities were determined using a multiple 
Gaussian fit/integration routine (209).  The total number of VLDL (VLDL#), LDL 
(LDL#), remnant lipoprotein (RLP#), dense low-density lipoprotein3 (LDL3#), dense 
low-density lipoprotein4 (LDL4#), HDL (HDL#) and buoyant high-density lipoprotein2b 
(HDL2b#) particles were determined in addition to the lipoprotein density.  The 
coefficient of variation for this analysis using known standards has been reported as 2-
3%.  Analysis of serum nonesterified fatty acids (NEFA) was performed colorimetrically 
using a commercially available kit (Wako Diagnostics, Richmond, Va).   
Isolation of protein and western blot analysis 
Western blot analysis of proteins was performed as previously described with minor 
modifications (56).  Briefly, tissue was weighed, powdered at the temperature of liquid 
nitrogen,
 
and then homogenized in cold buffer (25 mM HEPES, 4 mM EDTA,
 
25 mM 
benzamidine, 1 µM leupeptin, 1 µM pepstatin,
 
0.15 µM aprotinin, 2 mM 
phenylmethylsulfonyl fluoride,
 
pH 7.4).  The homogenate was then centrifuged (10,000 
g for 30
 
min at 4°C).  Protein concentration of the supernatant was determined according 
to the method described by Smith et al. (186).  Samples
 
were stored at -80°C until 
sodium dodecyl sulfate
 
(SDS)-polyacrylamide gel electrophoresis.
 
 
Immediately prior to gel electrophoresis, an aliquot of the supernatant was
 
diluted in 
an equal volume of buffer (125 mM Tris, pH 6.8, 4%
 
SDS, 20% glycerol, 200 mM DTT, 
and 0.002% bromophenol blue).
   
Protein was then separated by electrophoresis across a 
polyacrylamide gel and transferred to nitrocellulose membrane (Amersham Biosciences, 
Piscataway, NJ).  Membranes were then incubated in blocking solution (containing 5% 
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nonfat dried milk in Tris-buffered saline) at room temperature.  Following blocking, 
membranes were incubated with rabbit anti-PPARδ, PGC-1α, PPARα, carnitine 
palmitoyl transferase-Iβ (CPT-Iβ), fatty acid translocase (FAT/CD36), F1 ATPase, ATP 
binding cassette A1 (ABCA1), LDL receptor (LDLR), and lipoprotein lipase (LPL) 
(Santa Cruz Biotechnology, Santa Cruz, CA), AMPKα, and cytochrome c oxidase-IV 
(COX-IV)(Cell Signaling Technology, Danvers, MA).  The AMPKα antibody used 
detects total AMPKα1 and 2 expression. 
The membranes were then washed and incubated again with anti-rabbit IgG coupled 
to horseradish peroxidase
 
(Cell Signaling) and developed using chemiluminescence 
(Αlpha Innotech, FluorChem SP, San Leandro, CA).  Absorbance was normalized to a 
protein standard (obtained from rat quadriceps) loaded on each gel
 
and expressed as 
normalized absorbance units (AU).  
Statistical analysis 
 A timepoint (resting/untrained, exercised/untrained, and exercised/trained) by 
exercise training mode (LTM vs. ATM) by gender ANOVA repeated across timepoint 
was employed as the global analysis for each dependent variable of interest.  Dependent 
variables of interest included skeletal muscle protein expression of PPARδ, PPARα, 
PGC-1α, AMPKα, CD36/FAT, CPT-I, COX-IV, ABCA1, LDLR, and LPL.  Neither 
mode of aerobic exercise training nor gender significantly affected the exercise response 
for any of the variables of interest (P>0.05); therefore, we elected to remove these 
factors for all subsequent analyses. The comparison-wise error rate, α, was set at 0.05 for 
all statistical tests.  When significant F ratios were found, a Tukey-Kramer post hoc 
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analysis was used to distinguish differences among means.  Correlation analyses were 
performed using Pearson‘s product-moment correlations for PPARδ, PPARα, PGC-1α, 
and AMPK to target proteins and serum lipids and lipoproteins at each of the sample 
collection timepoints.  All data were analyzed using the Statistical Analysis System 
(SAS, version 9.13, Cary, NC) and expressed as mean ± SEM. 
Results 
Physical characteristics and nutritional intake before and after training.   
Physiologic characteristics of these subjects have been previously reported as part of 
a larger cohort (82).  For the subset of subjects included in the current study, body 
weight (-2.3 kg) and BMI (-0.7 kg·m
-2
) were significantly reduced following exercise 
training and VO2max (+3.6 mL·kg
-1
·min
-1
) was significantly increased (Table 4).  No 
other body composition variables tested were significantly affected by exercise training 
(Table 4).  Body fat %, lean body mass, VO2max, caloric expenditure, caloric intake, 
and carbohydrate intake were all different between men and women (Table 4).  No 
dietary or non-study physical activity changes were observed following exercise training 
(Table 4).   
Exercise enhances skeletal muscle protein content of PPARδ, PPARα, PGC-1α, and 
AMPKα in overweight and obese men and women.   
PPARα content was significantly increased following 12 wks of exercise training 
(exercised/trained), but was not significantly affected by a single session of exercise 
compared to the resting/untrained state (Figure 12A&B).  PPARδ content was elevated 
from baseline following both an acute session of aerobic exercise and was two-fold 
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greater in the exercised/trained state compared to the resting/untrained state; however, 
the difference in measured expression between the exercised/untrained and 
exercised/trained states was not significant (Figure 12A&C).  AMPKα content was 
enhanced following exercise training but not after a single session of exercise (Figure 
13A&B).  PGC-1α protein content, on the other hand, was enhanced following a single 
session of aerobic exercise and remained elevated in the exercised/trained state (Figure 
13A&C). 
  
Figure 12:  Influence of exercise and exercise 
training on PPARα and PPARδ expression in 
overweight and obese men and women.  A:  Sample 
immunoblot analysis of PPARα and PPARδ.  B:  
Quantification of the relative abundance of PPARα.  
C:  Quantification of the relative abundance of 
PPARδ.  *P<0.05 Compared to resting, untrained.  
Data are mean ± SEM. 
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Exercise enhances expression of PPAR and PGC-1α target proteins involved in 
oxidative and lipoprotein metabolism.   
Similar to PPARδ and PGC-1α, CD36/FAT protein content was enhanced following 
a single session of exercise and remained elevated in the exercised/trained state (Figure 
14A&B).  Expression of CPT-I (Figure 14A&C) and COX-IV (Figure 14A&D) 
proteins were significantly increased in the exercised/trained state compared to 
resting/untrained.  In addition, LPL expression was significantly enhanced following a 
Figure 13:  Influence of exercise and exercise training on 
AMPKα and PGC-1α expression in overweight and obese 
men and women.  A:  Sample immunoblot analysis of 
AMPKα and PGC-1α.  B:  Quantification of the relative 
abundance of AMPKα.  C:  Quantification of the relative 
abundance of PGC-1α.  D:  *P<0.05 Compared to 
resting, untrained.  Data are mean ± SEM. 
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single session of aerobic exercise (Figure 15A&B).  Protein expression of F1 ATPase 
(ATP synthase), ATP-binding cassette A1 (ABCA1) and LDL-receptor (LDLR) were 
not significantly affected by the exercise protocol.   
PPARδ and AMPKα protein content are correlated with the content of blood lipids and 
lipoproteins in the obese at rest and following exercise training.   
Table 5 shows the correlation of PPARα, PPARδ, PGC-1α, and AMPKα protein 
content to serum lipids and lipoproteins and target proteins.  Of note in all three exercise 
conditions (resting/untrained, exercised/untrained, and exercised/trained) AMPKα 
protein content was significantly positively correlated with HDL-C, HDL2b-C, HDL2a-C, 
and HDL2b-C particle number.  In addition, PPARδ protein content was significantly 
negatively correlated with total cholesterol in the resting/untrained and exercise/trained 
states.  PPARδ was also significantly negatively correlated with LDL-C, LDL3-C, LDL4-
C, LDL-C particle number, and LDL3-C particle number in the resting/untrained state.  
PPARδ content approached significant negative correlations with LDL4-C particle 
number in the resting/untrained state, and with LDL-C in the exercised/trained state.  In 
addition, in all three conditions PGC-1α protein content was significantly positively 
correlated with protein content of F1 ATPase. 
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Figure 14:  Influence of exercise and exercise training on 
CD36/FAT, CPT-I and COX-IV expression in overweight 
and obese men and women.  A:  Sample immunoblot 
analysis of CD36/FAT, CPT-I, and COX-IV.   
B:  Quantification of the relative abundance of 
CD36/FAT.  C:  Quantification of the relative abundance 
of CPT-I.  D:  Quantification of the relative abundance of 
COX-IV.  *P<0.05 Compared to resting, untrained.  Data 
are mean ± SEM. 
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Figure 15:  Influence of exercise and exercise training 
on LPL expression in overweight and obese men and 
women.  A:  Sample immunoblot analysis of LPL.  B:  
Quantification of the relative abundance of LPL.  
*P<0.05 Compared to resting, untrained.  Data are 
mean ± SEM. 
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Table 5: Correlation of PPARα , PPARδ, AMPKα, and PGC-
1α to blood lipids and lipoproteins and target proteins. 
  PPARα PPARδ AMPKα PGC-1α 
Resting, Untrained State 
F1 ATPase  -0.3374 0.0014 -0.3523 0.8487* 
CPT-I 0.6191 0.2810 -0.2765 0.2308 
TC  0.1860 -0.6021* 0.0199 -0.223 
LDL-C  0.1835 -0.5975* 0.066 -0.2545 
LDL3-C  -0.1104 -0.6307* 0.1834 -0.2342 
LDL4-C  -0.0642 -0.504† 0.3289 -0.056 
HDL-C  0.1469 -0.2082 0.5543* -0.0301 
HDL2B-C  0.2120 -0.1417 0.7234* -0.0341 
HDL2A-C  0.0387 -0.138 0.7376* -0.1404 
LDL PRT  0.1170 -0.6813* 0.0022 -0.2616 
LDL3 PRT  -0.1031 -0.6354* 0.1994 -0.2278 
LDL4 PRT  -0.0501 -0.4946† 0.3021 -0.0691 
HDL2B PRT  0.1977 -0.1552 0.7151* -0.045 
CRP  -0.1869 0.0772 -0.6124* -0.0109 
Exercised, Untrained State 
F1 ATPase  -0.2089 0.0897 -0.4765 0.7082* 
Glucose  0.5321* 0.0376 -0.2685 0.5071* 
HDL-C  -0.1527 -0.2788 0.7293* -0.0597 
HDL2B-C  -0.1030 -0.1266 0.7829* -0.1204 
HDL2A-C  -0.1359 -0.002 0.8684* -0.2549 
HDL3-C  -0.1451 -0.7219* -0.0211 0.2778 
HDL PRT  -0.1754 -0.4277 0.6058* 0.0223 
HDL2B PRT  -0.1008 -0.1247 0.7843* -0.1199 
HDL Density  0.0388 -0.2654 -0.7385* 0.1938 
Exercised, Trained State 
AMPK 0.6968† -0.5136 - -0.5837† 
COX-IV 0.5844† 0.18542 -0.3063 -0.2143 
F1 ATPase  -0.2380 0.3603 -0.4288 0.8909* 
TC  0.0722 -0.6212* 0.3955 -0.2903 
LDL-C  -0.1116 -0.5435† 0.5581 -0.2958 
HDL-C  0.2035 -0.6259* 0.7704* -0.4098 
HDL2B-C  0.1955 -0.5693† 0.7904* -0.3206 
HDL2A-C  0.1390 -0.5559† 0.8956* -0.357 
HDL PRT  0.1960 -0.6293* 0.6739* -0.4642 
HDL2B PRT  0.2081 -0.5672† 0.7958* -0.3234 
CRP  -0.1509 0.5672† -0.1213 -0.4659 
Insulin  -0.3020 0.6007* -0.0593 -0.0388 
HDL Density  -0.2611 0.532† -0.7561* 0.196 
Correlations for which any one of PPARα, PPARδ, PGC-1α, or 
AMPKα showed (*, P<0.05) or approached (†, P<0.10) 
significance are shown. 
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Discussion 
In the current study we have demonstrated enhanced expression of PPARs following 
aerobic exercise in overweight and obese men and women.  We further reveal for the 
first time the potential role of PPARδ and AMPKα in the regulation of blood lipids and 
lipoproteins following exercise.  The primary finding of this study was that a single 
session of aerobic exercise stimulates enhanced expression of PPARδ and PGC-1α in 
overweight and obese men and women; whereas, AMPKα and PPARα expression were 
significantly augmented only after 12 wks of exercise training, in the exercised/trained 
state.  These effects appear to mediate enhanced expression of proteins involved in 
oxidative and lipoprotein-lipid metabolism.  Our findings show that the induction of 
these proteins occurred when exercise training involved either ATM or LTM type 
exercise and regardless of gender.  These data provide new mechanistic insights as to 
how acute exercise and exercise training mediate oxidative adaptation and regulate blood 
lipid and lipoprotein concentrations in obese men and women. 
More specifically, we have shown that acute exercise induced an increase in PPARδ 
protein content in vastus lateralis muscle of untrained, overweight and obese men and 
women.  The fact that the highest observed PPARδ content was seen in the 
exercised/trained condition is evidence of a potential additive effect of acute exercise 
and exercise training on the expression of this protein (Figure 12A&C).  To our 
knowledge we are the first to report an acute exercise-induced increase in PPARδ 
protein content in humans, particularly in overweight and obese men and women.  
Others have shown increased PPARδ protein content after training (69), but the authors 
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did not make clear that they controlled for the timing of the last exercise session. Though 
our data suggest the possibility of an additive effect of acute exercise and exercise 
training on PPARδ protein content (Figure 12A&C), the difference between the 
exercised/untrained and exercised/trained states did not reach significance.   
Previous work has demonstrated that overexpression of PPARδ induces a muscle 
fiber-type transition to mitochondria rich type I myofibers and enhanced endurance 
performance (220).  Other studies have shown that PPARδ stimulation results in the 
expression of genes involved in oxidative metabolism, which can lead to reduced 
adiposity and normalization of several metabolic parameters associated with obesity 
(138-139).   Fritz et al. (70) have previously demonstrated increased PPARδ protein 
expression with a tendency toward an increase in mRNA expression following a 4 month 
low-intensity, self-supervised endurance exercise program in type 2 diabetics.  In 
addition, an acute session of exhaustive cycling exercise has been demonstrated to 
increase PPARδ mRNA content in healthy, normal weight men (142, 221).  In the 
present study, we expand on those findings by demonstrating that acute exercise induces 
the enhanced expression of PPARδ protein in overweight and obese men and women 
without the need to achieve exhaustion.  Moreover, our data suggest that the previous 
observations by Fritz et al. (69) may be explained as a response to the most recent 
exercise session rather than an adaptive response to the training stimulus. 
We also confirm previous findings (98) by demonstrating the upregulation of PPARα 
protein content following a regimen of aerobic exercise training (Figure 12A&B).  
However, despite previously described increased PPARα mRNA content following a 
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single session of exercise we were not able to confirm a significant increase in PPARα 
protein following acute exercise.  Thus, our data suggest that exercise training over a 
period of weeks may be necessary to evoke a significant rise in PPARα protein content 
in obese men and women.  Indeed, our results indicate at least a marginal acute rise in 
PPARα protein that in our subjects simply did not reach statistical significance (Figure 
12A&B), suggesting the accumulation of repeated exercise bouts may be necessary to 
elicit a significant enhancement in the expression of this protein.  
We also show that exercise-induced increases of PGC-1α content appear to be 
mediated primarily by acute exercise (Figure 13A&C).  Our data corroborate previously 
published results demonstrating the induction of PGC-1α expression following acute 
exercise in both human and rodent models (1, 4, 75, 130, 146).  Other researchers have 
also implicated exercise training as a stimulus for enhanced expression of PGC-1α (172, 
194, 204).  However, to our knowledge we are the first to assess the effects of acute 
exercise and exercise training on the expression of PGC-1α protein in a single study.  
Given that we measured an increase in PGC-1α expression following just one session of 
exercise with no significant additive effects observed after exercise training 
(exercised/trained condition), we suggest that exercise-induced augmentations of PGC-
1α protein content are largely mediated by the most recent session of exercise, and not 
an adaptive effect of exercise training.  Regardless, PGC-1α has been demonstrated to 
mediate adaptive effects consistent with enhanced mitochondrial biogenesis and 
oxidative capacity (147, 195).  It appears the influence of an exercise regimen on the 
expression of PGC-1α is limited to the response to the metabolic perturbations of the 
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most recent exercise session, rather than an adaptive mechanism stimulated by exercise 
training. 
Similar to PPARα, we have demonstrated augmented AMPKα protein content in the 
exercised/trained condition but not after a single session of exercise in the untrained state 
(Figure 13A&B).  Our data suggests that while acute exercise may induce the activation 
of AMPKα, enhanced AMPKα expression was only observed in the trained/exercised 
state, suggesting the importance for a chronic stimulus to induce this effect.  Acute 
exercise has previously been demonstrated to induce enhanced AMPK activity, 
measured by phosphorylation at Thr172, which was observed immediately post-exercise 
and returned to baseline by 2 h after exercise (131).  Exercise trained individuals express 
greater content of AMPKα1 but similar expression of the other AMPK subunits as 
sedentary individuals (158).  Our data describing the influence of an exercise training 
intervention on AMPKα expression are consistent with the findings of Sriwijitkamol et 
al. (194) in the obese Zucker rat, and of Clark et al. (34) in humans.  However, our 
findings differ from those of Leick et al. (131) who showed no influence of either acute 
exercise or exercise training on AMPKα protein content in PGC-1α knockout mice.  
Their findings may indicate the importance of PGC-1α in mediating this adaptive effect 
on AMPKα. 
While the induction of PPARα, PPARδ, PGC-1α, and AMPKα may not each be 
individually required to elicit the oxidative adaptations in skeletal muscle observed with 
exercise training, the systematic blunting of any one of these proteins significantly 
diminishes these adaptations (131, 172, 195).  Understanding the stimuli required to 
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induce activation and expression of these proteins is paramount to our ability to 
maximize the adaptive effects of exercise with regards to mitochondrial biogenesis and 
oxidative capacity.  Our data suggest that while acute aerobic exercise is sufficient to 
stimulate the expression of PPARδ and PGC-1α, exercise training is required for 
augmented expression of PPARα and AMPKα in overweight and obese humans.   
PPARδ has previously been demonstrated to elicit enhanced expression of proteins 
involved in oxidative metabolism and cholesterol transport (151, 160).  To test whether 
exercise-induced expression of PPARδ and related proteins (PPARα, PGC-1α, and 
AMPKα) elicited an effect on previously described transcriptional targets, we elected to 
assess the influence of exercise on proteins involved in both of these processes.  As 
PGC-1α is recognized as the master regulator of mitochondrial biogenesis, and 
stimulation of PPARδ has been purported to augment oxidative capacity (139), we also 
elected to assess the influence of our exercise regimen on markers of mitochondrial 
biogenesis.  Similar to the induction of PPARδ and PGC-1α with exercise in our sample 
of overweight and obese humans, we measured an increase in the expression of 
CD36/FAT following a single session of exercise, an increase which was maintained 
after 12 wks of exercise training (Figure 14A&B).  CPT-I protein content was 
significantly augmented in the exercise/trained state, and was accompanied by a small 
though not significant increase in CPT-I content following a single session of exercise 
(Figure 14A&C).  Our data regarding CD36/FAT and CPT-I are indicative of PPARδ 
mediated enhancements in oxidative protein expression, similar to that previously 
reported in skeletal muscle of humans treated with pharmacological PPARδ agonists 
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(192).  Interestingly, we did not detect an influence of exercise or exercise training on F1 
ATPase expression, which is thought to be a target of PGC-1α independent of its 
influence on PPAR.  We have further utilized the expression of COX-IV protein as a 
previously validated indicator of mitochondrial biogenesis (26, 97, 171).  From our 
assessment of COX-IV expression, we demonstrate augmented mitochondrial biogenesis 
in the exercised/trained state in our sample of overweight and obese men and women 
(Figure 14A&D).  Together, our findings indicate the viability of exercise to augment 
oxidative function, fatty acid transport and mitochondrial biogenesis in overweight and 
obese humans.  Our data are further suggestive of PPAR and PGC-1α mediation of these 
events.  These novel findings demonstrate the capacity of our sample of overweight and 
obese men and women to adapt to the stresses of an exercise regimen and further reveal 
important mechanisms by which these adaptations occur. 
In order to better understand how exercise and PPAR may influence cholesterol 
transport and metabolism we have also assessed the influence of our exercise protocol on 
the expression of lipoprotein metabolism and transport proteins: ABCA1, LDLR, and 
LPL.  The induction of these proteins in skeletal muscle represents the primary means by 
which PPARδ has been proposed to influence blood cholesterols (74).  We measured 
upregulated LPL expression following a single session of aerobic exercise in the 
untrained state, and this elevation persisted in the exercised/trained state (Figure 15).  
Contrastingly, we observed no detectable influence of our exercise protocol on the 
expression of either ABCA1 or LDLR.  Our findings that exercise did not influence 
ABCA1 content, despite enhanced expression of PPARs -α and -δ, contradict previous 
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studies indicating that the administration of a PPARδ agonist upregulated ABCA1 
expression (160, 192).  Sprecher et al. (192) demonstrated no influence of PPARδ 
activation on LPL expression in humans.  However, they suggested an increase in LPL 
activity due to the lipolytic effects observed with PPARδ agonism.  Increased LPL 
activity, as suggested by Sprecher et al. (192), would be consistent with previous 
observations by our laboratory following acute exercise (81).  The augmented LPL 
expression measured in this study supports the enhanced capability of the muscle to 
catabolize and absorb lipoprotein-associated lipid. 
To our knowledge, the first study to link the specific activation of PPARδ to changes 
in blood lipids and lipoproteins was performed by Oliver et al. (160).  They reported that 
obese rhesus monkeys treated with the PPARδ agonist GW501516 exhibited increased 
HDL-C concentrations along with reduced VLDL-TAG and LDL-C concentrations 
compared to vehicle treated animals.  In addition, the decrease in LDL-C concentration 
was mediated by a reduction in LDL particle number and concomitant reduction in the 
relative amount of small LDL particles (i.e., LDL3-C and LDL4-C).  Their work has been 
previously expanded by Sprecher et al. (191-192) in humans.  We expanded on these 
results in our present study by examining the possibility that skeletal muscle PPARδ 
may mediate previously described responses of blood lipids and lipoproteins to acute 
exercise and exercise training.  Considering that exercise-mediated changes in blood 
lipids and lipoproteins are dependent upon caloric expenditure, and that previous results 
demonstrated altered blood lipid and lipoprotein concentrations across the vascular bed 
of skeletal muscle (113), we hypothesized that skeletal muscle energy metabolism is a 
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key component to altered blood lipids.  Considering the previous findings by Oliver et 
al. (160) and Sprecher et al. (191-192), who also demonstrated the influence of PPARδ 
agonism on skeletal muscle proteins involved in lipoprotein transport and metabolism, 
we hypothesized that skeletal muscle PPARδ is a primary regulatory point for exercise-
induced changes in blood lipids and lipoproteins.   
Our data demonstrate that without exercise (resting/untrained condition) PPARδ is 
significantly negatively correlated with the concentration of TC and LDL-C (Table 5).  
This relationship between PPARδ and TC persisted following training while the 
relationship with LDL-C approached significance (P<0.1) in the exercised/trained state 
(Table 5).  In the resting/untrained state PPARδ is negatively correlated with the 
concentration and particle number of small LDL-C fractions LDL3-C and LDL4-C.  
These findings are consistent with the findings of Oliver et al. (160) regarding LDL-C.  
Interestingly, while PPARδ content was enhanced following acute exercise, the 
correlation between PPARδ and TC and LDL-C was no longer significant the 
exercised/untrained state.  Our findings suggest that any influence of PPARδ on LDL-C 
requires a consistent long term stimulus to affect changes in this lipoprotein fraction.  
However, further research is necessary to better define the role of PPARδ in the 
regulation of total cholesterol and LDL-C. 
Perhaps the most surprising finding of our study was that in overweight and obese 
men and women, skeletal muscle AMPKα protein content was positively correlated with 
HDL-C and its subfractions, regardless of exercise status (Table 5).  This correlation 
persisted across both forms of HDL2-C (HDL2a-C and HDL2b-C) and across HDL 
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particle numbers suggesting that AMPKα related alterations in HDL are mediated by 
particle number.  To our knowledge, we are the first to show such a connection between 
AMPKα and HDL-C with exercise or obesity.  While AMPK is a known stimulus for the 
oxidation of fatty acids, little is known to link skeletal muscle AMPK to lipoprotein and 
cholesterol metabolism.  An examination of previously published literature reveals that 
hepatic AMPK stimulation can inhibit cholesterol synthesis by phosphorylation and 
inhibition of HMG-CoA reductase (38).  AMPK is activated by statin treatment, which 
also targets the inhibition of HMG-CoA Reductase (198).  This mechanism provides a 
link between AMPK and cholesterol metabolism; however, it may not explain the link 
between skeletal muscle AMPK and HDL-C.  Previous research has also shown that 
obese Zucker rats treated with AICAR, an activator of AMPK, exhibit increased HDL-C 
and reduced TAG concentration (22).  In addition, genetic variants in the α2 subunit of 
AMPK have been associated with alterations in HDL-C (189) and apolipoprotein AI 
(ApoAI, the primary protein component of HDL-C) concentrations (224).  Interestingly, 
ApoAI has previously been demonstrated, in both skeletal muscle (88) and endothelial 
cells (53), to stimulate AMPK phosphorylation at Thr172, a site consistent with the 
activation of AMPK.  Therefore, while the exact mechanism remains unknown it is 
apparent that HDL-C and AMPK are engaged in a feedback relationship.   
In summary, we have shown that a single session of aerobic exercise induced 
enhanced expression of PPARδ and PGC-1α, whereas, enhanced expression of PPARα 
and AMPKα was only observed in the exercised/trained state.  We further demonstrate 
that neither mode (ATM or LTM) of aerobic exercise training nor gender influences this 
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response in overweight and obese men and women.  We corroborate the work of others 
(160, 192), in showing the potential role of PPARδ in the regulation of blood 
concentrations of TC and LDL-C, and expand on these findings by showing that PPARδ 
may be a primary mechanism for previously observed exercise training induced changes 
in these blood cholesterols.  Interestingly, we reveal for the first time that AMPK 
appears to be involved in the regulation of HDL-C and its subfractions following 
exercise, and that this regulation appears to occur by modulating the particle number of 
these cholesterol fractions.  Our data provide a new understanding as to how oxidative 
adaptation to exercise is mediated and by what mechanism exercise mediates changes in 
blood cholesterols. 
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CHAPTER IV 
HIGH VOLUME RESISTANCE EXERCISE ENHANCES PPARδ 
AND PGC-1α PROTEIN EXPRESSION, BUT NOT MARKERS OF 
MITOCHONDRIAL BIOGENESIS IN THE OBESE ZUCKER RAT 
 
Introduction  
The prevalence of obesity and diabetes has risen to epidemic proportions in the 
United States (27).  These disease states are often associated with dysregulated 
metabolism including reduced glucose uptake, altered protein turnover, and dysregulated 
lipid metabolism.  In particular, obesity is associated with increased rates of incomplete 
mitochondrial β-oxidation, an inability to switch to carbohydrate fuel supplies, the 
accumulation of intramuscular acylcarnitines, and a reduction of overall mitochondrial 
content (95, 120).  The peroxisome proliferator-activated receptors (PPARs) are a family 
of nuclear receptors involved in the regulation of lipid metabolism and glucose 
homeostasis which have been implicated in the treatment of several diseases.  PPARδ, in 
particular, appears to play a critical role in metabolic adaptation in skeletal muscle.  In 
addition, the transcriptional coactivator PPARγ coactivator-1α (PGC-1α) has been 
referred to as a ―master regulator of mitochondrial biogenesis‖ (147).  Due to their roles 
in metabolism, any intervention which may target enhanced content and function of 
PPARδ and PGC-1α could potentially ameliorate or repair previously mentioned 
metabolic diseases. 
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The PPAR family members show a tissue specific distribution.  PPARγ is primarily 
expressed in adipose tissue; however, PPARs -α and -δ are present in tissues with high 
metabolic activity, including liver and muscle.  Due to its relatively ubiquitous 
expression, PPARδ was once believed to serve as a redundant mechanism for the other 
PPAR isoforms.  In some of the first work to document the function of PPARδ, Muoio et 
al. (152) described what appeared to be compensatory regulation by PPARδ in skeletal 
muscle when PPARα was knocked out in mice.  Since then it has come to be accepted 
that the primary PPAR isoform in skeletal muscle is PPARδ.  When animals are bred to 
overexpress PPARδ, they exhibit an increase in oxidative myofiber content (220) and a 
general increase in muscle oxidative capacities similar to that observed with exercise 
training (199).  Despite such findings, the characterization of PPARδ‘s response to 
exercise is incomplete.  Mahoney, et al. (142) and Watt, et al. (221) have previously 
considered the effect of an acute bout of cycle exercise on PPAR mRNA expression in 
humans.  In both studies, PPARs -α and -δ exhibited increased mRNA expression at 3 
hours post exercise, however, protein content was not assessed in these studies.  The 
PPARδ response to exercise training has been reported in relatively few studies, and 
results are mixed with either no change (175) or increased (70) PPARδ protein content.  
Also, stimulation of PPARδ with a synthetic agonist has been shown to alter blood lipids 
and lipoproteins, including increases in HDL-cholesterol and decreases in triacylglycerol 
(TAG) and LDL-cholesterol concentrations (160).  However, it is not known whether 
this response may be mediated by PPARδ. 
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In contrast, PGC-1α has been characterized more extensively.  Originally identified 
and named for its function to stimulate PPARγ in brown adipose tissue (167), PGC-1α 
has since been identified as a coactivator of many transcription factors including all three 
PPAR isoforms and NRFs 1 and 2.  PGC-1α has been identified as a master regulator of 
mitochondrial biogenesis.  A relative consensus exists in the literature that PGC-1α 
mRNA and protein expression are enhanced with both acute exercise and exercise 
training (4, 71, 146, 172).  Sriwijitkamol et al. (194) have also previously demonstrated 
that seven weeks of exercise training induced greater PGC-1α protein expression in 
obese Zucker rats.  Moreover, RE elicits enhanced expression of PGC-1α mRNA (48).  
We have expanded on these previous works by describing the influence of a short term 
RE protocol on PGC-1α protein and mitochondrial biogenesis in the obese Zucker rat.   
In addition, due to its role in mitochondrial biogenesis, PGC-1α is considered to be 
tightly coupled to fatty acid oxidation (FAO).  However, previous work in lean and 
obese women showed that PGC-1α was uncoupled from FAO in obesity (97).   To date, 
it is not known if the discordance between PGC-1α expression and mitochondrial FAO 
with obesity is the result of the inability of PGC-1α to stimulate mitochondrial 
biogenesis or other disruptions with mitochondrial FAO.   
The purpose of this study was to test the hypothesis that purported markers of 
mitochondrial biogenesis respond similarly to short term, high volume resistance 
exercise in lean and obese Zucker rats.  To test this hypothesis, we explored the 
influence of obesity and high volume resistance exercise on PPARδ and PGC-1α, and 
whether changes in PPARδ and PGC-1α are associated with a response of downstream 
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target proteins and indices of mitochondrial biogenesis.  We further sought to understand 
whether obesity and RE influence blood lipids and lipoproteins, and how PPARδ and 
PGC-1α relate to blood lipid concentrations.  Results from this study will improve our 
understanding of metabolic dysfunction in obesity and how RE may potentially 
ameliorate such dysfunction. 
Methods 
Animals  
Lean (fa/-, n=16) and obese (fa/fa, n=14) Zucker rats were purchased (Charles River 
Laboratories, Wilmington, MA) at 16 weeks of age, and all methods were approved by 
the Institutional Animal Care and Use Committee of Texas A&M University.  All 
animals were singly housed in a secure, temperature and humidity controlled 
environment and maintained on a constant 12:12 h light-dark cycle with food and water 
provided ad libitum.  Animals were assigned to one of four conditions: lean-sedentary 
(SED, n=8), lean-resistance exercised (RE, n=8), obese-SED (n=6), and obese-RE (n=8).  
Prior to the study, animals were weighed and analyzed for body composition by dual 
energy x-ray absorptiometry (DXA) scans.  To perform scans, animals were anesthetized 
using a ketamine (Ketaset; 37.5 mg/kg BW) and medetomidine (Domitor; 0.25 mg/kg 
BW) cocktail administered by intraperitoneal (i.p.) injection and immediately awakened 
post-scan by administration of antisedan.  Using these data animals were matched such 
that body weight and composition were similar within lean and obese phenotypes (Table 
6).   
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Table 6:  Body weight and composition of lean and obese Zucker rats in SED or RE 
treatment groups.   
    Number Body Weight (g) %Body Fat Lean Mass (g) Fat Mass (g) 
Lean SED 8 384.3±24.1 16.2±3.6 312.5±21.0 60.6±16.1 
  RE 8 383.0±17.0 16.2±1.5 312.5±15.2 60.3±6.9 
Obese SED 6 587.0±97.8 62.8±2.8 209.3±37.3 354.6±69.1 
  RE 8 585.8±55.3 60.0±3.0 228.5±35.4 340.0±22.1 
No significant differences were seen between SED and RE treatments within each 
phenotype.  Phenotypes were significantly different for body weight, % body fat, lean mass, 
and fat mass; P<0.05.  Data are mean ± SE. 
 
 
Operant conditioning and resistance exercise 
All animals were operantly conditioned to the RE protocol over a period of two 
weeks, consisting of 6 total sessions.  The exercise protocol has been previously 
described (67) and resembles that of a traditional ―squat‖ performed by humans in a 
weight room.  Briefly, rats were taught to press an illuminated lever in a specially 
designed cage to avoid a brief foot shock stimulus (<3 mA, 60 Hz; 1-5 V).  This 
movement facilitates a full extension and flexion of the hindlimb.  During the final two 
conditioning sessions, a non-weighted Velcro vest was placed over the scapulae and the 
animals were required to perform the same movement.  Once operantly conditioned, 
animals performed the exercise with little or no requirement for shock.   
The experimental protocol consisted of 4 RE sessions (RE1-RE4) over an 8-day 
period, and was progressive in nature, with weight and repetitions increased with each 
session such that during RE3 and RE4 animals performed an average of 88 repetitions 
per session.   During the RE sessions, the Velcro vest was placed over the scapulae and 
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additional weight added to the vest.  All RE animals received the same absolute amount 
of additional overload such that during RE4 animals performed 80g (18 repetitions), 
130g (16 repetitions), 180g (14 repetitions), 230g (30 repetitions), and 280g (6 
repetitions).  SED animals experienced only normal cage activity during the experiment.  
The total number of shocks administered to each RE animal was recorded and SED 
animals were given the average number of shocks received by the RE animals.  Operant 
conditioning and experimental RE sessions were all separated by 48-72 h and conducted 
during the animals‘ dark cycle.  Muscles were harvested and animals sacrificed on the 
9
th
 day. 
To measure mitochondrial protein synthesis rates in skeletal muscle, an i.p. 99.9% 
deuterium oxide (
2
H2O) bolus injection (20ul/g BW) was administered to each animal 24 
h prior to sacrifice (approximately 8 hours prior to last exercise session), and 4% 
2
H2O 
was provided ad libitum in the drinking water throughout the last day. The use of 
2
H2O 
as a metabolic label allows for assessing long-term biosynthesis of macromolecules in a 
variety of species under free-living conditions (25), including obese rodent models (3). 
An important distinction between the 
2
H2O method and traditional in vivo precursor-
product protocols is that 
2
H2O does not rely on amino acid transporters for intracellular 
enrichment, and measurements can be done over long periods of time in non-fasted 
states. As a result, a 24 h enrichment period with 
2
H2O ultimately gives a more realistic 
assessment of cumulative protein synthesis rates, since it accounts for daily activity- and 
sleep-patterns and allows for normal food consumption (72).   
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Tissue and blood collection 
Consistent with previous research (64) all tissue samples were collected 16 h 
following exercise.  Fasting blood samples (12 h fast) were collected from the lateral 
saphenous vein 16 h following RE3 for analysis of serum lipids and cholesterols.  To 
allow for a better comparison of the fasting blood samples to the post RE4 condition, the 
total volume of work (weight * repetitions) completed during RE3 and RE4 was 
approximately matched.  Blood samples were again collected by cardiac puncture at the 
time of sacrifice (post-RE4).  All blood samples were collected in vacutainers containing 
either EDTA for plasma separation or a gel with a clot activator for serum separation, 
and frozen at -80°C until analysis.  
On the morning of muscle harvest, rat chow was withdrawn 4 h prior to muscle 
excision and the animals were transported to the core laboratory.  Approximately 16 h 
following RE4, animals were anaesthetized using ketamine (Ketaset; 37.5 mg/kg BW) 
and medetomidine (Domitor; 0.25 mg/kg BW) by i.p. injection.  Two mL of whole 
blood were collected by cardiac puncture; the hindlimb muscles were quickly harvested 
and the animal euthanized.  Fat, blood, and connective tissue were removed from 
muscles before snap-freezing in liquid nitrogen, and were subsequently pulverized 
before storing at -80°C until further analyses. Each group (lean RE, lean SED, obese RE 
and obese SED) was represented on any given experimental day, and selected in a 
random order to eliminate potential bias.   
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Assessment of blood lipids and lipoproteins 
All lipid and lipoprotein analyses were performed using serum collected after RE3 
and RE4.  Analysis of serum nonesterified fatty acids (NEFA), total cholesterol, LDL-
cholesterol and HDL-cholesterol was performed colorimetrically using commercially 
available kits (Wako Diagnostics, Richmond, Va).  All lipid and lipoprotein 
concentrations are expressed in mmol/L. 
Isolation of protein and western blot analysis 
All muscle tissue analyses were performed using mixed gastrocnemius.  Western 
blot analysis of proteins was performed as previously described with minor 
modifications (56).  Briefly, tissue was weighed, powdered at the temperature of liquid 
nitrogen,
 
and then homogenized in cold buffer (25 mM HEPES, 4 mM EDTA,
 
25 mM 
benzamidine, 1 µM leupeptin, 1 µM pepstatin,
 
0.15 µM aprotinin, 2 mM 
phenylmethylsulfonyl fluoride,
 
pH 7.4).  The homogenate was then centrifuged (10,000 
g for 30
 
min at 4°C).  Protein concentration of the supernatant was determined according 
to the method described by Smith et al. (186).  Samples
 
were stored at -80°C until 
sodium dodecyl sulfate
 
(SDS)-polyacrylamide gel electrophoresis.
 
 
Before gel electrophoresis, an aliquot of the supernatant was
 
diluted in an equal 
volume of buffer (125 mM Tris, pH 6.8, 4%
 
SDS, 20% glycerol, 200 mM DTT, and 
0.002% bromophenol blue).
   
Protein was then separated by electrophoresis across an 8% 
polyacrylamide gel and transferred to nitrocellulose membrane (Amersham Biosciences, 
Piscataway, NJ).  Membranes were then incubated in blocking solution (containing 5% 
nonfat dried milk in Tris-buffered saline) at room temperature.  Following blocking, 
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membranes were incubated with rabbit anti-PPARδ, PGC-1α, CPT-Iβ, FAT/CD36, F1 
ATPase (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-LKB1 (Ser 428), 
AMPKα, phospho-AMPKα (Thr172), cytochrome c oxidase IV (COX-IV), and α-actinin 
(Cell Signaling Technology, Danvers, MA).  The membranes were then washed and 
incubated again with anti-rabbit IgG coupled to horseradish peroxidase
 
(Cell Signaling) 
and developed using chemiluminescence (Αlpha Innotech, FluorChem SP, San Leandro, 
CA).  Absorbance
 
was normalized to a protein standard (obtained from rat quadriceps) 
loaded on each gel
 
and expressed as normalized absorbance units (AU).  
Isolation of skeletal muscle mitochondria 
For the analysis of mitochondrial fractional protein synthesis rates (mtFSR), 
mitochondrion were isolated from mixed gastrocnemius muscle based on a previously 
described procedure with modifications (173).  Enrichments of sub fractions were 
confirmed with immunoblotting using COX-IV (mitochondrial), and α-actinin 
(myofibrillar), specific antibodies. A recent study by the Endocrine Research Unit at 
Mayo Clinic College of Medicine reported a 75% purity of the sub-fraction containing 
subsarcolemmal mitochondria with a similar isolation procedure (105). The protocol 
used to isolate contractile proteins and intermyofibrillar mitochondria previously has 
been confirmed to yield robust enrichments as evidenced by electron microscopy (225). 
Frozen gastrocnemius muscle (100 mg) was thawed and gently homogenized with 50 
slow and compressive strokes of a glass-pestle (Dounce homogenization) in ice-cold 
mitochondrial isolation buffer 1 (10 mM Hepes, 200 mM Sucrose, 50 mM Mannitol, 2 
mM EDTA disodium salt, Sigma P8340 protease inhibitor cocktail, pH 7.4). The 
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homogenate was centrifuged at 600 x g for 10 min at 4°C, followed by careful removal 
of the supernatant (cytosolic proteins and subsarcolemmal mitochondria) from the pellet 
(myofibrillar, nuclear, and stromal proteins, intermyofibrillar mitochondria).  
Subsarcolemmal mitochondria were obtained by centrifugation of the supernatant at 
10,000 x g for 10 min (4°C) and were stored in mitochondrial isolation buffer 2 (50 mM 
Hepes, 5 mM EGTA, 1 mM ATP, 100 mM KCl, 5 mM MgSO4, Sigma P8340 protease 
inhibitor cocktail, pH 7.4) until combined with the intermyofibrillar (IMF) mitochondria 
for assessment of protein synthesis. The remaining supernatant, containing cytosolic 
proteins, was precipitated with 95% ethanol (50% [v/v] in total solution) during low-
speed centrifugation at 700 x g for 10 min (4°C) and thereafter dried.  
The pellet produced by the centrifugation of the original homogenate was suspended 
in mitochondrial isolation buffer 3 (100 mM KCl, 50 mM Tris, 5 mM MgCl2 
hexahydrate, 1 mM EDTA disodium salt, 10 mM β-glycerophosphate disodium salt, 50 
mM NaF, 1.5% BSA, Sigma P8340 protease inhibitor cocktail, pH 7.5) and centrifuged 
at 650 x g for 3 min at4°C. The resulting pellet was homogenized in the same buffer 
with a glass pestle using shear and compression to release the IMF mitochondria, 
followed by centrifugation at 650 g for 4 min at 4°C to collect the organelle-rich 
supernatant. IMF mitochondria were then pelleted by centrifugation at 10,000 x g for 10 
min (4°C) and combined with the SS mitochondrial fraction. The mitochondrial-rich 
sub-fractions were washed in isolation buffer 2 and ethanol, followed by high-speed 
centrifugation and drying in preparation for protein synthesis measurements.  
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Assessment of mitochondrial protein synthesis rates by deuterium oxide 
2
H2O enrichment of body water/plasma.  The assessment of mtFSR was performed 
as described previously (72), with the modification that the mitochondrial subfraction 
was the primary source of protein assessed.  Briefly, labeling (
2
H) of body water was 
assessed by exchange with acetone as described by Yang, et al. (235). The reaction 
occurred with 20 µL of a sample/standard, 2 µL of 10N NaOH and 4 µL of a 5% 
(vol/vol) solution of acetone in acetonitrile for 24 h. Acetone was removed by the 
addition of 0.6 ml of chloroform and 0.5 g Na2SO4. The samples were mixed and 0.1 ml 
of the chloroform transferred to a GCMS vial. The samples were analyzed using an 
Agilent 5975C-MSD equipped with an Agilent 7890 GC system (GCMS), and a HP-5ms 
capillary column (30 m × 0.25 mm × 0.25 µm). The following temperature program 
were used: 60ºC initial, increased by 20°C/min to 100ºC, increased by 50ºC/min to 
220ºC, and held for 1 min. The sample was injected at a spit ratio of 40:1 with a helium 
flow of 1 mL/min. Acetone eluted at (1.7 min). The mass spectrometer was operated in 
electron impact mode (70eV). Selective ion monitoring of mass-to-charge ratios (m/z) 58 
(M) and 59 (M + 1) was conducted using a dwell time of 10 ms per ion.  All plasma 
samples were measured twice (prepared on two separate occasions) and an average value 
of the two runs was used for all calculations. 
2
H-alanine enrichment in skeletal muscle.  Enrichment of the mitochondrial-rich 
fraction was determined by measuring protein-bound 
2
H-alanine (EA) as previously 
described (72). Briefly, about 0.030 g of mitochondrion was homogenized on ice in 0.3 
ml of a 10% (wt/vol) TCA and centrifuged at 800 x g at 4°C for 15 min. The supernatant 
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was discarded and the protein pellet washed 3 additional times with TCA. The protein 
pellet was then dissolved in 6 N HCl (0.13 mL/0.01 g tissue, 200 uL) and reacted at 
100ºC for 18 h. Homogenates were centrifuged at 14,000 rpm at 4ºC for 30 min. An 
aliquot (50 uL) of the hydrolysate was dried for 1 h at 110 ºC and thereafter derivatized 
with a 3:2:1 (vol:vol:vol) ratio (0.1 mL) of methyl-8 reagent (Pierce, Rockford, IL), 
methanol and acetonitrile for 1 h at 70. The resulting methyl-8 /
2
H-alanine derivative 
was transferred to a GC/MS vial and analyzed with an Agilent 5975C VL MSD 
equipped with an Agilent 7890A GC system (HP-5ms capillary column, 30 m x 0.25 
mm x 0.24 µm) to determine 
2
H-labeling of protein-bound alanine. The initial 
temperature of the column program was set at 90°C and held for 5 min, increased by 
5°C/min to 130°C, which was further increased at a rate of 40°C/min to 240 °C and held 
for 5 min, all steps performed at a constant helium flow of 1 mL/min. Peak abundances 
of ions 99 and 100 were extracted from chromatograms and M+1/M ratios were used to 
calculate % enrichment of protein-bound alanine using a regression formula generated 
by 
2
H-alanine standards (R
2
 = 0.999). 
2
H-labeling of alanine were readily detected in all 
sub-fractions using a 20:1 split ratio for mixed proteins, 10:1 split ratio for myofibrillar 
and cytosolic proteins, and 5:1 split ratio for mitochondrial proteins. All samples were 
analyzed three times, which included complete re-preparation of the frozen hydrolysate 
on each occasion, to account for variations in preps as well as GC/MS analysis. An 
average value of the three runs was used for all FSR calculations. 
Calculations. Fractional synthesis rates of mixed, myofibrillar, cytosolic, and 
mitochondrial proteins were calculated using the equation 
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EA x [EBW x 3.7 x t (h)]
-1
 x 100 
where EA represents amount of protein-bound 
2
H-alanine (mole % excess), EBW is the 
quantity of 
2
H2O in body water (mole % excess), and 3.7 represents the exchange of 
2
H 
between body water and alanine [i.e. 3.7 of 4 carbon-bound hydrogens of alanine 
exchange with water, (55)]. This equation assumes that 
2
H-labeling of body water 
equilibrates with free alanine more rapidly than alanine is incorporated into newly made 
protein and that protein synthesis is linear over the study (231).  
Statistical analysis 
The independent factors in this study were exercise (RE vs. SED), and phenotype 
(lean vs. obese).  Dependent variables of interest included protein content of PPARδ, 
PGC-1α, and select target proteins (CD36/FAT, CPT-I, COX-IV, and F1 ATPase), 
phosphorylation of AMPK and LKB1, mtFSR, and serum lipid and lipoprotein 
concentrations.  An exercise by phenotype (2X2) ANOVA was employed as the global 
analysis for each dependent variable of interest.  The comparison-wise error rate, α, was 
set at 0.05 for all statistical tests.  When significant F ratios were found, a Fisher‘s LSD 
post hoc analysis was used to distinguish differences among means.  Correlation 
analyses were performed using Pearson‘s product-moment correlations for PPARδ, 
PGC-1α, and AMPK to target proteins and serum lipids and lipoproteins.  All data were 
analyzed using the Statistical Analysis System (SAS, version 9.13, Cary, NC) and 
expressed as mean ± SE. 
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Results 
Serum lipid and lipoprotein concentrations are greater in obese compared to lean 
Zucker rats.   
Serum lipid and lipoprotein concentrations for lean and obese Zucker rats are shown 
in Table 7.  Because RE did not alter serum lipids and lipoproteins in either the fasted 
(RE3) or fed (RE4) state, data were collapsed across exercise treatment for each 
phenotype.  Serum NEFA concentrations were greater in obese compared to lean rats.  
Total cholesterol was greater in obese rats, driven by greater HDL-cholesterol 
concentrations in this phenotype.  No differences were seen in LDL-cholesterol 
concentrations between phenotypes. 
 
 
 
 
 
Table 7:  Serum lipids and lipoproteins of lean and obese Zucker rats.   
 Lean Obese 
Post-RE3 
NEFA (mmol/L) 0.85±0.06 1.46±0.07* 
Total Cholesterol (mmol/L) 2.61±0.43 7.25±0.48* 
LDL-Cholesterol (mmol/L) 1.40±0.12 1.36±0.13 
HDL-Cholesterol (mmol/L) 2.27±0.59 7.47±0.65* 
   
Post-RE4 
NEFA (mmol/L) 0.44±0.05 0.64±0.06* 
Total Cholesterol (mmol/L) 2.88±0.43 4.43±0.48* 
LDL-Cholesterol (mmol/L) 1.57±0.17 1.97±0.19* 
HDL-Cholesterol (mmol/L) 1.59±0.33 3.05±0.36* 
Serum lipids were measured 16 h after RE3 (12 h fast) and RE4 (4 h 
fast).  No significant effect of exercise treatment was seen, therefore data 
are collapsed across exercise.  *P<0.05 compared to lean.  Data are 
mean ± SE. 
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Resistance exercise yields enhanced PPARδ content and has a differential effect on 
PGC-1α content in lean and obese Zucker rats.   
In this study we have shown that resistance exercise results in greater expression of 
PPARδ protein regardless of phenotype (Figure 16A&B).  Furthermore, we show that 
PGC-1α content is greater following resistance exercise in obese animals but not in lean 
animals (Figure 16A&C). 
Phosphorylation of AMPK is enhanced following RE in lean but not obese Zucker rats.   
Resistance exercise did not influence phosphorylated LKB1 (Ser 428), however, lean 
animals displayed a greater amount of phosphorylated LKB1 than did obese (Figure 
17A&B).  We have shown that despite no effect of phenotype or RE on the content of 
AMPKα, there was greater than a two-fold increase in the phosphorylation of AMPKα at 
Thr172 in lean, but not obese Zucker rats following RE (Figure 17A&C).  Post-RE 
AMPK phosphorylation in the lean Zucker was also more than two-fold greater than 
AMPK phosphorylation of the obese Zucker rat regardless of exercise treatment. 
Changes in expression of CPT-I and F1 ATPase are concomitant with PPARδ and PGC-
1α, respectively.   
We did not observe a significant effect of RE on the content of CD36/FAT, but lean 
animals exhibited a greater content of CD36 than obese (Figure 18A&B).  Similar to 
PPARδ, greater content of CPT-I was measured in both lean and obese RE animals 
compared to SED.  Lean animals also showed greater total expression of CPT-I than 
obese littermates (Figure 19A&B).  F1 ATPase was differentially affected by RE based 
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on phenotype; similarly to PGC-1α, F1 ATPase content was greater in obese RE animals 
compared to SED (Figure 19A&D), whereas no effect of RE on this protein was seen in 
lean animals (Figure 19A&D). 
 
 
Figure 16:  Expression of PPARδ and PGC-1α in 
lean and obese Zucker rats in SED or RE   
treatments.  A:  Sample immunoblot analysis of 
PPARδ and PGC-1α.  B:  Quantification of the 
relative abundance of PPARδ.  C:  Quantification 
of the relative abundance of PGC-1α.  *P<0.05 
Compared to lean.  #P<0.05 Different between 
treatments within phenotype.  †P<0.05 Different 
between phenotype within treatment.  ‡P<0.05 
Different between phenotype and treatment.  
Data are mean ± SE. 
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Figure 17:  Phosphorylation of LKB1 and 
AMPKα at Thr172 in lean and obese Zucker 
rats in SED or RE treatments.  A:  Sample 
immunoblot analysis of pAMPK and AMPK.  B:  
Quantification of phosphorylated LKB1.  C:  
Quantification of the relative phosphorylation 
of AMPK.  *P<0.05 Compared to lean.  #P<0.05 
Different between treatments within 
phenotype.  †P<0.05 Different between 
phenotype within treatment.  ‡P<0.05 
Different between phenotype and treatment.  
Data are mean ± SE. 
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Mitochondrial biogenesis is not enhanced following RE in obese Zucker rats despite 
enhanced PGC-1α protein content.   
To assess mitochondrial biogenesis we examined COX-IV protein content and 
mitochondrial protein synthesis rates in skeletal muscle using 
2
H2O. COX-IV expression 
was two-fold greater in the SED state in obese animals compared to lean (Figure 19C).  
RE repressed COX-IV expression in obese Zucker rats such that a difference in the 
expression of COX-IV between phenotypes was no longer seen (Figure 19C).  We 
demonstrated enhanced mtFSR following RE in lean, but not obese, Zucker rats (Figure 
20). 
 
Figure 18:  Expression of CD36/FAT in lean 
and obese Zucker rats in.  No effect of 
exercise treatment was seen.  Therefore, 
data have been collapsed across exercise.  A:  
Sample immunoblot analysis of CD36/FAT.  
B:  Quantification of the relative abundance 
of CD36/FAT.  *P<0.05 Compared to lean.  
Data are mean ± SE. 
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Figure 19:  Expression of PPARδ and PGC-1α 
target proteins in lean and obese Zucker rats 
in SED or RE treatments.  A:  Sample 
immunoblot analysis of CPT-I, COX-IV, and F1 
ATPase.  B:  Quantification of the relative 
abundance of CPT-I.  C:  Quantification of the 
relative abundance of COX-IV.  D:  
Quantification of the relative abundance of F1 
ATPase.  *P<0.05 Compared to lean.  #P<0.05 
Different between treatments within 
phenotype.  †P<0.05 Different between 
phenotype within treatment.  ‡P<0.05 
Different between phenotype and treatment.  
Data are mean ± SE. 
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Expression of CPT-I and COX-IV are correlated with expression of PPARδ, and serum 
HDL-cholesterol concentrations are correlated with PPARδ in the SED state.   
Correlational data are shown in Table 8.  Significant correlational findings were:  
PPARδ was positively correlated with post-RE4 NEFA concentrations in lean animals, 
PPARδ and AMPK were both positively correlated with CPT-I protein content, and 
PPARδ was positively correlated with post-RE4 HDL-cholesterol concentrations in the 
SED state.  Furthermore, PPARδ was consistently negatively correlated with COX-IV 
content.   
 
  
Figure 20:  Mitochondrial protein synthesis in 
lean and obese Zucker rats in SED or RE 
conditions.  Figure is adapted from that in 
Nilsson et al. (manuscript in review).  #P<0.05 
Different between treatments within 
phenotype.  ‡P<0.05 Different between 
phenotype and treatment.  Data are mean ± 
SE. 
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Table 8:  Pearson‘s product-moment correlation matrix of 
PPARδ, PGC-1α, and AMPKα to serum lipids and lipoproteins 
and other skeletal muscle proteins measured.   
  PPARδ PGC-1α AMPK 
Lean  (n=16) 
4-NEFA r 
sig. 
0.74094 
0.0010 
-0.29710 
0.4045 
0.28284 
0.3630 
CPT-I r 
sig. 
0.56521 
0.0555 
0.31704 
0.4442 
0.60774 
0.0623 
COX-IV r 
sig. 
-0.78400 
0.0073 
-0.88679 
0.1132 
0.10221 
0.8472 
Obese (n=14) 
CD36 R 
sig. 
0.58596 
0.0453 
0.22220 
0.5372 
0.29689 
0.3753 
CPT-I R 
sig. 
0.79768 
0.0033 
0.3023 
0.3959 
0.60769 
0.0473 
Resistance Exercise (n=16) 
CPT-I R 
sig. 
0.62227 
0.0307 
-0.15450 
0.6915 
0.61571 
0.0437 
COX-IV R 
sig. 
-0.64160 
0.0455 
-0.44725 
0.4501 
-0.36673 
0.4184 
Sedentary (n=14) 
4-NEFA r 
sig. 
0.72051 
0.0037 
0.08780 
0.7974 
0.14883 
0.6443 
4-TC r 
sig. 
0.67911 
0.0076 
0.15452 
0.6501 
-0.38821 
0.2124 
4-HDL r 
sig. 
0.6571 
0.0107 
-0.04117 
0.9043 
-0.26412 
0.4068 
CPT-I r 
sig. 
0.45790 
0.1567 
0.71193 
0.0314 
0.62693 
0.0524 
All Animals (n=30) 
4-NEFA r 
sig. 
0.52906 
0.0032 
0.12214 
0.5979 
0.13497 
0.5295 
4-TC r 
sig. 
0.26019 
0.1728 
0.50586 
0.0193 
0.11146 
0.6041 
4-LDL r 
sig. 
0.11144 
0.5649 
0.49126 
0.0237 
0.11212 
0.6019 
4-HDL r 
sig. 
0.38702 
0.0381 
0.19164 
0.4053 
0.12452 
0.5021 
CPT-I r 
sig. 
0.53179 
0.0090 
0.14589 
0.5635 
0.60404 
0.0037 
COX-IV r 
sig. 
-0.61310 
0.0068 
-0.29595 
0.4064 
-0.13775 
0.6536 
Correlations for which any one of PPARδ, PGC-1α, or AMPKα 
showed significance (P<0.05) are shown. 
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Discussion  
The primary findings of this study were that high volume RE increased PPARδ 
protein content in lean and obese Zucker rats.  However, PGC-1α protein content was 
elevated following RE in obese, but not lean, Zucker rats.  Furthermore, the content of 
CPT-I and F1 ATPase followed similar patterns to PPARδ and PGC-1α, respectively, 
indicating an effective functional response of these oxidative control-point proteins to 
exercise.  High volume RE has previously been demonstrated to enhance muscle 
oxidative potential (203) and fat metabolism (161).  Here we provide evidence this effect 
may be mediated by PPARδ and PGC-1α.   We have also shown a significant positive 
correlation between PPARδ muscle protein content and blood HDL-cholesterol in the 
SED animals, suggesting PPARδ may be important in the regulation of this cholesterol 
fraction in the sedentary state.  Interestingly, the elevated expression of PGC-1α in the 
obese Zucker rat in response to exercise did not result in an increase in mtFSR or COX-
IV.  Conversely, mtFSR was elevated in lean animals after exercise, even though PGC-
1α protein content was unchanged.  These results suggest that increased mitochondrial 
biogenesis in response to exercise is not dependent on changes in PGC-1α expression.   
To our knowledge, we are the first to show that short-term high volume RE is 
capable of elevating PPARδ and PGC-1α protein content in skeletal muscle, and to link 
elevated expression of these proteins to the metabolic adaptations that occur following 
exercise.  Previous work has demonstrated that overexpression of PPARδ induces a 
muscle fiber-type transition to mitochondria rich type I myofibers and enhanced 
endurance performance (220).  Other studies have shown that PPARδ stimulation results 
129 
 
 
in the expression of genes involved in oxidative metabolism, and can lead to reduced 
adiposity and normalization of several metabolic parameters associated with obesity 
(138-139).  Fatty acids (e.g., NEFA) and their derivatives are ligands for the activation 
of all three PPAR isoforms (8), and PPARδ has been called a ―fatty acid sensor‖ since its  
activity is highly inducible by fatty acids (168).  In our study, PPARδ content was 
strongly correlated with serum NEFA concentrations in the lean Zucker rat.  However, 
this association between serum NEFA and PPARδ was not seen in the obese Zucker rat, 
which may suggest an inability of NEFA to fully activate PPARδ in the obese animal.  
In addition, we have shown that PPARδ content is positively correlated with HDL-
cholesterol in the sedentary state, which may indicate a role of PPARδ in the regulation 
of HDL-cholesterol concentrations in the absence of exercise.  However, it is likely that 
exercise mediated PPARδ regulation of serum lipid and lipoprotein concentrations 
requires a long term training regimen which should be further explored.   
Furthermore, in contrast to findings in previous studies (194), PGC-1α  was not 
significantly suppressed in the sedentary state in obese Zucker rats.  Similar to previous 
work with treadmill training (194), we demonstrated that high volume RE enhances 
PGC-1α protein content in the obese Zucker rat, but not in the lean.  The present study 
suggests that the ability of the obese Zucker rat to respond to an exercise stimulus is 
congruent with enhanced muscle oxidative potential. 
It is important to acknowledge the importance of AMP-activated protein kinase 
(AMPK) in the stimulation of PPARδ and PGC-1α.  In fact, Kramer et al. (122) have 
shown that PPARδ stimulated increases in FAO are abolished when AMPKα has been 
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silenced.  Further evidence also shows that phosphorylation of AMPKα is a potent 
stimulator of PGC-1α transcription (101).  In our study we observed that lean, but not 
obese animals, exhibited enhanced phosphorylation of AMPKα at Thr172 following RE.  
These findings are consistent with those of a previous study in which an attenuation of 
AMPK phosphorylation at Thr172 followed moderate intensity exercise in obese and 
type 2 diabetic humans compared to lean controls (193).  Our data suggest that the 
ability to activate AMPK following an exercise stimulus in the obese may be impaired.  
This is in stark contrast to our data showing that PGC-1α protein was enhanced 
following RE in obese animals rather than lean, as it is believed that AMPK 
phosphorylation is an important stimulus of PGC-1α transcription (101).  To further 
understand these upstream effects, we have also examined the influence of phenotype 
and exercise on LKB1, an important AMPK kinase.  Our data reveal that lean animals 
exhibit greater levels of phosphorylated LKB1 (Ser 428), and that RE had no effect on 
the level of phosphorylation in either phenotype.  We should note that the assessment of 
signaling responses in our present study was conducted 16 h following the last exercise 
bout, which may not be the optimal time point to assess LKB1 and AMPK activation 
responses (phosphorylation) to exercise in either phenotype. 
To identify the functional significance of PPARδ and PGC-1α activation it was 
necessary to understand the influence of our RE stimulus on proteins that are known 
transcriptional targets of PPARδ and PGC-1α.  Although we found a small phenotypic 
effect on the expression of CD36/FAT, whereby, lean animals exhibited greater 
expression of this protein, RE had no influence on its expression.  This observation is 
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consistent with previously published data in which RE had no effect on CD36 mRNA in 
nonobese humans (236).  However, the primary effect of exercise on this PPARδ target 
appears to be a subcellular relocalization rather than altered total expression (96).  Our 
findings related to the effect of exercise on CD36 are in contrast to studies using 
pharmaceutical PPARδ agonists where CD36 content is enhanced (192).  The slight 
depression of  CD36 expression in the obese Zucker rat compared to lean is not 
consistent with reports showing no phenotypic differences (89), and should be further 
explored as a potential mechanism contributing to metabolic dysfunction in the obese.   
In the present study CPT-I, a known rate-limiting element of FAO, revealed greater 
protein content in both lean and obese animals after RE compared to SED conditions, 
suggesting that RE facilitated CPT-I expression in the present study.  This finding is 
consistent with another report in which elevated CPT-I mRNA content was measured 
following endurance exercise (130).  The altered expression of CPT-I is thought to be 
mediated by PPARδ, since the PPARδ agonist GW501516 facilitated CPT-I expression 
induced in humans (192) and cultured human cells (122).  We found the expression 
pattern of CPT-I to be correlated with changes in PPARδ protein content, and this 
association persisted regardless of phenotype in the present study.  These results support 
the notion that high volume RE stimulates PPARδ leading to enhanced ability to oxidize 
fatty acids via enhanced expression of PPARδ targets.   
To further expand on the notion that RE facilitates an improvement in FAO, we 
assessed the effect of exercise and phenotype on the F1 ATPase (a subunit of ATP 
synthase).  The F1 ATPase is an important mitochondrial metabolic protein that is 
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thought to be a target of PGC-1α, independent of its stimulation of PPARδ.  A recent 
study by Garcia-Roves et al. (71) demonstrated that the expression of PGC-1α, PPARδ, 
and ATP synthase are elevated after swim training.  In the present study, we 
demonstrated that RE resulted in elevated protein content of PGC-1α in obese Zucker 
rats, and this elevation was concomitant with elevated F1 ATPase.  Lean rats did not 
exhibit altered expression of either protein following resistance exercise.   At this time, 
we cannot account for the phenotypic differences in these responses, but are confident 
that exercise induced alterations of PGC-1α are accompanied by altered expression of 
specific proteins responsible for mitochondrial substrate delivery and oxidation.  
Recognizing that PGC-1α is considered the master regulator of mitochondrial 
biogenesis, we have employed both conventional (COX-IV) and novel (mtFSR) 
approaches to the assessment of mitochondrial biogenesis.  We have previously used 
2
H2O as a stable isotope label allowing the assessment of fractional synthesis rates over 
the course of 24 h in mixed muscle (72).  By employing this methodology to isolated 
mitochondria we were able to assess cumulative mtFSR in the present study.  Previous 
studies have assessed mtFSR (19, 84, 225); however, our laboratory is the first to assess 
mtFSR based on a cumulative 24 h measurement.  Furthermore, we are the first to 
employ the assessment of mtFSR for the study of PGC-1α induced mitochondrial 
biogenesis.  In the present study, we demonstrated that mitochondrial rates of synthesis 
are similar between phenotypes, but that RE facilitated an increase in mtFSR only in the 
lean animals.  The observation that exercise can elevate mtFSR is supported by 
Wilkinson et al. (225), who demonstrated increased mtFSR following exercise in 
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relatively untrained, healthy individuals.  Guillet et al. (84) found elevated mtFSR 
following resistance exercise, which is consistent with our present work.  It is 
perplexing, however, that we did not measure enhanced mtFSR following exercise in 
obese animals, even though PPARδ and PGC-1α proteins were elevated in this 
phenotype in response to the exercise regimen.  Our data suggest that the role of PGC-1α 
on mitochondrial biogenesis is not mediated by altered mtFSR, given that we do not 
observe any association between the expression of PGC-1α and mtFSR, regardless of 
phenotype.   
A more conventional way to explore mitochondrial biogenesis is by examining 
changes in  COX-IV expression (26, 97, 171) and/or activity (135).  In our study COX-
IV expression was two-fold greater in obese SED animals compared to lean 
counterparts.  Furthermore, in the present study we did not find any association with 
changes in COX-IV and RE that would suggest the induction of mitochondrial 
biogenesis.  However, it should be noted that our study was conducted over 9 days, 
whereas prolonged training may produce different results. 
Previous findings have shown that exercise-induced COX-IV expression is likely a 
result of stimulated PGC-1α and PPARδ (71).  There are two primary points to observe 
from our data.  First, the abundance of COX-IV in obese SED animals is indicative of 
greater mitochondrial volume.  We have noted in our studies that mitochondrial protein 
is about 31% greater per unit wet muscle mass in obese animals than lean (Nilsson et al., 
manuscript in review).  Taken together these data suggest a higher mitochondrial density 
in obese animals than lean, in contradiction to previous work suggesting reduced 
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mitochondrial content in the obese (95).  Second, unlike mtFSR, COX-IV was not 
enhanced following RE in lean animals.  Our data suggest that the use of a single marker 
as an indicator of mitochondrial biogenesis should be viewed with caution.  Combined 
with our findings for PPARδ and PGC-1α protein response and markers of 
mitochondrial biogenesis, our data indicate that in the obese Zucker rat PGC-1α content 
is uncoupled from mitochondrial biogenesis, whether it is assessed on the basis of COX-
IV expression or mtFSR.  Thus, we corroborate the work of others (97) who reported 
that FAO may be uncoupled from PGC-1α with obesity.  Our study offers an explanation 
for this previous observation as the coupling of FAO and PGC-1α likely relies upon 
PGC-1α induced mitochondrial biogenesis.  The failure to induce mtFSR suggests a 
mechanism for metabolic dysfunction in the obese. 
In summary, high volume resistance exercise induced expression of PPARδ and 
PGC-1α content in the obese Zucker rat.  Our data suggest that PPARδ may be important 
in the regulation of blood HDL-cholesterol concentrations in the sedentary state; 
however, this relationship is not apparent 16 h following short term, high volume RE.  
PPARδ and PGC-1α appear to mediate enhanced specific expression of substrate 
delivery and oxidative proteins following RE, including CPT-I and F1 ATPase.  
However, such stimulation of PPARδ and PGC-1α does not result in increased 
mitochondrial biogenesis, as assessed by COX-IV expression or mtFSR, in the obese 
Zucker rat. This suggests that improved metabolism following exercise with obesity is 
due to enhanced substrate delivery and ATP production rather than elevated 
mitochondrial volume.  These results have important implications related to our 
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understanding of mitochondria-mediated control of metabolism with obesity, as well as 
how this control is affected by exercise.  
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CHAPTER V 
CONCLUSIONS 
 
These studies were carried out with the primary goal to enhance understanding of the 
regulation of lipid metabolism in obesity, and how exercise influences dyslipidemia and 
lipid metabolism in the obese.  The first study was designed to further comprehend how 
the obese respond to exercise and exercise training with respect to blood lipids and 
lipoproteins.  The second study was devised to better understand how lipid metabolism 
is regulated in skeletal muscle of obese individuals following exercise and exercise 
training and how this regulation may influence blood lipids and lipoproteins.  The third 
study was employed to develop a greater understanding of differences in regulation of 
lipid metabolism between lean and obese phenotypes and to achieve an improved 
mechanistic understanding of how exercise regulates lipid metabolism and oxidative 
function. 
Exercise and Blood Lipids and Lipoproteins with Obesity 
The first study was conducted to test the hypothesis that both acute exercise and 
exercise training would elicit anti-atherogenic effects on blood lipids and lipoproteins in 
overweight and obese men and women.  Additionally, the influence of exercise training 
on the transient response to acute exercise was tested.  Data from this study showed that 
exercise training sufficient to elicit the expenditure of 1500 kcal·wk
-1
 appears to be more 
efficacious to elicit anti-atherogenic effects on blood lipids and lipoproteins with obesity 
than a single session of exercise, and that this effect occurred regardless of the mode of 
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exercise training employed.  Interestingly, how HDL-C is modified differs between men 
and women.  In men, an increase in total HDL-C concentration was measured; however, 
in women a shift in HDL-C subfractions was observed.  This shift involved a reduction 
in the smaller, more dense HDL3-C subfraction and augmentation of the larger, less 
dense HDL2-C subfraction and was measured with a concomitant reduction in HDL-C 
mean density.  This shift in HDL-C subfractions is consistent with enhanced reverse 
cholesterol transport and a reduction in atherogenic risk (91, 177, 201).   
Conversely, a single bout of exercise with the expenditure of 400 kcal had little 
effect on blood lipids and lipoproteins regardless of exercise training status in this study.  
Acute exercise did induce a reduction in the ratio of TC: HDL-C in men, however, an 
increase in hsCRP and NEFA (in women) was also observed.  In addition, exercise 
training did not affect the transient response to a single session of exercise in the sample 
of overweight and obese men and women. 
These findings support the hypothesis that exercise training would elicit changes in 
blood lipid and lipoprotein concentrations and particle numbers consistent with reduced 
atherogenic risk.  However, acute exercise of 400 kcal did not prove to be a potent 
stimulus of these effects.  Perhaps due to the lack of effect of a single session of exercise 
on these CVD risk markers, no influence was observed of exercise training on transient 
responses to acute exercise. 
Exercise and PPARs with Obesity 
The second study explored the possibility that PPARs are a primary mediator of 
oxidative adaptation to exercise and serve as a principal mechanism for alterations in 
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lipids and lipoproteins following exercise.  Therefore, the following hypotheses were 
tested: 1) acute exercise and exercise training would augment skeletal muscle content of 
PPARδ and related proteins (PPARα, PGC-1α, and AMPKα), 2) enhanced PPARδ 
content would be associated with augmented content of target proteins involved in fatty 
acid and lipoprotein transport and metabolism, and 3) PPARδ content would be 
correlated with blood concentrations of lipids and lipoproteins at rest and following 
exercise.   
In this study, skeletal muscle content of PPARδ and PGC-1α was enhanced 
following a single bout of aerobic exercise.  In addition, content of PPARα and AMPKα 
was enhanced following 12 wks of exercise training.  These data demonstrate the roles 
of acute exercise and exercise training in augmenting the content of proteins involved in 
metabolic regulation and adaptation.  Enhanced expression of proteins involved in 
oxidative function and adaptation and lipoprotein metabolism, which are transcriptional 
targets of PPAR, was measured.  Moreover, mitochondrial biogenesis, as assessed by 
COX-IV content, was enhanced following exercise training.  Similar to results in the 
first study, exercise training-induced adaptations occurred regardless of the mode of 
exercise training employed.  With regards to the regulation of blood lipids and 
lipoproteins, PPARδ content was correlated with the serum concentration of total and 
LDL-cholesterol, whereas AMPKα content was correlated with the concentration of 
HDL-C and its subfractions.   
These data support the hypothesis that exercise augments the expression of PPARδ, 
PPARδ-related proteins, and transcriptional targets of PPARδ.  However, while a single 
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session of aerobic exercise enhanced expression of PPARδ and PGC-1α, a significant 
influence of exercise on PPARα and AMPKα was only seen in the exercised, trained 
condition.  Additionally, exercise did augment the protein content of purported PPARδ 
transcriptional targets.  While a relationship was observed between PPARδ and total and 
LDL-C concentrations this effect was not seen with respect to HDL-C.  Therefore, while 
PPAR may be involved in the regulation of blood lipids and lipoproteins further research 
is necessary to better define such regulation.  These data indicate the importance of 
skeletal muscle in the regulation of lipid and lipoprotein concentrations.  Furthermore, 
PPARδ and AMPKα appear to serve as primary mediators of this function of skeletal 
muscle. 
Exercise and PPAR in the Lean and Obese Zucker Rat 
In the third study, the influence of obesity and high volume resistance exercise on 
lipid and lipoprotein metabolism was explored in a rodent model.  High volume RE was 
chosen in this study as a model of the ATM exercise utilized in the first two studies.  The 
rationale for using RE is that ATM exercise may induce a hypertrophic response (82) 
which is not consistent with other forms of aerobic exercise.  In contrast, high volume 
RE induces similar hypertrophic responses to ATM exercise while also showing the 
potential to induce oxidative adaptations similar to that seen with aerobic exercise (161, 
203).   
Therefore, in this study the following hypotheses were tested: 1) high volume RE 
would enhance PPAR and PGC-1 content in lean and obese Zucker rats, 2) these effects 
would be associated with augmented content of PPAR and PGC-1 target proteins 
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involved in FA transport and metabolism, as well as, enhanced mitochondrial 
biogenesis, and 3) PPARδ content would be correlated with blood concentrations of 
lipids and lipoproteins at rest and following exercise in both phenotypes.   
In study 3, high volume RE augmented PPARδ expression, regardless of phenotype.  
In comparison, high volume RE induced the expression of PGC-1α in obese animals 
only.  Perhaps the most novel finding of this study was that despite enhanced PGC-1α 
content, obese Zucker rats showed no significant exercise-induced mitochondrial 
biogenesis.  These data demonstrate that despite the ability to induce signaling 
conducive of mitochondrial biogenesis and the expression of proteins involved in 
oxidative function (such as CPT-I and F1 ATPase), obese animals exhibit an impairment 
in the ability to exhibit mitochondrial biogenesis.  It is not known why obese animals 
appear resistant to such a response.  However, given an already elevated mitochondrial 
volume measured in the obese animals, such a response may not be necessitated by the 
exercise paradigm.  The measures of mitochondrial biogenesis used in this study are 
reliant upon the induction of protein synthesis (COX-IV expression and mtFSR).  
However, obese animals may exhibit an impaired ability to induce enhanced rates of 
protein synthesis.  Previous observations have suggested already elevated rates of 
protein synthesis in obese Zucker rats compared to lean in the basal state; therefore, 
basally elevated protein synthesis may impair the ability to induce augmented protein 
synthesis with the exercise paradigm (68). 
These data support the hypothesis that high volume RE would elicit augmented 
PPARδ and PGC-1α content in the obese Zucker rat.  However, PGC-1α was not 
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augmented by high volume RE in lean littermates.  Similarly, high volume RE yielded 
concurrent enhancements in target proteins involved in FA transport and oxidative 
metabolism.  By contrast, these data do not support the hypothesis that these responses 
would result in mitochondrial biogenesis in the obese Zucker rat, nor was a significant 
relationship between PPARδ and blood lipids and lipoproteins observed. 
Comprehensive Conclusions 
Primary findings of these studies include: 1) exercise-induced changes in lipid and 
lipoprotein concentrations in the obese appear to be primarily mediated by exercise 
training, 2) PPARδ and AMPKα expression are induced by exercise and appear to serve 
as regulatory points for lipid and lipoprotein concentrations at rest and following 
exercise, and 3) despite induction of PPARδ and PGC-1α following exercise, the obese 
Zucker rat failed to undergo significant mitochondrial biogenesis.   In the second study 
the most consistent finding regarding the role of skeletal muscle in lipid and lipoprotein 
concentrations was that AMPKα was correlated with HDL-C and its subfractions in all 
conditions.  What makes this more intriguing is that the primary influence of exercise on 
cholesterol in the sample of obese humans was an exercise training effect on HDL-C and 
its subfractions.  Similarly, AMPKα expression was induced only after exercise training.  
That these effects occurred in parallel provides further evidence for the impact of 
AMPKα on HDL-C.  In addition, the relationship observed in study two between 
PPARδ, AMPKα and blood cholesterols in obese humans was not present in the Zucker 
rat.  While mechanisms related to the discrepant findings between studies are unclear, it 
may represent species-specific differences for the role of skeletal muscle in regulating 
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blood cholesterols in humans and rats.  Alternatively,  the induction of AMPKα 
expression and the exercise-induced alterations in HDL-C in the human studies occurred 
after 12 wks of exercise training; whereas, observations from the third study were 
obtained after four sessions of exercise in 9 days.  Therefore, it is possible that a longer 
term training protocol, even in rats, may demonstrate similar relationships as seen in this 
sample of humans.  While a similar relationship between PPARδ and cholesterol was 
hypothesized despite species differences in cholesterol metabolism, these differences 
should be considered.  Very simply, humans are LDL-C animals, that is the primary 
cholesterol fraction in human serum is LDL-C, whereas, rats are HDL-C animals.  These 
species differences may be reflective not only of hepatic differences in cholesterol 
metabolism but also in differences in the metabolism and transport of cholesterol by 
peripheral tissues, such as skeletal muscle. 
Similarly, induction of mitochondrial biogenesis was observed in the sample of 
overweight and obese human subjects but not in the obese Zucker rat.  As discussed, the 
measures of mitochondrial biogenesis utilized in both models are based on enhanced 
protein content and synthesis.  It is possible that the obese Zucker rat is already 
operating at a maximum rate of protein synthesis and therefore may not be capable of 
eliciting enhanced mtFSR (68).  However, a single bout of exercise did not induce a 
significant enhancement in mitochondrial biogenesis in the sample of human subjects, 
this effect occurred only after exercise training.  Therefore, it is also likely that to 
observe such a response a longer term stimulus would be necessary in the Zucker rat.  In 
addition, while there are recognized differences in the exercise paradigm, the high 
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volume RE employed in the third study did induce enhanced mtFSR in the lean Zucker 
rat.  Therefore, an effect of mitochondrial biogenesis can be expected with this protocol. 
Finally, in the obese Zucker rat enhanced expression of F1 ATPase (subunit of ATP 
synthase) was measured following exercise.  This effect was not seen in the human 
subjects.  This disparity may be a primary difference in the exercise paradigm.  While 
many of the effects measured were consistent between the exercise paradigms regarding 
the enhancement of oxidative function, the exercise protocol used in the third study 
likely involves a more explosive muscle contraction than the treadmill paradigms used in 
the human studies.  This may, in fact, necessitate the induction of F1 ATPase, to provide 
a higher rate of ATP production with the high volume RE paradigm but not with the 
treadmill paradigms. 
Significance 
These studies enhance understanding of the regulation of skeletal muscle energy 
metabolism and its link to disease, in particular obesity.  The presented data 
demonstrating the efficacy of exercise training to improve CVD risk factors in 
overweight and obese men and women better enable practitioners to utilize aerobic 
exercise as a therapeutic agent in this population.  These effects appear to occur 
regardless of the mode of exercise training utilized, ATM or LTM.  Additionally, these 
data provide evidence of how lipid and lipoprotein concentrations are regulated both at 
rest and following exercise.  By demonstrating the potentially important role of skeletal 
muscle PPARδ and AMPKα expression in regulating lipids and lipoproteins, strategies 
may be developed to target these proteins in an effort to improve CVD risk.  In addition, 
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data demonstrating the influence of high volume RE in the lean and obese Zucker rat 
improve the understanding of how metabolism may be dysregulated in the obese 
condition.  The demonstration that PGC-1α content is uncoupled from mitochondrial 
biogenesis in these animals may explain previous findings that PGC-1α is uncoupled 
from FAO in obese humans.   
Limitations and Delimitations 
Delimitations.   
The delimitations of the human studies include:  otherwise healthy, overweight and 
obese adult men and women, nonsmokers who are not taking medications known to alter 
lipid metabolism, acute exercise of 400 kcal, exercise training of 1500 kcal·wk
-1
 using 
either LTM or ATM modes, fasting blood and muscle samples obtained after three days 
without exercise or 24 h post-exercise, blood lipid and lipoprotein concentrations 
adjusted for shifts in plasma volume following acute exercise, the content of the proteins 
measured.  The delimitations of study 3 (obese Zucker rat) include:  lean and obese 
Zucker rats, the high volume RE model employed, the content of the proteins that were 
measured, phosphorylation of AMPKα and LKB1, and concentration of the blood lipids 
and lipoproteins measured (TC, HDL-C, LDL-C, NEFA), and assessment at 16 h post-
exercise.   
Furthermore, these studies are delimited to the assessment of the protein content of 
the targets of interest.  As a transcription factor, the direct effect of PPAR, and of PGC-
1α as a transcriptional coactivator, is on the transcription of DNA to mRNA, rather than 
mRNA translation to protein.  Therefore, the most direct measure of the effect of PPAR 
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would have been to assess mRNA content of target genes.  However, the measurement 
of protein of these target genes provides a greater look at the functional effect of 
upregulating the PPAR pathway following an exercise stimulus.   
Limitations.   
Limitations of the human studies include:  all subjects resided in the same 
geographical area, dietary and activity analysis was based on self-reported information, 
findings relate only to otherwise healthy physically inactive overweight and obese men 
and women, self-reported exercise abstinence during sample collection periods, and 
subject compliance.  Limitations of study 3 (obese Zucker rat) include:  findings are 
limited to male lean and obese Zucker rats, findings cannot be extrapolated beyond the 
short term of the exercise protocol, findings are specific to the exercise protocol and to 
assessment of samples at 16 h post-exercise.  
In addition, due to the descriptive nature of these studies, the described relationship 
between PPAR, PGC-1α and AMPKα with target proteins and blood lipids and 
lipoproteins is merely indicative of a regulatory role of these proteins on the described 
effects.  To prove this cause/effect relationship it would be necessary to inhibit the 
PPAR, PGC-1α and AMPKα pathways in an effort to blunt the observed effects on 
known targets.  A reduced or eliminated effect would then directly indicate the necessity 
for these proteins in mediating oxidative function, and blood lipids and lipoproteins.   
Summary 
In summary, in this dissertation the ability of exercise to induce metabolic 
adaptations in the obese which are likely mediated by PPAR has been demonstrated.  
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The induction of significant changes in blood lipids and lipoproteins in the obese appears 
to be primarily regulated by the performance of an exercise training program.  Together 
with previous data, the current data suggest that the attainment of such a training 
adaptation requires the expenditure of at least 1500 kcal·wk
-1
.  In both human and rat 
models of obesity exercise induced augmented expression of PPARδ and PGC-1α 
following a single bout of exercise.  In the human model exercise training further 
increased expression of PPARα and AMPKα following exercise training.  These 
findings were seen with a concomitant induction of proteins involved in oxidative 
transport and function in both models.  This indicates the ability of both the obese rat 
and human to adapt to exercise in a manner consistent with enhanced oxidative function 
which is likely mediated by PPAR.  The data presented in this dissertation describe the 
likely regulation of blood lipids and lipoproteins by skeletal muscle, and more 
specifically by PPARδ and AMPKα. 
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APPENDIX A 
 
INFORMED CONSENT 
 
Molecular Basis for the Lipid Response to Acute Exercise Before and After 
Exercise Training 
 
You have been asked to participate in a research study of the effects of acute 
exercise and blood lipids and lipoproteins.  You were contacted through posted notices 
or word-of-mouth.  Your participation is completely voluntary, and that you were 
selected as a possible participant because of your physical conditions that are suitable 
for this study.  Twenty people will be recruited to participate in this study.  The purpose 
of this study is:  1) to analyze the way your body responds to acute exercise and 
exercise training; and 2) to investigate a potential mechanism for how this occurs. 
 You will be asked to perform several procedures requiring a total of about 4 
hours in the laboratory to test your physical fitness and health.  These tests may require 
that you visit the laboratory on two separate days.  You will be asked to perform a 
graded exercise test (GXT) by walking or running on a land-based, motorized treadmill 
until you are exhausted.  While you are doing this test, you will be asked to have 
electrodes attached to your chest to measure the activity of your heart through an 
electrocardiogram (ECG), you will be asked to breathe through a mouthpiece connected 
to a machine to measure the amount of oxygen your body is using, and your blood 
pressure will be measured.  After the GXT, you will be asked to have an earlobe stick 
with a small lancet like ones used for finger sticks so that about two drops of blood can 
be collected to measure a substance in your blood (lactic acid) produced by exercise.  
You will be asked to also be asked to perform tests to measure your muscle strength, 
endurance, and flexibility.  Your body bone density and body fat will be measured by 
lying at rest wearing exercise clothing in a DEXA (Dual Energy X-ray Absorptiometry) 
scanning machine.  This machine will scan the body with a small amount of X-ray 
radiation.  The radiation exposure is comparatively less than the amount of natural 
radiation you would be subjected to flying in an airplane from Houston to Dallas.  
Anytime you feel uncomfortable in the machine you can remove yourself from it.  You 
will be asked to also have circumference measures taken on parts of your body, 
including your hip and abdomen.  You will be asked to breathe through a mouthpiece 
attached to a machine to measure your breathing capacity and the health of your lungs.  
During these tests a local physician will be present and consult with each individual 
prior to exercise as well as review each subject’s ECG and make an assessment as to 
your cardiovascular risk, if the physician determines that you are at risk for 
cardiovascular disease you will be referred to a cardiologist and removed from the study 
at least until the time that the cardiologist gives written consent for your participation. 
 At least one week after these measures have been taken, you will be asked to 
complete an acute session on a motorized treadmill.  During these exercise sessions, 
your heart rate, blood pressure, and oxygen uptake will be measured.  Twenty-four 
hours before and again 24 hours following the acute exercise session the researchers 
will take blood and muscle samples.  First, you will be asked to have about 3 to 4 
teaspoons (15 to 20 ml) of blood drawn from a vein in your arm so that your blood fats 
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and cholesterol can be measured.  Also at these times, you will be asked to give a small 
piece of muscle from your thigh muscle.  The amount of muscle that will be taken is 
about the size of a pea.  Muscle samples will be stored for measurement of factors 
related to your muscles use of fats and cholesterol, leftover sample will be stored by the 
AESL for potential future use as relates to the context of this study.  These samples will 
be used to measure cellular mechanisms and factors related to lipids and cholesterol 
before and after exercise.  Blood and muscle samples will be stored by the AESL for 
potential future measurements related to the context of this experiment. 
 Once you complete the exercise sessions on the water treadmill, you will be 
assigned at random to complete an exercise training program on either the land-based 
treadmill or the water treadmill.  The training program will last 12 weeks, and require 
you to train 3 times per week for about 20 minutes to an hour each day.  You will have a 
personal trainer from the Applied Exercise Physiology Laboratory staff assigned to 
supervise each training session, and each session will be personalized for you.  You will 
be asked to walk or run on your assigned treadmill for each training session until you 
expend about 500 kilocalories of energy.  The physical effort required to complete each 
exercise session will be easy to moderate at the beginning, but will steadily increase 
from moderate to hard as you get in better physical condition.   
 After 12 weeks of training, you will be asked to repeat all the measures taken at 
the beginning of the study, including blood sampling, maximal effort GXT, body 
composition, lung tests, and assessment of my muscle strength, endurance, and 
flexibility.  Values obtained from these measurements will be used to compare to your 
pre-training values to see how well the training program worked.  In addition you will be 
asked to repeat the acute exercise session and subsequent muscle biopsy. 
 The physical exertion required of you in this study will range from easy to 
maximal effort.  During exercise there are physical risks to you including: muscle and 
bone strains and sprains, abnormal blood pressure, fainting, abnormal heart beats, 
shortness of breath, and in rare instances heart attack. 
 The data collected during this study is confidential and the names of all the 
subjects will be entered as a code in data analysis to ensure the confidentiality.  The 
records of this study will be kept private.  No identifiers linking you to the study will be 
included in any sort of report that might be published.  Research records will be stored 
securely and only Nicholas P. Greene and his research collaborators will have access 
to the records.  Your decision whether or not to participate will not affect your current 
relations with Texas A&M University.  If you decide to participate, you are free to refuse 
any situations that may be objectionable.  You can withdraw at any time without your 
relations with the university, job, benefits, etc., being affected.  You can contact 
Stephen F. Crouse at 112 Netum Steed Laboratory, (979) 845-3999 (s-
crouse@tamu.edu) with any questions about this study.  If Stephen F. Crouse is not 
available, you can contact the department head, Robert Armstrong. 
 This research has been reviewed by the Institutional Review Board – Human 
Subjects in Research, Texas A&M University.  For research-related problems or 
questions regarding subjects’ rights, you can contact the Institutional Review Board 
through Ms. Angelia M. Raines, Director of Research Compliance, Office of Vice 
President for Research at (979) 458-4067 (araines@vprmail.tamu.edu). 
 Please be sure you have read the above information, asked questions and 
received answers to your satisfaction.  You will be given a copy of the consent form for 
your records.  By signing this document, you consent to participate in the study. 
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Signature of Participant:   Date:  
 
 
 
Signature of Investigator:  Date:  
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APPENDIX B 
 
ACTIVITY RECORD AND COMPLIANCE FORM 
 
  
Name:                  Age:   Ht:               Wt:                 
 
Address:      Phone:     (W)  
        (H) 
  _____________________  Occupation:   
              
 
 
DIRECTIONS:  This Seven Day Physical Activity Record is designed to measure your 
habitual physical activities over the course of one week.  You are asked to record your 
sleep habits as well as the physical activities you participated in over the course of the 
past seven days; include both occupational and leisure-time physical activities.  
 
1. BEFORE READING ANY FURTHER, PLEASE REVIEW 
ATTACHMENT 1 FOR EXAMPLES OF LIGHT, MODERATE, HARD, 
AND VERY HARD PHYSICAL ACTIVITIES! 
 
2. DO NOT RECORD LIGHT ACTIVITIES.  See Attachment 1 for examples 
of LIGHT ACTIVITIES.  Most of you will spend the majority of your waking 
hours in light activity.  For example, a laboratory worker may be on their feet all 
day and may feel "fatigued", but the energy cost is in the "light" category.  
However, we need you to record the number of hours you spend sleeping. 
 
3. For all other physical activities, which may be classified as moderate, hard, or 
very hard, DOCUMENT ONLY THE TIME ACTUALLY SPENT 
PERFORMING THE ACTIVITY:  Include both occupational and leisure-time 
activities.  For example, the laboratory worker in the illustration given above 
may spend a number of hours stocking shelves with supplies, which would likely 
be moderate exercise.  It is unlikely, however, that they would spend an 8 hour 
day performing this task, and time should be subtracted for lunch, breaks, etc.  
Similarly, being at the pool for 2 hours but swimming for 15 minutes should be 
recorded as 15 minutes, not 2 hours. 
 
4. For this record to be representative of your normal physical activity habits, it is 
critical that the week's activities be "normal" for you.  For example, a week in 
which you take a holiday or a few days vacation would clearly NOT be a 
"normal" week for you.  IF THE UPCOMING WEEK'S ACTIVITIES WILL 
NOT REPRESENT YOUR NORMAL ACTIVITY PATTERNS, THEN 
PLEASE DO NOT COMPLETE THIS FORM - WAIT FOR A WEEK 
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THAT WILL REFLECT YOUR NORMAL PHYSICAL ACTIVITY 
PATTERNS.  Note that a week is not necessarily Sunday through Saturday, but 
may be any consecutive 7 day period. 
 
5. Use the record forms beginning on the next page to record; (1) the physical 
activity, (2) the total hours/minutes spent performing the activity, (3) and rate 
how hard you worked at the particular physical activity.  Use the following scale 
to rate how hard you worked. 
 
6.  Return this completed record to the laboratory staff at your next laboratory 
visit. 
 
SCALE TO RATE HOW HARD YOU WORK 
 
1 - Barely breaking a sweat; breathing just slightly elevated. 
2 - Moderate sweating; breathing significantly above normal, but 
could talk normally. 
3 - Heavy sweating; breathing very heavy to nearly winded, could 
NOT talk normally. 
 
PLEASE GO TO THE NEXT PAGE TO BEGIN YOUR SEVEN DAY ACTIVITY 
RECORD 
 
*From:  Blair et al., Assessment of habitual physical activity by a seven day recall in a 
community survey and controlled experiments.  Am. J. Epidem. 122:794-804, 1985. 
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DAY ONE 
 
Date:                    Day of Week:      
 
 
 
Activity  
 
TOTAL TIME 
(Hours:Minutes) 
 
HOW 
HARD 
(1,2,3) 
 
Sleeping, including naps 
  
   
   
   
   
   
 
 
 
DAY TWO 
 
Date:               Day of Week:      
 
 
Activity  
 
TOTAL TIME 
(Hours:Minutes) 
 
HOW 
HARD 
(1,2,3) 
 
Sleeping, including naps 
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DAY THREE 
 
Date:                    Day of Week:      
 
 
 
Activity  
 
TOTAL TIME 
(Hours:Minutes) 
 
HOW 
HARD 
(1,2,3) 
 
Sleeping, including naps 
  
   
   
   
   
   
   
 
 
 
DAY FOUR 
 
Date:               Day of Week:      
 
 
Activity 
 
TOTAL TIME 
(Hours:Minutes) 
 
HOW 
HARD 
(1,2,3) 
 
Sleeping, including naps 
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DAY FIVE 
 
Date:                    Day of Week:      
 
 
 
Activity 
 
TOTAL TIME 
(Hours:Minutes) 
 
HOW 
HARD 
(1,2,3) 
 
Sleeping, including naps 
  
   
   
   
   
   
 
 
 
DAY SIX 
 
Date:               Day of Week:      
 
 
Activity 
 
TOTAL TIME 
(Hours:Minutes) 
 
HOW 
HARD 
(1,2,3) 
 
Sleeping, including naps 
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DAY SEVEN 
 
Date:                    Day of Week:      
 
 
 
Activity 
 
TOTAL TIME 
(Hours:Minutes) 
 
HOW 
HARD 
(1,2,3) 
 
Sleeping, including naps 
  
   
   
   
   
   
 
 
 CONCLUDING QUESTIONS 
 
1. Would you say that during the past week you were (check one): 
_____less active than usual 
_____about as active as usual 
_____more active than usual 
 
2. Which statement most nearly describes your attitude toward leisure-time physical 
activity? 
_____I absolutely detest physical activity and exertion of any type. 
_____I do not enjoy physical activity or exertion of any type. 
_____I do not like activities which make me sweat, but I do like some 
types of light activities. 
_____I enjoy light physical activity of many types, and occasionally like 
hard physical activity. 
_____I thoroughly enjoy all types of physical activities, even those which 
are hard and very hard. 
 
3. When you have time off from work (weekends/vacations) or during work breaks 
(lunch, etc), how often do you participate in physical activities, including recreational 
sports, which would be considered moderate to very hard? 
_____Never 
_____Seldom 
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_____Sometimes/Irregularly 
_____Frequently/Regularly 
_____Almost Always 
 
THANK YOU VERY MUCH FOR YOUR TIME AND ACCURACY IN 
COMPLETING THIS 
QUESTIONNAIRE.  THIS INFORMATION IS INDISPENSABLE FOR OUR 
STUDY, AND WE THANK YOU FOR YOUR WILLINGNESS TO COOPERATE IN 
COMPLETING THIS FORM. 
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ACTIVITY COMPLIANCE 
 
 
 
NAME:______________________________                               
DATE:______________ 
 
 
 
1. My activity level (has / has not) changed from the last activity record submitted. 
 
 
2. My activities have changed as follows: 
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________ 
 
 
 
 
                                                          Printed Name ___________________________ 
 
                                                          Signature _______________________________ 
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APPENDIX C 
 
3 DAY DIET RECORD AND COMPLIANCE FORM 
 
APPLIED EXERCISE SCIENCE LABORATORY 
HYDROWORX PROJECTS 
THREE DAY DIET RECORD 
 
 
Name:_____________________      Age:______      Ht:________     Wt:_______ 
 
 
DIRECTIONS:  This Three Day Diet Record is designed to measure your food intake 
over the course of three consecutive days.  Please make sure that ONE recorded day is a 
weekend.  Because of this requirement, this record should be filled out Thursday, 
Friday, Saturday OR Sunday, Monday, Tuesday.    
 
1. Records should be kept over a time period that best represents your ―normal‖ 
eating patterns for 2 weekdays and one weekend day.  For example, if Monday is 
a work holiday, it is unlikely that you will eat as you normally would.   
 
2. Record ALL food and drink (including water) that you consume on each day.  
Record both the type of food or drink and the amounts consumed. 
 
3. Please be as specific on foods and amounts as possible.  For example, if you eat a 
turkey sandwich, please record the type of bread (white, whole wheat, rye, etc), 
number of slices of meat, and any additional items (cheese, tomato, mayonnaise, 
etc).  Also include brand names of items when possible.  For help in determining 
what is considered a serving, see the serving size chart on page 2 for some 
common food items. 
 
4. Page 3 shows a sample day of the diet record.  Please read this to help you 
become familiar with the recording format. 
 
5. If you have any questions about filling out the record, please contact laboratory 
staff for assistance. 
 
6. Return this record to the laboratory staff once it is complete.  
 
 
Please do not change your diet in any way during the course of the study.  
Maintain normal eating habits, please do not begin a “diet”.  If you travel, don’t 
worry, these changes from normal are only temporary.   
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Serving Size Chart 
 
 
        1 Cup cereal flakes or 1 baked potato = size of a fist 
 
    ½ cup cooked rice, pasta or potato = size of an ice cream scoop 
 
 
      1 pancake = size of a CD 
 
        1 cup of salad greens or 1 medium fruit = size of a baseball 
 
          ½ cup fresh fruit or vegetables = size of a standard light bulb 
 
     ¼ cup dried fruit = 1 large egg 
 
 
         3 oz. meat, fish, poultry = size of a deck of cards 
 
 
          2 Tbsp peanut butter = size of a golf ball 
 
 1 ½ oz. cheese = 4 stacked dice or 2 cheese slices; 1 tsp margarine, 
butter and spreads = 1 dice 
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DAY 1          Date: _________          Day of 
Week:___________________ 
 
    
 
# of servings 
# of 
servings 
Food Eaten  or amount Food Eaten  or amount 
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    DAY 2          Date: _________          Day of 
Week:___________________ 
 
    
 
# of servings 
# of 
servings 
Food Eaten or amount Food Eaten or amount 
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    DAY 3          Date: _________          Day of 
Week:___________________ 
 
    
 
# of servings 
# of 
servings 
Food Eaten or amount Food Eaten or amount 
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    DAY 1          Date: SAMPLE         Day of Week: _SAMPLE DAY__ 
 
 
# of servings 
# of 
servings 
Food Eaten  or amount Food Eaten  or amount 
Breakfast       
coffee (caffinated) 1-8oz cup     
   w/ half&half 2 Tbsp     
Raisin Bran cereal 1 cup     
    w/ 1% milk 1 cup     
Multivitamin 1 vitamin     
Lunch       
Turkey sandwich (homemade)       
    w/ turkey deli meat 3 slices     
    w/ Kraft American cheese 1 slice     
    w/ Lite mayo 2 Tbsp     
    w/ whole wheat bread 2 slices     
apple 1 medium     
Lay's potato chips 1 snack bag     
Sprite 12oz can     
Snacks       
water 20oz bottle     
Nature's Own honey granola bar 2 bars     
Hershey's Kisses 3 kisses     
Dinner       
McDonald's Big Mac       
    w/ cheese and mayo       
french fries medium     
Bluebell Vanilla Ice Cream 2 scoops     
    w/ chocolate syrup 2 Tbsp     
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DIET COMPLIANCE 
 
 
 
NAME:______________________________                               
DATE:______________ 
 
 
 
1. My diet (has / has not) changed from the last diet record submitted. 
 
 
2. My diet changed as follows: 
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
__________________________________________________________
______________________________________ 
 
 
 
 
                                                          Printed Name _____________________ 
 
                                                          Signature ________________________
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APPENDIX D 
 
ACUTE EXERCISE WORKSHEET 
PRE-EXERCISE DATA 
Name:                                                                                     Date:               Age: _______   Height:        in Weight:  lb Medical History:                                                   
Medications/Doses:                                                 
Target: Intensity  % Duration  min VO2target   L · min
-1    
Exercise1:         Speed mph Grade % Energy expenditure  kcal 
Exercise2:         Speed mph Grade %         RHR_______bpm         
Exercise3:         Speed mph Grade %         RSBP_____mmHg      RDBP___mmHg 
EXERCISE DATA 
Note:  Collect and record data (ie: VO2, HR, RER, RPE)  throughout the 1
st minute of warm-up, and 
during the exercise periods indicated below. Adjust the treadmill elevation as necessary to maintain the 
prescribed VO2. 
Time 
(min) 
Speed 
(mph) 
Grade  
(%) 
 HR 
(bpm) 
 RPE VO2 
(L/min) 
RER  Comments 
Warmup 
0-3 
 
3.0 
 
0 
     
Exercise  
3-5 
 
 
      
10-12         
20-22        
30-32        
40-42        
Cool Down        
0-3 2.2 0      
5-7        
 POSTEXERCISE DATA 
Duration   min  
 
Total Kcal    Comments        
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APPENDIX E 
 
SAMPLE TRAINING LOG 
 
12 WEEK EXERCISE LOG 
Texas A&M University Applied Exercise Science Lab 
 
NAME:_________________  PHONE:______________ 
VO2MAX: ________ 
 
 
SPOT CHECK VO2 
WEEK: 1    DATES: _____ - _____        INTENSITY: 50-60% VO2: ________ 
TARGET SPEED:    JET: 
TARGET KCAL: 250 TARGET HR: _______ TARGET TIME: ______ 
DATE: _______  DATE: ________  DATE: _______ 
PRE-WT: _______  PRE-WT: ________ PRE-WT: _______ 
RBP:        /         RBP:         /          RBP:        /____        
RHR: _____   RHR: ______  RHR: ______ 
EXER HR: ______  EXER HR: ________ EXER HR: ________ 
RPE: ______  RPE: _______  RPE: _______ 
SPEED: _______  SPEED: ________  SPEED: _______ 
JET: _______  JET: ________  JET: _______ 
TIME: _______  TIME: ________  TIME: ________ 
POST-WT: ________ POST-WT: ________ POST-WT: _________ 
POST-BP:        /____ POST-BP:        /____ POST-BP:        /____  
POST-HR: ________ POST-HR: ________ POST-HR: ________ 
PAIN: _________  PAIN: _________  PAIN: _________ 
COMMENT:           
 ______________________________________________________          
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WEEK: 2    DATES: _____ - _____        INTENSITY: 60-65% VO2: ________ 
TARGET SPEED:   JET: 
TARGET KCAL: 300 TARGET HR: _______ TARGET TIME:________ 
DATE: _______  DATE: ________  DATE: _______ 
PRE-WT: _______  PRE-WT: ________ PRE-WT: _______ 
RBP:        /         RBP:         /          RBP:        /____        
RHR: _____   RHR: ______  RHR: ______ 
EXER HR: ______  EXER HR: ________ EXER HR: ________ 
RPE: ______  RPE: _______  RPE: _______ 
SPEED: _______  SPEED: ________  SPEED: _______ 
JET: _______  JET: ________  JET: _______ 
TIME: _______  TIME: ________  TIME: ________ 
POST-WT: ________ POST-WT: ________ POST-WT: _________ 
POST-BP:        /____ POST-BP:        /____ POST-BP:        /____      
POST-HR: ________ POST-HR: ________ POST-HR: ________ 
PAIN: _________  PAIN: _________  PAIN: _________ 
COMMENT:           
 ______________________________________________________          
   
 
WEEK: 3    DATES: _____ - _____        INTENSITY: 65-70% VO2: _______ 
TARGET SPEED:   JET: 
TARGET KCAL: 350 TARGET HR: _______ TARGET TIME: ______ 
DATE: _______  DATE: ________  DATE: _______ 
PRE-WT: _______  PRE-WT: ________ PRE-WT: _______ 
RBP:        /         RBP:         /          RBP:        /____        
RHR: _____   RHR: ______  RHR: ______ 
EXER HR: ______  EXER HR: ________ EXER HR: ________ 
RPE: ______  RPE: _______  RPE: _______ 
SPEED: _______  SPEED: ________  SPEED: _______ 
JET: _______  JET: ________  JET: _______ 
TIME: _______  TIME: ________  TIME: ________ 
POST-WT: ________ POST-WT: ________ POST-WT: _________ 
POST-BP:        /____ POST-BP:        /____ POST-BP:        /____ 
POST-HR: ________ POST-HR: ________ POST-HR: ________  
PAIN: _________  PAIN: _________  PAIN: _________    
COMMENT:           
 ______________________________________________________          
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APPENDIX F 
 
ZUCKER RAT EXERCISE LOG 
 
Rat #: ______ Cohort:_________  Type: Lean or Obese 
 
Session Shocks Repetitions Notes 
Weight Pred 
Reps 
Actual 
Reps 
OC1 
 
Date: 
 N/A 50   
    
    
    
OC2 
 
Date: 
 N/A 50   
    
    
    
OC3  N/A 50   
    
Date:     
    
OC4 
 
Date: 
 NoRT 50   
    
    
    
OC5 
 
Date: 
 NoRT 50   
    
    
    
OC6 
 
Date: 
 NoRT 35-40   
    
    
 80g 10-15  
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Rat #: ______ Cohort:_________  Type: Lean or Obese 
 
 
 
Session Shocks Repetitions Notes 
Weight Pred 
Reps 
Actual 
Reps 
RT1 
 
Date: 
 30 14   
 80 12  
 130 10  
 180 8  
 230 6  
RT2 
 
Date: 
 80 16   
 80 16  
 130 10  
 180 10  
 230 8  
RT3 
 
Date: 
 80 18   
 130 16  
 180 14  
 180 14  
 230 8  
RT4 
 
Date: 
 80 18   
 130 16  
 180 14  
 180 14  
 230 8  
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APPENDIX G 
 
SAMPLE STATISTICAL CODE AND RAW DATA FOR CHAPTER II 
 
 
Variable Definitions: 
 
Independent Variables 
 Unique Identifier ID 
Gender (M F) GENDER 
Age (years) AGE 
Height (inches) HEIGHT 
Treadmill Type (LAND or WATER) MODE 
Timepoint TIMEPT 
Training Time Point (PRE or POST) TRAINING 
Acute Exercise (Rest or 24) EX 
 
Dependent Variables 
Total Cholesterol St Joseph's (mg/dL) TCS 
HDL Cholesterol St Joseph's (mg/dL) HDLS 
LDL Cholesterol St Joseph's (mg/dL) LDLS 
Triglycerides St Joseph's (mg/dL) TAGS 
Glucose St Joseph's (mg/dL) GLUCOSES 
Total Cholesterol Spectracell Analysis (mg/dL) TCSPE 
Triglycerides Spectracell Analysis (mg/dL) TAGSPE 
VLDL-Cholesterol Spectracell Analysis (mg/dL) VLDLSPE 
LDL-Cholesterol Spectracell Analysis (mg/dL) LDLSPE 
Remnant Lipoprotein Spectracell Analysis (mg/dL) RLPSPE 
IDL-Cholesterol Spectracell Analysis (mg/dL) IDLSPE 
LDL3-Cholesterol Spectracell Analysis (mg/dL) LDL3SPE 
LDL4-Cholesterol Spectracell Analysis (mg/dL) LDL4SPE 
HDL-Cholesterol Spectracell Analysis (mg/dL) HDLSPE 
HDL2b-Cholesterol Spectracell Analysis (mg/dL) HDL2BSPE 
HDL2a-Cholesterol Spectracell Analysis (mg/dL) HDL2ASPE 
HDL3-Cholesterol Spectracell Analysis (mg/dL) HDL3SPE 
Total Cholesterol: HDL-C ratio Spectracell Analysis TCHDLSPE 
VLDL-Cholesterol Particle Number Spectracell VLDLPRT 
LDL-Cholesterol Particle Number Spectracell LDLPRT 
Remnant Lipoprotein Particle Number Spectracell  RLPPRT 
LDL3-Cholesterol Particle Number Spectracell  LDL3PRT 
LDL4-Cholesterol Particle Number Spectracell  LDL4PRT 
HDL-Cholesterol Particle Number Spectracell  HDLPRT 
HDL2b-Cholesterol Particle Number Spectracell  HDL2BPRT 
LDL Mean Density Spectracell Analysis (g/cm^3) LDLDENS 
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Lipoprotein (a) Spectracell Analysis (mg/dL) LPaSPE 
C-Reactive Protein Spectracell Analysis (mg/dL) CRPSPE 
Insulin Spectracell Analysis (uIU/mL) INSULIN 
HDL Mean Density Spectracell Analysis (g/cm^3) HDLDENS 
 
 
Repeated Measures ANOVA 
Data were analyzed using the Statistical Analysis System (SAS) version 9.2.  SAS 
process for data analysis used was PROC MIXED.  By use of PROC MIXED the best 
statistical fit to the repeated-measures effects was able to be chosen for each dependent 
variable of interest.  Sample code: 
 
PROC MIXED; 
CLASS ID  GENDER  ACUTEEX Train; 
MODEL TCS= GENDER  ACUTEEX Train GENDER*ACUTEEX GENDER*Train 
Train*ACUTEEX GENDER*Train*ACUTEEX  ; 
REPEATED ACUTEEX*Train/ SUB=ID TYPE=CS R RCORR ; 
LSMEANS GENDER  ACUTEEX Train GENDER*ACUTEEX GENDER*Train 
Train*ACUTEEX GENDER*Train*ACUTEEX / PDIFF=ALL ADJUST=TUKEY ; 
RUN; 
 
QUIT;  
 
The above code allows for the analysis of any main or interactive effects of gender, 
acute exercise, and exercise training.  The statement ―REPEATED‖ allows for the 
system to model the statistic based on the repeated-measures variables indicated, for this 
analysis: ACUTEEX and Train.  The statement TYPE on this line of code provides a 
place to input methods of modeling for the covariance matrix of the repeated variables.  
The following two lines set up post hoc analysis across all conditions in the MODEL 
statement.  Differences here are determined across all levels (PDIFF=ALL) using the 
Tukey-Kramer method.  
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Raw data of all blood variables after adjustment for changes in plasma volume 
subsequent to each of the experimental acute exercise sessions. 
 
Obs   ID   GENDER  AGE  HEIGHT  MODE   TIMEPT  ACUTEEX  TRAIN    TCS      HDLS     LDLS 
 
   1  JG1     M      40   68.0   Water    1      Rest    Pre    259.000  45.0000  178.000 
   2  JG1     M      40   68.0   Water    2      24      Pre    210.955  29.4355     . 
   3  JG1     M      40   68.0   Water    3      Rest    Post   194.000  30.0000     . 
   4  JG1     M      40   68.0   Water    4      24      Post   163.947  34.1162     . 
   5  RK2     F      51   64.5   Water    1      Rest    Pre    203.000  58.0000  132.000 
   6  RK2     F      51   64.5   Water    2      24      Pre    204.344  56.1945  131.802 
   7  RK2     F      51   64.5   Water    3      Rest    Post   183.000  50.0000   94.000 
   8  RK2     F      51   64.5   Water    4      24      Post   170.741  53.7162   96.881 
   9  GB3     M      39   73.0   Water    1      Rest    Pre    147.000  47.0000   84.000 
  10  GB3     M      39   73.0   Water    2      24      Pre    149.130  49.7101   89.275 
 
 Obs    TAGS   GLUCOSES   TCSPE    TAGSPE  VLDLSPE   LDLSPE   RLPSPE   IDLSPE  LDL3SPE  LDL4SPE 
 
   1  180.000    88.000  290.000  167.000  32.0000  200.000  57.0000  50.0000  35.0000  11.0000 
   2     .       80.457  225.378  226.065  44.3496  129.516  41.7985  35.3227  32.0847  10.4006 
   3     .       83.000  193.000  204.000  40.0000   97.000  29.0000  23.0000  25.0000  10.0000 
   4     .       86.238  163.000  160.157  31.2732   78.657  27.4825  21.7965  22.7441   6.6337 
   5   66.000    91.000  218.000   93.000  18.0000  141.000  57.0000  50.0000  12.0000   4.0000 
   6   80.716    88.889  227.026  115.863  23.2952  146.004  58.3401  50.8816  15.0193   5.0064 
   7  196.000    87.000  218.000  136.000  28.0000  128.000  56.0000  50.0000  12.0000   7.0000 
   8  102.636    86.330  213.906  118.943  23.9805  126.617  59.4715  51.7978  12.4698   4.7961 
   9   79.000   105.000  125.000   61.000  12.0000   71.000  23.0000  21.0000   9.0000   4.0000 
  10   48.696    96.377  139.594   64.826  12.7826   82.072  29.2174  26.1739   9.3333   3.6522 
 
 Obs   HDLSPE   HDL2BSPE   HDL2ASPE   HDL3SPE   TCHDLSPE   VLDLPRT    LDLPRT    RLPPRT   LDL3PRT 
 
   1  59.0000    18.0000     5.0000   35.0000    4.91525   121.000   1361.00   242.000   329.000 
   2  51.5122    17.8576     5.2003   28.4544    4.37524   169.745    936.05   177.594   304.167 
   3  56.0000    23.0000     5.0000   28.0000    3.44643   154.000    726.00   125.000   238.000 
   4  53.0697    19.9011     4.7384   28.4302    3.07143   121.302    585.66   116.564   214.174 
   5  59.0000    26.0000    11.0000   23.0000    3.69492    70.000    879.00   243.000   115.000 
   6  57.6249    25.6451    10.4215   21.5583    3.93972    88.889    925.68   247.256   143.041 
   7  61.0000    31.0000    12.0000   19.0000    3.57377   109.000    807.00   236.000   115.000 
   8  62.3492    30.6950    12.4698   19.1844    3.43077    93.044    791.36   254.193   114.147 
   9  42.0000    14.0000     5.0000   23.0000    2.97619    47.000    465.00    99.000    85.000 
  10  44.7391    16.4348     6.8986   21.4058    3.12018    48.696    528.55   123.768    88.261 
 
 Obs  LDL4PRT     HDLPRT     HDL2BPRT    LDLDENS     LPaSPE     CRPSPE    INSULIN    HDLDENS 
 
   1  135.000    11753.00     1660.00     1.0323     9.6000    0.30000     15.100     1.101 
   2  128.535     9982.58     1601.29     1.0336     9.8118    0.11774      7.261     1.098 
   3  118.000    10279.00     2077.00     1.0339     8.8000    0.23000      8.800     1.093 
   4   85.291    10141.05     1799.63     1.0343     7.5814    0.31273     12.415     1.096 
   5   53.000    10149.00     2317.00     1.0300     8.4000    0.05000      5.400     1.090 
   6   62.325     9777.84     2308.06     1.0305     7.2542    0.06130      7.459     1.089 
   7   90.000     9774.00     2757.00     1.0306     6.1000    0.05000     14.400     1.085 
   8   58.512     9980.67     2773.10     1.0306     5.9472    0.06715      5.180     1.085 
   9   47.000     8184.00     1223.00     1.0310     8.3000    0.10000     11.000     1.100 
  10   45.652     8294.49     1475.07     1.0307     6.8986    0.14203      7.609     1.095 
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 Obs   ID   GENDER  AGE  HEIGHT  MODE   TIMEPT  ACUTEEX  TRAIN    TCS      HDLS     LDLS 
 
  11  GB3     M      39   73.0   Water    3      Rest    Post   159.000  50.0000   97.000 
  12  GB3     M      39   73.0   Water    4      24      Post   162.487  49.8427  101.679 
  13  RR5     F      42   64.5   Water    1      Rest    Pre    247.000  69.0000  152.000 
  14  RR5     F      42   64.5   Water    2      24      Pre    247.295  66.2214  163.484 
  15  RR5     F      42   64.5   Water    3      Rest    Post   229.000  65.0000  143.000 
  16  RR5     F      42   64.5   Water    4      24      Post   226.246  60.5308  144.877 
  17  DD7     F      58   63.0   Land     1      Rest    Pre    189.000  57.0000  112.000 
  18  DD7     F      58   64.0   Land     2      24      Pre    191.119  61.7759  112.934 
  19  DD7     F      58   65.0   Land     3      Rest    Post   186.000  59.0000  110.000 
  20  DD7     F      58   66.0   Land     4      24      Post   190.651  59.0342  116.133 
 
 Obs    TAGS   GLUCOSES   TCSPE    TAGSPE  VLDLSPE   LDLSPE   RLPSPE   IDLSPE  LDL3SPE  LDL4SPE 
 
  11   62.000    94.000  130.000   59.000  12.0000   78.000  26.0000  23.0000   9.0000   4.0000 
  12   56.821    95.698  134.575   56.821  10.9654   82.739  25.9182  22.9276   9.9685   3.9874 
  13  128.000    96.000  259.000  132.000  26.0000  169.000  53.0000  46.0000  20.0000   7.0000 
  14   88.985    90.020  239.018   85.363  13.6582  167.519  44.8029  40.5606  20.9011   6.8291 
  15  107.000    96.000  237.000  103.000  20.0000  159.000  59.0000  53.0000  17.0000   5.0000 
  16  106.177    93.277  234.185  104.192  20.8385  156.785  48.6231  43.6615  15.8769   5.9538 
  17   99.000    73.000  194.000   67.000  12.0000  112.000  29.0000  26.0000  15.0000   7.0000 
  18   82.046    86.872  188.417   62.645  10.7143  109.942  27.8957  24.9999  14.3822   7.5289 
  19   83.000    90.000  183.000   59.000  10.0000  106.000  32.0000  30.0000  14.0000   7.0000 
  20   75.486    90.971  189.684   60.002   9.6777  114.197  31.9365  30.0010  15.4844   7.7422 
 
 Obs   HDLSPE   HDL2BSPE   HDL2ASPE   HDL3SPE   TCHDLSPE   VLDLPRT    LDLPRT    RLPPRT   LDL3PRT 
 
  11  40.0000    14.0000     6.0000   20.0000    3.25000    44.000    515.00   110.000    87.000 
  12  41.8679    13.9560     4.9843   22.9276    3.21429    40.871    545.28   111.648    94.701 
  13  63.0000    26.0000     9.0000   27.0000    4.11111   101.000   1109.00   223.000   194.000 
  14  57.8402    24.1087     8.1742   25.4538    4.13238    52.770   1099.90   190.386   198.664 
  15  59.0000    25.0000    11.0000    2.0000    4.01695    77.000   1000.00   251.000   159.000 
  16  56.5615    23.8154     7.9385   23.8154    4.14035    78.392   1009.18   206.400   148.846 
  17  70.0000    28.0000    11.0000   31.0000    2.77143    44.000    756.00   123.000   141.000 
  18  67.7604    29.7297     9.6525   28.3783    2.78063    40.540    745.17   118.726   136.100 
  19  67.0000    28.0000    10.0000   30.0000    2.73134    38.000    704.00   136.000   133.000 
  20  65.8086    29.0332     9.6777   28.0654    2.88235    36.775    765.51   135.488   146.134 
 
 Obs  LDL4PRT     HDLPRT     HDL2BPRT    LDLDENS     LPaSPE     CRPSPE    INSULIN    HDLDENS 
 
  11   47.000     7705.00     1224.00     1.0307     9.9000    0.11000      6.000     1.097 
  12   46.852     8030.65     1259.03     1.0307    11.7629    0.11962      7.377     1.099 
  13   87.000    11149.00     2353.00     1.0307      .        0.09000     15.800     1.092 
  14   84.846    10282.94     2168.75     1.0306     5.8978    0.06208      5.898     1.092 
  15   60.000    10012.00     2255.00     1.0305      .        0.09000      8.700     1.090 
  16   75.415     9966.74     2178.12     1.0301      .        0.06946      7.938     1.092 
  17   87.000    12550.00     2524.00     1.0309    75.9000    0.17000      7.000     1.094 
  18   93.629    11800.16     2670.84     1.0309    73.2624    0.21235      6.564     1.091 
  19   83.000    11982.00     2500.00     1.0311    75.9000    0.14000      8.000     1.092 
  20   96.777    11509.73     2607.18     1.0311    74.9057    0.22259      8.807     1.091 
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 Obs   ID   GENDER  AGE  HEIGHT  MODE   TIMEPT  ACUTEEX  TRAIN    TCS      HDLS     LDLS 
 
  21  BB8     M      49   70.0   Water    1      Rest    Pre    198.000  49.0000  136.000 
  22  BB8     M      50   69.0   Water    2      24      Pre    186.236  45.8122  124.490 
  23  BB8     M      51   68.0   Water    3      Rest    Post   234.000  53.0000  151.000 
  24  BB8     M      52   67.0   Water    4      24      Post   223.333  49.4009  139.969 
  25  JC9     M      35   75.0   Water    1      Rest    Pre    173.000  46.0000  112.000 
  26  JC9     M      35   75.0   Water    2      24      Pre    176.895  48.5382  113.256 
  27  JC9     M      35   75.0   Water    3      Rest    Post   180.000  46.0000  110.000 
  28  JC9     M      35   75.0   Water    4      24      Post   179.419  43.5876  113.531 
  29  SD11    F      59   62.0   Land     1      Rest    Pre    218.000  79.0000  130.000 
  30  SD11    F      59   62.0   Land     2      24      Pre    226.136  80.9112  135.889 
 
 Obs    TAGS   GLUCOSES   TCSPE    TAGSPE  VLDLSPE   LDLSPE   RLPSPE   IDLSPE  LDL3SPE  LDL4SPE 
 
  21   66.000    97.000  167.000   63.000  10.0000  122.000  19.0000  17.0000  20.0000   7.0000 
  22   80.669    86.645  153.371   55.572   9.0628  105.866  15.5363  12.9469  17.4285   6.4735 
  23  151.000   103.000  204.000   79.000  15.0000  133.000  26.0000  22.0000  23.0000   7.0000 
  24  168.786   107.035  203.779  101.889  20.5837  131.736  27.7880  22.6421  30.8756   9.2627 
  25   74.000    85.000  169.000   73.000  14.0000  109.000  23.0000  20.0000  21.0000   6.0000 
  26   74.425   100.312  161.902   66.120  11.9728  103.225  19.8467  16.5030  21.7883   6.4718 
  27  120.000    91.000  177.000   78.000  15.0000  115.000  27.0000  23.0000  19.0000   5.0000 
  28  110.490    90.216  177.391   80.080  16.2186  115.558  27.3690  23.3143  19.2596   6.0820 
  29   46.000    87.000  194.000   46.000   6.0000  115.000  15.0000  14.0000  24.0000   8.0000 
  30   48.754    89.210  224.580   60.580   8.9210  133.400  22.0950  19.3979  22.5099   5.6015 
 
 Obs   HDLSPE   HDL2BSPE   HDL2ASPE   HDL3SPE   TCHDLSPE   VLDLPRT    LDLPRT    RLPPRT   LDL3PRT 
 
  21  35.0000    11.0000     5.0000   19.0000    4.77143    39.000    852.00    83.000   191.000 
  22  38.5420    11.3534     5.1788   22.0098    3.97933    34.857    745.94    65.730   166.318 
  23  55.0000    18.0000     5.0000   32.0000    3.70909    59.000    929.00   112.000   219.000 
  24  51.4593    18.5253     5.1459   27.7880    3.96000    78.218    965.38   118.356   292.289 
  25  47.0000    16.0000     6.0000   25.0000    3.59574    52.000    760.00    98.000   198.000 
  26  46.7045    16.2873     7.4425   22.9748    3.46651    46.381    738.86    84.133   207.096 
  27  47.0000    16.0000     7.0000   24.0000    3.76596    59.000    786.00   114.000   181.000 
  28  46.6286    15.2050     5.0683   26.3553    3.80435    60.820    788.63   115.558   183.473 
  29  73.0000    31.0000    12.0000   30.0000    2.65753    23.000    827.00    66.000   231.000 
  30  82.2597    39.2108    17.2196   25.8293    2.73014    34.232    918.03    93.359   213.689 
 
 Obs  LDL4PRT     HDLPRT     HDL2BPRT    LDLDENS     LPaSPE     CRPSPE    INSULIN    HDLDENS 
 
  21   84.000     6921.00      964.00     1.0316      .        0.21000     10.100     1.096 
  22   79.673     7712.38     1017.83     1.0316      .        0.19918      9.860     1.099 
  23   84.000    10958.00     1607.00     1.0323      .        0.25000     27.200     1.100 
  24  120.415     9849.31     1624.06     1.0332      .        0.28817     23.877     1.097 
  25   71.000     9059.00     1417.00     1.0326    10.4000    0.45000     15.300     1.098 
  26   79.818     8785.42     1463.70     1.0329    10.8941    0.61482     11.002     1.096 
  27   63.000     8904.00     1437.00     1.0318    11.3000    0.60000     10.000     1.097 
  28   69.943     9192.93     1333.98     1.0319    12.1640    0.62847     12.265     1.101 
  29   93.000    12739.00     2781.00     1.0324     7.3000    0.09000      5.600     1.092 
  30   69.501    13292.26     3528.97     1.0317     9.2322    0.18672      5.705     1.086 
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 Obs   ID   GENDER  AGE  HEIGHT  MODE   TIMEPT  ACUTEEX  TRAIN    TCS      HDLS     LDLS 
 
  31  SD11    F      59   62.0   Land     3      Rest    Post   227.000  85.0000  126.000 
  32  SD11    F      59   62.0   Land     4      24      Post   229.002  84.7408  130.138 
  33  KN12    M      29   71.0   Land     1      Rest    Pre    190.000  34.0000  125.000 
  34  KN12    M      30   71.0   Land     2      24      Pre    193.046  32.8814  120.919 
  35  KN12    M      31   71.0   Land     3      Rest    Post   187.000  32.0000  102.000 
  36  KN12    M      32   71.0   Land     4      24      Post   189.409  32.1811  112.174 
  37  TS16    M      37   72.5   Land     1      Rest    Pre    138.000  68.0000   63.000 
  38  TS16    M      37   72.5   Land     2      24      Pre    138.749  68.3972   62.535 
  39  TS16    M      37   72.5   Land     3      Rest    Post   154.000  70.0000   69.000 
  40  TS16    M      37   72.5   Land     4      24      Post   151.682  71.1975   67.070 
 
 Obs    TAGS   GLUCOSES   TCSPE    TAGSPE  VLDLSPE   LDLSPE   RLPSPE   IDLSPE  LDL3SPE  LDL4SPE 
 
  31   80.000    90.000  222.000   79.000  14.0000  131.000  25.0000  22.0000  18.0000   6.0000 
  32   72.635    85.750  207.817   78.688  15.1323  178.561  26.2293  23.2028  17.1499   6.0529 
  33  154.000   126.000  180.000   85.000  17.0000  122.000  27.0000  23.0000  21.0000   6.0000 
  34  197.289   109.251  167.377   86.658  17.2893  113.070  25.5627  22.8049  19.4107   5.9399 
  35  265.000   134.000  181.000   80.000  15.0000  127.000  26.0000  23.0000  27.0000   7.0000 
  36  227.107    93.785  175.617   81.832  15.6308  120.449  25.7449  22.9865  18.3892   6.4362 
  37   33.000    89.000  115.000   41.000   8.0000   51.000  11.0000   9.0000   9.0000   6.0000 
  38   37.130    82.077  120.965   41.136   7.9145   54.620  10.4550   8.5985   9.8687   5.0809 
  39   73.000    89.000  146.000   61.000  13.0000   66.000  16.0000  13.0000  11.0000   6.0000 
  40   65.006    95.962  145.490   67.070  14.4459   61.911  14.4459  12.3822  11.3503   6.1911 
 
 Obs   HDLSPE   HDL2BSPE   HDL2ASPE   HDL3SPE   TCHDLSPE   VLDLPRT    LDLPRT    RLPPRT   LDL3PRT 
 
  31  77.0000    35.0000    16.0000   25.0000    2.88312    54.000    889.00   107.000   176.000 
  32  74.6526    35.3086    17.1499   22.1940    2.78378    58.511    806.05   112.988   166.455 
  33  41.0000    13.0000     3.0000   25.0000    4.39024    64.000    841.00   114.000   200.000 
  34  36.9121    12.5162     3.6064   20.7895    4.53448    66.824    775.37   108.191   184.560 
  35  39.0000    13.0000     3.0000   22.0000    4.64103    59.000    891.00   111.000   255.000 
  36  39.5368    13.7919     3.6778   22.9865    4.44186    61.604    817.40   111.255   176.536 
  37  56.0000    27.0000    10.0000   20.0000    2.05357    31.000    377.00    46.000    90.000 
  38  58.4307    28.2383    11.7252   18.3695    2.07023    30.290    396.70    44.947    93.802 
  39  67.0000    32.0000    12.0000   23.0000    2.17910    49.000    472.00    66.000   108.000 
  40  68.1019    33.0191    11.3503   23.7325    2.13636    55.720    449.89    62.943   111.440 
 
 Obs  LDL4PRT     HDLPRT     HDL2BPRT    LDLDENS     LPaSPE     CRPSPE    INSULIN    HDLDENS 
 
  31   75.000    12582.00     3150.00     1.0312    10.2000    0.13000      6.100     1.087 
  32   80.705    11946.43     3177.78     1.0315    11.1979    0.21185      7.566     1.085 
  33   77.000     8282.00     1198.00     1.0320      .        0.79000     46.800     1.101 
  34   73.188     7209.52     1126.45     1.0324      .         .          24.290     1.099 
  35   85.000     7605.00     1198.00     1.0329     5.0000    0.38000    105.700     1.099 
  36   76.315     7754.73     1224.72     1.0316     4.5973    0.44134     91.119     1.099 
  37   72.000     9314.00     2393.00     1.0324      .        0.02000       .        1.086 
  38   62.535     9426.11     2540.47     1.0321      .        0.02931       .        1.085 
  39   68.000    11111.00     2863.00     1.0321      .        0.05000       .        1.086 
  40   70.166    11289.44     2954.18     1.0324      .        0.05159       .        1.086 
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 Obs   ID   GENDER  AGE  HEIGHT  MODE   TIMEPT  ACUTEEX  TRAIN    TCS      HDLS     LDLS 
 
  41  CM19    M      35   65.0   Land     1      Rest    Pre    161.000  44.0000  100.000 
  42  CM19    M      35   65.0   Land     2      24      Pre    151.664  45.7069   86.220 
  43  CM19    M      35   65.0   Land     3      Rest    Post   163.000  40.0000   88.000 
  44  CM19    M      35   65.0   Land     4      24      Post   152.480  37.1426   84.060 
  45  GJ20    M      51   68.0   Land     1      Rest    Pre    200.000  33.0000  127.000 
  46  GJ20    M      52   68.0   Land     2      24      Pre    191.242  32.3797  128.507 
  47  GJ20    M      53   68.0   Land     3      Rest    Post   206.000  38.0000  142.000 
  48  GJ20    M      54   68.0   Land     4      24      Post   215.087  39.7083  150.009 
  49  MP22    F      51   67.0   Water    1      Rest    Pre       .       .         . 
  50  MP22    F      52   67.0   Water    2      24      Pre       .       .         . 
 
 Obs    TAGS   GLUCOSES   TCSPE    TAGSPE  VLDLSPE   LDLSPE   RLPSPE   IDLSPE  LDL3SPE  LDL4SPE 
 
  41   87.000    98.000  152.000   77.000  15.0000  103.000  34.0000  30.0000  11.0000   4.0000 
  42   98.685   104.918  150.937   81.649  16.5168   99.932  29.1901  25.1388  14.0237   4.3629 
  43  173.000    94.000  162.000  110.000  23.0000  104.000  27.0000  24.0000  16.0000   6.0000 
  44  154.435    93.834  144.661   98.721  20.5262   87.969  22.4811  19.5488  15.6390   4.8872 
  45  200.000    92.000  187.000  103.000  21.0000  124.000  26.0000  21.0000  43.0000  15.0000 
  46  152.792    89.044  191.647  110.799  22.5646  123.447  31.1654  25.7014  41.2841  11.3329 
  47  131.000    94.000  203.000   90.000  18.0000  135.000  24.0000  20.0000  41.0000  10.0000 
  48  129.052   100.374  205.160   84.932  15.4421  136.773  24.2662  20.9572  45.2234  13.2361 
  49     .         .        .        .       .         .       .        .        .        . 
  50     .         .        .        .       .         .       .        .        .        . 
 
 Obs   HDLSPE   HDL2BSPE   HDL2ASPE   HDL3SPE   TCHDLSPE   VLDLPRT    LDLPRT    RLPPRT   LDL3PRT 
 
  41  33.0000    10.0000     4.0000   19.0000    4.60606    59.000    665.00   142.000   104.000 
  42  34.5918    10.8034     4.3629   19.4254    4.36336    63.366    666.90   123.616   132.965 
  43  36.0000    11.0000     4.0000   21.0000    4.50000    88.000    706.00   115.000   151.000 
  44  35.1878    10.7518     3.9098   20.5262    4.11111    79.172    608.94    96.766   144.661 
  45  42.0000    15.0000     6.0000   21.0000    4.45238    80.000    985.00   111.000   409.000 
  46  45.5339    17.1005     6.2736   22.1598    4.20889    87.020    949.13   132.554   392.603 
  47  50.0000    20.0000     6.0000   24.0000    4.06000    68.000   1014.00   103.000   388.000 
  48  54.0474    18.7512     6.6181   28.6782    3.79592    58.459   1059.99   104.786   431.277 
  49    .          .          .         .         .           .          .        .         . 
  50    .          .          .         .         .           .          .        .         . 
 
 Obs  LDL4PRT     HDLPRT     HDL2BPRT    LDLDENS     LPaSPE     CRPSPE    INSULIN    HDLDENS 
 
  41   51.000     6648.00      864.00     1.0303     7.9000     .          21.400     1.100 
  42   54.017     6836.29      970.23     1.0311     7.3754    0.83103     23.165     1.098 
  43   77.000     7125.00     1004.00     1.0318     9.1000    0.58000     12.500     1.099 
  44   66.466     7141.16      958.87     1.0321     8.1127    0.57669     21.797     1.100 
  45  181.000     7875.00     1350.00     1.0344    46.6000    0.15000      4.800     1.096 
  46  139.637     8482.46     1542.08     1.0344    45.3315    0.25297      5.161     1.092 
  47  119.000     9223.00     1767.00     1.0338    46.6000    0.10000      5.900     1.092 
  48  163.245    10315.34     1643.48     1.0342    47.4294    0.12133      6.397     1.095 
  49     .            .           .        .          .         .            .         . 
  50     .            .           .        .          .         .            .         . 
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 Obs   ID   GENDER  AGE  HEIGHT  MODE   TIMEPT  ACUTEEX  TRAIN    TCS      HDLS     LDLS 
 
  51  MP22    F      53   67.0   Water    3      Rest    Post      .       .         . 
  52  MP22    F      54   67.0   Water    4      24      Post      .       .         . 
  53  GA24    M      49   69.5   Land     1      Rest    Pre    163.000  37.0000   88.000 
  54  GA24    M      49   69.5   Land     2      24      Pre    153.502  37.1214   91.299 
  55  GA24    M      49   69.5   Land     3      Rest    Post   189.000  38.0000  124.000 
  56  GA24    M      49   69.5   Land     4      24      Post   194.804  40.2312  131.281 
  57  HW14    F       .     .    Land     1      Rest    Pre    183.000  43.0000  102.000 
  58  HW14    F       .     .    Land     2      24      Pre    170.893  44.7577  101.722 
  59  HW14    F       .     .    Land     3      Rest    Post      .       .         . 
  60  HW14    F       .     .    Land     4      24      Post      .       .         . 
 
 Obs    TAGS   GLUCOSES   TCSPE    TAGSPE  VLDLSPE   LDLSPE   RLPSPE   IDLSPE  LDL3SPE  LDL4SPE 
 
  51     .         .        .        .       .         .       .        .        .        . 
  52     .         .        .        .       .         .       .        .        .        . 
  53  189.000   108.000  154.000  137.000  29.0000   87.000  32.0000  25.0000  18.0000   7.0000 
  54  126.413   108.354  140.359  101.733  21.3699   82.169  31.0014  26.5869  16.1528   5.5180 
  55  133.000   103.000  171.000  107.000  22.0000  111.000  35.0000  31.0000  21.0000   8.0000 
  56  115.400   111.165  168.336   82.580  15.8807  113.282  32.8202  28.5853  19.0569   7.4110 
  57  192.000    89.000  173.000   77.000  15.0000  101.000  28.0000  24.0000  17.0000   6.0000 
  58  123.084    88.498  167.841   72.223  13.7325   99.993  31.6356  27.9736  14.5463   6.0016 
  59     .         .        .        .       .         .       .        .        .        . 
  60     .         .        .        .       .         .       .        .        .        . 
 
 Obs   HDLSPE   HDL2BSPE   HDL2ASPE   HDL3SPE   TCHDLSPE   VLDLPRT    LDLPRT    RLPPRT   LDL3PRT 
 
  51    .          .          .         .         .           .          .        .         . 
  52    .          .          .         .         .           .          .        .         . 
  53  38.0000    13.0000     4.0000   21.0000    4.05263   113.000    622.00   137.000   173.000 
  54  36.8204    12.2400     4.2138   20.3666    3.81199    82.269    566.85   131.430   153.502 
  55  38.0000    12.0000     4.0000   22.0000    4.50000    85.000    766.00   147.000   200.000 
  56  40.2312    13.7633     4.2349   22.2330    4.18421    60.347    777.10   137.633   183.158 
  57  56.0000    19.0000     8.0000   28.0000    3.08929    59.000    692.00   117.000   162.000 
  58  54.1161    17.5979     4.9844   31.6356    3.10150    52.895    670.35   134.273   138.342 
  59    .          .          .         .         .           .          .        .         . 
  60    .          .          .         .         .           .          .        .         . 
 
 Obs  LDL4PRT     HDLPRT     HDL2BPRT    LDLDENS     LPaSPE     CRPSPE    INSULIN    HDLDENS 
 
  51     .            .           .        .          .         .            .         . 
  52     .            .           .        .          .         .            .         . 
  53   87.000     7494.00     1169.00     1.0335    22.4000    0.17000     14.200     1.098 
  54   68.223     7174.46     1102.61     1.0330    23.4768     .          17.156     1.098 
  55   96.000     7561.00     1099.00     1.0327    27.0000    0.04000      8.600     1.099 
  56   88.932     7837.67     1212.23     1.0322    29.6440    0.02117     10.058     1.098 
  57   74.000    10569.00     1748.00     1.0321    15.4000    0.45000      8.800     1.096 
  58   74.257    10714.38     1576.69     1.0319    15.4618    0.46792      7.222     1.101 
  59     .            .           .        .          .         .            .         . 
  60     .            .           .        .          .         .            .         . 
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 Obs   ID   GENDER  AGE  HEIGHT  MODE   TIMEPT  ACUTEEX  TRAIN    TCS      HDLS     LDLS 
 
  61  PR15    F       .     .    Water    1      Rest    Pre    172.000  54.0000   97.000 
  62  PR15    F       .     .    Water    2      24      Pre    175.999  50.7480  102.576 
  63  PR15    F       .     .    Water    3      Rest    Post      .       .         . 
  64  PR15    F       .     .    Water    4      24      Post      .       .         . 
  65  KE23    F       .     .    Land     1      Rest    Pre    187.000  43.0000  125.000 
  66  KE23    F       .     .    Land     2      24      Pre    188.403  42.5427  126.615 
  67  KE23    F       .     .    Land     3      Rest    Post      .       .         . 
  68  KE23    F       .     .    Land     4      24      Post      .       .         . 
  69  CR21    M       .     .    Water    1      Rest    Pre    214.000  35.0000  138.000 
  70  CR21    M       .     .    Water    2      24      Pre    210.819  34.2448  132.698 
 
 Obs    TAGS   GLUCOSES   TCSPE    TAGSPE  VLDLSPE   LDLSPE   RLPSPE   IDLSPE  LDL3SPE  LDL4SPE 
 
  61  104.000    99.000  172.000   61.000  11.0000  104.000  25.0000  23.0000  14.0000   7.0000 
  62  113.373   105.815  181.613   77.310  14.5766  109.378  34.6598  30.8807  14.5766   5.2908 
  63     .         .        .        .       .         .       .        .        .        . 
  64     .         .        .        .       .         .       .        .        .        . 
  65   94.000    91.000  201.000   76.000  13.0000  136.000  49.0000  44.0000  13.0000   5.0000 
  66   96.228    94.202  182.934   68.271  11.4460  123.374  39.9091  36.9716  13.1680   5.4698 
  67     .         .        .        .       .         .       .        .        .        . 
  68     .         .        .        .       .         .       .        .        .        . 
  69  203.000    91.000  259.000  204.000  40.0000  168.000  46.0000  38.0000  33.0000  10.0000 
  70  221.521    92.033  267.002  197.764  38.0973  179.785  49.4409  42.3779  30.3922   9.8454 
 
 Obs   HDLSPE   HDL2BSPE   HDL2ASPE   HDL3SPE   TCHDLSPE   VLDLPRT    LDLPRT    RLPPRT   LDL3PRT 
 
  61  58.0000    22.0000     7.0000   29.0000    2.96552    40.000    705.00   104.000   136.000 
  62  57.7664    22.1348     7.5582   27.9654    3.14393    56.147    720.19   146.845   138.207 
  63    .          .          .         .         .           .          .        .         . 
  64    .          .          .         .         .           .          .        .         . 
  65  53.0000    20.0000     6.0000   27.0000    3.79245    50.000    859.00   206.000   126.000 
  66  48.1138    17.5235     5.1659   25.4243    3.80211    43.556    789.07   169.158   124.589 
  67    .          .          .         .         .           .          .        .         . 
  68    .          .          .         .         .           .          .        .         . 
  69  52.0000    15.0000     5.0000   31.0000    4.98077   152.000   1181.00   195.000   313.000 
  70  49.1198    14.1260     5.6718   29.3221    5.43573   146.610   1232.81   209.749   288.940 
 
 Obs  LDL4PRT     HDLPRT     HDL2BPRT    LDLDENS     LPaSPE     CRPSPE    INSULIN    HDLDENS 
 
  61   83.000    10741.00     1942.00     1.0310    46.1000    0.20000     11.000     1.096 
  62   64.785    10658.17     1992.13     1.0311    50.1002    0.30233     14.037     1.094 
  63     .            .           .        .          .         .            .         . 
  64     .            .           .        .          .         .            .         . 
  65   67.000     9886.00     1794.00     1.0297    24.4000     .           7.600     1.096 
  66   67.866     9152.76     1572.05     1.0304    25.6269     .           8.103     1.097 
  67     .            .           .        .          .         .            .         . 
  68     .            .           .        .          .         .            .         . 
  69  127.000    10512.00     1363.00     1.0329    18.5000    0.56000     24.600     1.102 
  70  121.997     9953.45     1269.20     1.0321    20.7609    0.65279     17.443     1.101 
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 Obs   ID   GENDER  AGE  HEIGHT  MODE   TIMEPT  ACUTEEX  TRAIN    TCS      HDLS     LDLS 
 
  71  CR21    M       .     .    Water    3      Rest    Post      .       .         . 
  72  CR21    M       .     .    Water    4      24      Post      .       .         . 
 
 Obs    TAGS   GLUCOSES   TCSPE    TAGSPE  VLDLSPE   LDLSPE   RLPSPE   IDLSPE  LDL3SPE  LDL4SPE 
 
  71     .         .        .        .       .         .       .        .        .        . 
  72     .         .        .        .       .         .       .        .        .        . 
 
 Obs   HDLSPE   HDL2BSPE   HDL2ASPE   HDL3SPE   TCHDLSPE   VLDLPRT    LDLPRT    RLPPRT   LDL3PRT 
 
  71    .          .          .         .         .           .          .        .         . 
  72    .          .          .         .         .           .          .        .         . 
 
 Obs  LDL4PRT     HDLPRT     HDL2BPRT    LDLDENS     LPaSPE     CRPSPE    INSULIN    HDLDENS 
 
  71     .            .           .        .          .         .            .         . 
  72     .            .           .        .          .         .            .         . 
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APPENDIX H 
 
SAMPLE STATISTICAL CODE AND RAW DATA FOR CHAPTER III 
 
 
Variable Definitions: 
Independent Variables 
 Unique Identifier ID 
Gender (M F) GENDER 
Age (years) AGE 
Height (inches) HEIGHT 
Treadmill Type (LAND or WATER) MODE 
Timepoint TIMEPT 
Training Time Point (PRE or POST) TRAINING 
Acute Exercise (Rest or 24) EX 
 
Definition of TIMEPT variable 
TIMEPT has 4 levels corresponding to each combination of 
acute exercise and training times such that:  
- 1 = pretraining, resting (immediate pre-ex for blood variables, 
3 days pre-ex for muscle) 
-2= pretraining, 24 h postexercise 
-3= posttraining, resting (immediate pre-ex for blood variables, 
no muscle biopsy attained 
-4= posttraining, 24 h postexercise for blood and muscle 
 
Dependent Variables 
 
 
 Peroxisome Proliferator-Activated Receptor δ  PPARD 
PPARδ "Relative Phosphorylation" PPARDPHO 
PPARδ "Total Phosphorylation" TOTALPHOS 
AMP-activated Protein Kinase α AMPK 
PPARγ Coactivator-1α PGC1a 
F1 ATPase (primary subunit of ATP Synthase) F1ATPase 
Carnitine-Palmitoyl Transferase-I CPTI 
FAT/CD36 (Fatty Acid Translocase) CD36 
Cytochrome C Oxidase-IV COXIV 
Peroxisome Proliferator-Activated Receptor α PPARα 
ATP Binding Cassette A1 ABCA1 
Lipoprotein Lipase LPL 
LDL Receptor LDLR 
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Repeated Measures ANOVA 
Data were analyzed using the Statistical Analysis System (SAS) version 9.2.  SAS 
process for data analysis used was PROC MIXED to determine change in content of the 
above listed proteins due to the exercise intervention.  By use of PROC MIXED the best 
statistical fit to the repeated-measures effects was able to be chosen for each dependent 
variable of interest.  Because only one muscle sample was obtained after exercise 
training the analysis for protein content was based on the TIMEPT variable for repeated 
measures, defined above.  Sample code: 
 
PROC MIXED; 
CLASS ID  GENDER  TIMEPT; 
MODEL LPL= TIMEPT  ; 
REPEATED TIMEPT/ SUB=ID TYPE=CSH RCORR ; 
LSMEANS TIMEPT  / PDIFF=ALL ADJUST=TUKEY ; 
RUN; 
 
QUIT;  
 
The above code allows for the analysis of any main or interactive effects of gender, 
acute exercise, and exercise training.  The statement ―REPEATED‖ allows for the 
system to model the statistic based on the repeated-measures variables indicated, for this 
analysis: TIMEPT.  The statement TYPE on this line of code provides a place to input 
methods of modeling for the covariance matrix of the repeated variables.  The following 
two lines set up post hoc analysis across all conditions in the MODEL statement.  
Differences here are determined across all levels (PDIFF=ALL) using the Tukey-Kramer 
method. 
 
Correlations 
For the assessment of correlation correlation of PPARδ, PPARα, PGC-1α, and AMPKα 
to blood lipid and lipoprotein variables the PROC CORR process was used.   
 Blood lipid and lipoprotein raw data presented in Appendix G 
This process enabled the assessment of Pearson‘s Product-Moment correlations on all 
variables of interest.  Sample Code: 
 
PROC SORT; 
BY TIMEPT; 
 
PROC CORR;  
  
BY TIMEPT; 
    VAR PPARD PPARDPHO TOTALPHOS AMPK PGC1a PPARa ABCA1 LPL; 
 
    WITH  VO2PEAKR PPARD PPARDPHO TOTALPHOS AMPK PGC1a F1ATPase 
CPTI CD36 COXIV PPARa ABCA1 LPL TCS HDLS LDLS TAGS GLUCOSES
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 TCSPE TAGSPE VLDLSPE LDLSPE RLPSPE
 IDLSPE LDL3SPE LDL4SPE HDLSPE HDL2BSPE
 HDL2ASPE HDL3SPE TCHDLSPE VLDLPRT LDLPRT
 RLPPRT LDL3PRT LDL4PRT HDLPRT HDL2BPRT
 LDLDENS LPaSPE CRPSPE INSULIN HDLDENS NEFA; 
RUN; 
 
QUIT;  
 
To assess correlations at each collection period in which blood and muscle samples were 
each obtained it was first necessary to sort data by variable TIMEPT.  Therefore, prior to 
running PROC CORR, PROC SORT was run for this variable.  This was followed by 
PROC CORR which allowed the assessment of correlations at each level of TIMEPT for 
protein variables of interest with all protein and blood variables.  
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Obs  ID  GENDER AGE HEIGHT MODE  TIMEPT ACUTEEX TRAIN  PPARD PPARDPHO TOTALPHOS   AMPK 
 
     1 JG1    M     40  68.0  Water   1     Rest   Pre    .       .          .     0.50617 
     2 JG1    M     40  68.0  Water   2     24     Pre    .       .          .     0.58025 
     3 JG1    M     40  68.0  Water   3     Rest   Post   .       .          .      . 
     4 JG1    M     40  68.0  Water   4     24     Post   .       .          .     1.14815 
     5 RK2    F     51  64.5  Water   1     Rest   Pre   1.0600  0.38679    0.41    . 
     6 RK2    F     51  64.5  Water   2     24     Pre   3.9200  0.30867    1.21    . 
     7 RK2    F     51  64.5  Water   3     Rest   Post   .       .          .      . 
     8 RK2    F     51  64.5  Water   4     24     Post  0.7700  0.24675    0.19    . 
     9 GB3    M     39  73.0  Water   1     Rest   Pre   1.6400  0.22561    0.37   0.60000 
    10 GB3    M     39  73.0  Water   2     24     Pre   1.3300  0.62406    0.83   0.70000 
    11 GB3    M     39  73.0  Water   3     Rest   Post   .       .          .      . 
    12 GB3    M     39  73.0  Water   4     24     Post  3.4100  0.06452    0.22   1.17500 
    13 RR5    F     42  64.5  Water   1     Rest   Pre   0.5000  0.38000    0.19   1.12500 
    14 RR5    F     42  64.5  Water   2     24     Pre   2.6700  0.12360    0.33   1.35000 
    15 RR5    F     42  64.5  Water   3     Rest   Post   .       .          .      . 
    16 RR5    F     42  64.5  Water   4     24     Post  2.2600  0.08850    0.20   1.67500 
    17 DD7    F     58  63.0  Land    1     Rest   Pre   2.4300  0.35802    0.87    . 
    18 DD7    F     58  64.0  Land    2     24     Pre   1.3300  0.42105    0.56    . 
    19 DD7    F     58  65.0  Land    3     Rest   Post   .       .          .      . 
    20 DD7    F     58  66.0  Land    4     24     Post  2.0100  0.36318    0.73    . 
    21 BB8    M     49  70.0  Water   1     Rest   Pre   1.1000  0.23636    0.26    . 
    22 BB8    M     50  69.0  Water   2     24     Pre   1.7800  0.19663    0.35    . 
    23 BB8    M     51  68.0  Water   3     Rest   Post   .       .          .      . 
 
   Obs  PGC1a    F1ATPase     CPTI      CD36     COXIV     PPARa     ABCA1      LPL       LDLR 
 
     1 0.77647     4.9605   0.98139   0.63868   1.63750   1.29730   1.17857   0.85553   0.95279 
     2 1.21765     4.0855   1.01270   0.79414   1.72750   1.32432   1.02679   1.44724   0.55365 
     3  .           .        .         .         .         .         .         .         . 
     4 0.85490     1.9539   1.26693   0.67719   1.75750   2.31532   1.14286   2.07161   0.52361 
     5 0.94118     2.4243   1.23580   0.63158   1.04125   1.68468   1.38393   1.66960   0.69099 
     6 1.48431     4.4441   1.00864   0.74561   1.17600   1.15315   0.98214   1.96859   0.57082 
     7  .           .        .         .         .         .         .         .         . 
     8 1.39216     4.2730    .        0.85088   1.37400   1.54054    .         .         . 
     9 1.19391    11.3684   0.89474   1.61078   0.95333   1.21429   0.89286   1.11368   0.99379 
    10 1.56233     9.1278   0.96053   2.22607   1.40333   1.23469   0.84821   1.33702   0.74534 
    11  .           .        .         .         .         .         .         .         . 
    12 1.69252     6.8947   0.89912   2.18822   1.45000   1.23469   0.87500   1.12575   0.66460 
    13 1.01662     8.4211   0.88596   1.00426   1.11688   1.38776   0.92857   1.10060   1.07453 
    14 1.31302     7.6617   0.96053   1.36291   1.41125   1.54082   1.01786   1.13883   0.93789 
    15  .           .        .         .         .         .         .         .         . 
    16 1.47368     8.2632    .        1.51529   1.64625   2.20408   1.00893   1.35211   0.81988 
    17 1.03704     7.9792   0.71397   0.86239   0.91950   0.75862   0.90323   0.56470   1.42553 
    18 1.81893     6.7083   0.83885   1.09174   0.73100   0.51724   0.70968   0.76178   0.93617 
    19  .           .        .         .         .         .         .         .         . 
    20 1.52675     8.9792    .        0.84404   1.09850   0.60920   0.74194   0.41045   1.01064 
    21 1.12346     9.3854   0.21569   1.04587   1.15050   0.71264   0.48387   0.36075   0.75532 
    22 1.10288    13.8229   0.43137   1.27523   1.41450   0.79310   0.89516   0.61782   1.21809 
    23  .           .        .         .         .         .         .         .         . 
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   Obs  ID  GENDER AGE HEIGHT MODE  TIMEPT ACUTEEX TRAIN  PPARD PPARDPHO TOTALPHOS   AMPK 
 
    24 BB8    M     52  67.0  Water   4     24     Post  0.2000  0.35000    0.07    . 
    25 JC9    M     35  75.0  Water   1     Rest   Pre   2.3800  0.21008    0.50   0.66667 
    26 JC9    M     35  75.0  Water   2     24     Pre    .      0.35989    6.46   1.33333 
    27 JC9    M     35  75.0  Water   3     Rest   Post   .       .          .      . 
    28 JC9    M     35  75.0  Water   4     24     Post  4.6900  0.25800    1.21   0.88889 
    29 SD11   F     59  62.0  Land    1     Rest   Pre   0.2100  0.42857    0.09   1.66667 
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    30 SD11   F     59  62.0  Land    2     24     Pre   0.8000  0.38750    0.31   2.33333 
    31 SD11   F     59  62.0  Land    3     Rest   Post   .       .          .      . 
    32 SD11   F     59  62.0  Land    4     24     Post  0.4400  0.43182    0.19   4.00000 
    33 KN12   M     29  71.0  Land    1     Rest   Pre   1.5000  0.58667    0.88   0.35772 
    34 KN12   M     30  71.0  Land    2     24     Pre   1.3700  0.33577    0.46   0.53659 
    35 KN12   M     31  71.0  Land    3     Rest   Post   .       .          .      . 
    36 KN12   M     32  71.0  Land    4     24     Post  8.0600  0.37345    3.01   1.32520 
    37 TS16   M     37  72.5  Land    1     Rest   Pre   2.9300  0.40956    1.20   1.47967 
    38 TS16   M     37  72.5  Land    2     24     Pre   4.1500  0.39036    1.62   0.93496 
    39 TS16   M     37  72.5  Land    3     Rest   Post   .       .          .      . 
    40 TS16   M     37  72.5  Land    4     24     Post  5.0200  0.34462    1.73   1.57724 
    41 CM19   M     35  65.0  Land    1     Rest   Pre   2.8600  0.26224    0.75   0.23810 
    42 CM19   M     35  65.0  Land    2     24     Pre   3.9500  0.32152    1.27   0.36905 
    43 CM19   M     35  65.0  Land    3     Rest   Post   .       .          .      . 
    44 CM19   M     35  65.0  Land    4     24     Post  8.6700  0.32641    2.83   0.76190 
    45 GJ20   M     51  68.0  Land    1     Rest   Pre   0.2000  0.35374    1.56   1.17857 
    46 GJ20   M     52  68.0  Land    2     24     Pre   2.2800  0.26754    0.61   0.96429 
 
   Obs  PGC1a    F1ATPase     CPTI      CD36     COXIV     PPARa     ABCA1      LPL       LDLR 
 
    24 1.25103    12.3542   0.62745   1.28440   1.30900   0.79310   0.88710   0.78149   1.11170 
    25 0.62745     8.3115   0.89773    .        1.65000    .        0.62617   0.59302   1.75000 
    26 0.82353     4.9180   1.18182    .        1.35833    .        0.92523   1.17442   1.65385 
    27  .           .        .         .         .         .         .         .         . 
    28 0.69935     6.8852   0.87500    .        2.24833    .        0.66355   1.08140   1.55769 
    29 0.43791     7.9180   0.61072    .        0.96875    .        0.53271   1.17110   1.18269 
    30 0.35294     7.9344   1.07241    .        1.10375    .        0.50467   0.81395   1.37500 
    31  .           .        .         .         .         .         .         .         . 
    32 0.30719     7.9016   1.39746    .        0.84500    .        0.47664    .        2.08654 
    33 1.33333    20.0833   1.04967   1.03712   0.83400   1.34673   0.69828   0.48528   0.66964 
    34 1.65714    18.6667   0.96026   1.23242   0.80200   3.69347   1.00862   0.63347   0.65774 
    35  .           .        .         .         .         .         .         .         . 
    36  .           .        .         .         .         .         .         .         . 
    37 1.68571    21.3333   1.05629   0.98969   0.78550    .        0.86207   0.54791   0.56250 
    38 1.60000    29.0833   1.35430   1.27835   0.94850   1.32663   0.65517   0.62663   0.72619 
    39  .           .        .         .         .         .         .         .         . 
    40 2.11429    24.9167   1.70199   1.50773   1.50225   2.03518   0.91379   0.78439   0.79464 
    41 1.33673    18.0000    .        1.47191   0.91733   1.16854   0.68462   1.15163   1.19512 
    42 1.23469    18.0909    .        1.40449   0.85983   1.04494   0.67692   1.11905   1.33740 
    43  .           .        .         .         .         .         .         .         . 
    44 1.67347    25.9545    .        1.65169   1.12750   1.38202   0.80000   1.56391   1.32114 
    45 1.15306    27.0000    .        1.34140   0.90175   1.10112   0.78462   1.59398   1.54065 
    46 1.57143    21.1364    .        1.46126   1.14100   1.06742   0.90000   1.82331   1.65041 
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   Obs  ID  GENDER AGE HEIGHT MODE  TIMEPT ACUTEEX TRAIN  PPARD PPARDPHO TOTALPHOS   AMPK 
 
    47 GJ20   M     53  68.0  Land    3     Rest   Post   .       .          .      . 
    48 GJ20   M     54  68.0  Land    4     24     Post  3.5900  0.34540    1.24   0.76190 
    49 MP22   F     51  67.0  Water   1     Rest   Pre   0.4025  0.35404    0.57   0.13830 
    50 MP22   F     52  67.0  Water   2     24     Pre   0.7550  0.30464    0.92   0.26596 
    51 MP22   F     53  67.0  Water   3     Rest   Post   .       .          .      . 
    52 MP22   F     54  67.0  Water   4     24     Post   .       .          .      . 
    53 GA24   M     49  69.5  Land    1     Rest   Pre   1.6225  0.33128    2.15   0.28723 
    54 GA24   M     49  69.5  Land    2     24     Pre   3.6775  0.38953    5.73   0.53191 
    55 GA24   M     49  69.5  Land    3     Rest   Post   .       .          .      . 
    56 GA24   M     49  69.5  Land    4     24     Post  3.0300  0.37129    4.50   0.28723 
    57 HW14   F      .    .   Land    1     Rest   Pre   0.8125  0.23692    0.77   0.07879 
    58 HW14   F      .    .   Land    2     24     Pre   0.5575  0.22870    0.51   0.16364 
    59 HW14   F      .    .   Land    3     Rest   Post   .       .          .      . 
    60 HW14   F      .    .   Land    4     24     Post   .       .          .      . 
    61 PR15   F      .    .   Water   1     Rest   Pre    .       .          .     0.49091 
    62 PR15   F      .    .   Water   2     24     Pre    .       .          .     0.92727 
    63 PR15   F      .    .   Water   3     Rest   Post   .       .          .      . 
    64 PR15   F      .    .   Water   4     24     Post   .       .          .      . 
    65 KE23   F      .    .   Land    1     Rest   Pre    .       .          .      . 
    66 KE23   F      .    .   Land    2     24     Pre    .       .          .      . 
    67 KE23   F      .    .   Land    3     Rest   Post   .       .          .      . 
    68 KE23   F      .    .   Land    4     24     Post   .       .          .      . 
    69 CR21   M      .    .   Water   1     Rest   Pre    .       .          .      . 
 
   Obs  PGC1a    F1ATPase     CPTI      CD36     COXIV     PPARa     ABCA1      LPL       LDLR 
 
    47  .           .        .         .         .         .         .         .         . 
    48 1.63265    16.4091    .         .        0.94825   1.88764   0.76154   1.89223   1.03659 
    49 2.22222    14.4000   0.73832   0.85000   0.71625   0.53642   1.21739   0.81614   1.01802 
    50 4.85185    18.6000   0.87850   1.55000   1.27500   1.12583   1.44928   1.11031   1.40541 
    51  .           .        .         .         .         .         .         .         . 
    52  .           .        .         .         .         .         .         .         . 
    53 3.03704    55.2000   1.10280   1.20000   1.06800   1.09272   1.68116   0.67892   1.74775 
    54 5.44444    60.4000   1.08411   1.28750   1.60850   0.96689   1.97101   0.91839   1.43243 
    55  .           .        .         .         .         .         .         .         . 
    56 4.14815    53.0000   1.20561   1.06250   1.16600   1.03974   2.15942   0.85112   1.19820 
    57 2.25000    40.5000   0.87654   0.68182   0.91000   0.36585   0.54667   0.53621   0.67811 
    58 3.08333    56.1667   1.01235   1.09917   1.09000   0.34146   0.58667   0.47845   0.55794 
    59  .           .        .         .         .         .         .         .         . 
    60  .           .        .         .         .         .         .         .         . 
    61 6.91667      .        .        0.55785    .        1.97561   0.61333   0.92672    . 
    62 9.33333      .        .        0.47107    .        3.07317   0.70667   0.95086    . 
    63  .           .        .         .         .         .         .         .         . 
    64  .           .        .         .         .         .         .         .         . 
    65  .           .        .         .         .         .         .         .         . 
    66  .           .        .         .         .         .         .         .         . 
    67  .           .        .         .         .         .         .         .         . 
    68  .           .        .         .         .         .         .         .         . 
    69  .           .        .         .         .         .         .         .         . 
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   Obs  ID  GENDER AGE HEIGHT MODE  TIMEPT ACUTEEX TRAIN  PPARD PPARDPHO TOTALPHOS   AMPK 
 
    70 CR21   M      .    .   Water   2     24     Pre    .       .          .      . 
    71 CR21   M      .    .   Water   3     Rest   Post   .       .          .      . 
    72 CR21   M      .    .   Water   4     24     Post   .       .          .      . 
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APPENDIX I 
 
SAMPLE STATISTICAL CODE AND RAW DATA FOR CHAPTERS II AND III 
DEMOGRAPHICS, PHYSIOLOGIC ADAPTATION, DATA AND ACTIVITY 
 
 
Variable Definitions: 
 
Independent Variables 
 Unique Identifier ID 
Gender (M F) GENDER 
Age (years) AGE 
Height (inches) HEIGHT 
Treadmill Type (LAND or WATER) MODE 
Timepoint TIMEPT 
Training Time Point (PRE or POST) TRAINING 
Acute Exercise (Rest or 24) EX 
 
 
Dependent Variables 
Descriptive Variables 
Resting Energy Expenditure (kcal/day) RMR 
Peak Measure VO2 (ml/min) VO2PEAKA 
Peak Measure VO2 (ml/kg/min) VO2PEAKR 
Bruce GXT time (sec) BRUCTIME 
Body Weight (lbs) BODYWT 
Body Mass (kg) BODYMASS 
Chest (skinfolds) (mm) CHEST 
Axilla (skinfolds) (mm) AXILLA 
Triceps (skinfolds) (mm) TRICEP 
Subscapula (skinfolds) (mm) SUBSCAP 
Abdominals (skinfolds) (mm) ABDOM 
Suprailiac (skinfolds) (mm) SUPRAIL 
Thigh (skinfolds) (mm) THIGH 
Sum of skinfold measurements (mm) SUM 
Body Density (Skinfolds) BODYDENS 
Body Mass Index BMI 
Body Fat % (Skinfold) PERCFTSK 
Waist Circumference (inches) WAIST 
Hip Circumference (inches) HIP 
Waist : Hip Ratio WHRATIO 
Body Fat % (DEXA) PERCFTDX 
% Android Fat (DEXA) ANDROID 
% Gynoid Fat (DEXA) GYNOID  
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Android : Gynoid Ratio (DEXA) AGRATIO 
Lean Body Mass (g) (DEXA) LBM 
Left arm percent fat (DEXA) LAPERFAT 
Left leg percent fat (DEXA) LLPERFAT 
Left trunk percent fat (DEXA) LTRPRFAT 
Left total percent fat (DEXA) LTOPRFAT 
Right arm percent fat (DEXA) RAPERFAT 
Right leg percent fat (DEXA) RLPERFAT 
Right trunk percent fat (DEXA) RTRPRFAT 
Right total percent fat (DEXA) RTOPRFAT 
Arms percent fat (DEXA) ARMPRFAT 
Legs percent fat (DEXA) LEGPRFAT 
Trunk percent fat (DEXA) TRUPRFAT 
Left arm fat mass (g) (DEXA) LAFAT 
Left leg fat mass (g) (DEXA) LLFAT 
Left trunk fat mass (g) (DEXA) LTRFAT 
Left total fat mass (g) (DEXA) LTOFAT 
Right arm fat mass (g) (DEXA) RAFAT 
Right leg fat mass (g) (DEXA) RLFAT 
Right trunk fat mass (g) (DEXA) RTRFAT 
Right total fat mass (g) (DEXA) RTOFAT 
Arms fat mass (g) (DEXA) ARMFAT 
Legs fat mass (g) (DEXA) LEGFAT 
Trunk fat mass (g) (DEXA) TRUFAT 
Left arm lean mass (g) (DEXA) LALEAN 
Left leg lean mass (g) (DEXA) LLLEAN 
Left trunk lean mass (g) (DEXA) LTRLEAN 
Left totat lean mass (g) (DEXA) LTOLEAN 
Right arm lean mass (g) (DEXA) RALEAN 
Right leg lean mass (g) (DEXA) RLLEAN 
Right trunk lean mass (g) (DEXA) RTRLEAN 
Right total lean mass (g) (DEXA) RTOLEAN 
Arms lean mass (g) (DEXA) ARMLEAN 
Legs lean mass (g) (DEXA) LEGLEAN 
Trunk lean mass (g) (DEXA) TRULEAN 
Fat Mass (g) (DEXA) FATMASS 
Bone Mineral Content (g) (DEXA) BMC 
Bone Mineral Density (DEXA) BMD 
Daily Activity and Dietary Intake 
 Caloric Expenditure through Daily Activity (kcal) ACTIVITY 
Recommended Dietary Caloric Intake (kcal) RECTOTCAL 
Actual Dietary Caloric Intake (kcal) ACTTOTCAL 
Dietary Carbohydrate Intake (g) CHO  
Dietary Total Fat Intake (g) TOTFAT  
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Dietary Monounsaturated Fatty Acid Intake (g) MONO 
Dietary Polyunsaturated Fatty Acid Intake (g) POLY  
Dietary Saturated Fatty Acid Intake (g) SAT  
Dietary Protein Intake (g) PRO  
Data were analyzed using the Statistical Analysis System (SAS) version 9.2.  SAS 
process for data analysis used was PROC MIXED.  By use of PROC MIXED the best 
statistical fit to the repeated-measures effects was able to be chosen for each dependent 
variable of interest.  Sample code: 
 
PROC MIXED; 
CLASS ID  GENDER TRAINING; 
MODEL BMI= GENDER  TRAINING GENDER*TRAINING  ; 
REPEATED TRAINING/ SUB=ID TYPE=UN R RCORR ; 
LSMEANS GENDER  TRAINING GENDER*TRAINING / PDIFF=ALL 
ADJUST=TUKEY ; 
RUN; 
 
QUIT;  
 
The above code allows for the analysis of any main or interactive effects of gender, 
acute exercise, and exercise training.  The statement ―REPEATED‖ allows for the 
system to model the statistic based on the repeated-measures variables indicated, for this 
analysis: TRAINING.  The statement TYPE on this line of code provides a place to 
input methods of modeling for the covariance matrix of the repeated variables.  The 
following two lines set up post hoc analysis across all conditions in the MODEL 
statement.  Differences here are determined across all levels (PDIFF=ALL) using the 
Tukey-Kramer method.  
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Body composition and physiologic adaptation measures 
                                          The SAS System            12:25 Sunday, May 30, 2010  29 
 
  Obs  ID  GENDER AGE HEIGHT MODE  TRAINING  RMR VO2PEAKA VO2PEAKR BRUCTIME BODYWT BODYMASS 
 
    1 JG1    M     40  68.0  Water   PRE    2041   2809     35.10     625    175.5   79.800 
    2 JG1    M     40  68.0  Water   POST   2035   3111     39.40     660    174.0   79.100 
    3 RK2    F     51  64.5  Water   PRE    1295   2344     27.90     443    184.0   83.600 
    4 RK2    F     51  64.5  Water   POST   1453   2434     28.60     488    187.0   85.000 
    5 GB3    M     39  73.0  Water   PRE    1301   3530     36.60     609    213.0   96.800 
 
  Obs CHEST AXILLA TRICEP SUBSCAP ABDOM SUPRAIL THIGH  SUM  BODYDENS   BMI   PERCFTSK WAIST 
 
    1  46.0  40.5   33.0    41.0   49.5   23.0   48.5 281.5  0.97800 26.7400  53.0000  37.5 
    2  35.5  26.5   25.5    33.5   40.0   22.5   40.5 224.0  1.00300 26.5100  41.3600  36.0 
    3  31.5  45.0   36.0    30.0   34.5   27.5   50.0 254.5  0.97100 31.1600  56.4200  35.0 
    4  34.5  41.0   29.5    36.5   36.5   26.0   49.0 253.0  0.97200 31.6700  56.0800  35.0 
    5  53.5  42.5   38.0    43.5   44.5   31.0   56.0 309.0  0.96700 28.1600  58.6300  43.0 
 
  Obs  HIP WHRATIO PERCFTDX ANDROID GYNOID AGRATIO  LBM  LAPERFAT LLPERFAT LTRPRFAT LTOPRFAT 
 
    1 40.0   0.94    29.5     39.8   34.3    1.16  54133   21.0     27.6     34.3     29.5 
    2 39.0    .      28.9     38.3   32.4    1.18  53391   20.7     25.4     34.9     28.9 
    3 46.0   0.76    44.6     46.4   52.1    0.89  44534   39.6     51.3     42.8     44.4 
    4 45.5   0.77    44.8     46.4   50.9    0.91  45039   38.2     51.3     43.2     44.9 
    5 45.0   0.96    42.0     51.1   41.3    1.24  53617   30.0     40.4     47.6     42.2 
 
  Obs RAPERFAT RLPERFAT RTRPRFAT RTOPRFAT ARMPRFAT LEGPRFAT TRUPRFAT LAFAT LLFAT LTRFAT LTOFAT 
 
    1   21.1     27.6     34.3     29.4     21.0     27.6     34.3     938  3440   6698  11433 
    2   20.7     25.4     34.9     28.9     20.7     25.4     34.7     945  3143   6370  10792 
    3   39.5     51.3     42.9     44.9     39.6     51.3     42.9    1674  7722   8373  18298 
    4   38.3     51.3     43.2     44.6     38.3     51.3     43.2    1548  7852   8509  18289 
    5   29.7     40.5     47.6     41.9     29.9     40.4     47.6    1478  6735  11008  19589 
 
  Obs RAFAT RLFAT RTRFAT RTOFAT ARMFAT LEGFAT TRUFAT LALEAN LLLEAN LTRLEAN LTOLEAN RALEAN 
 
    1   973  3516   6364  11169  1911    6957  13062  3526    9037  12831   27335   3647 
    2   978  3199   6393  10880  1923    6342  12764  3626    9218  11877   26602   3736 
    3  1518  7812   7920  17622  3192   15534  16294  2552    7326  11173   22930   2320 
    4  1379  8074   8217  18211  2926   15926  16726  2499    7456  11205   22459   2221 
    5  1383  6525  10860  19292  2861   13260  21868  3446    9918  12105   26847   3267 
 
  Obs RLLEAN    RTRLEAN    RTOLEAN    ARMLEAN    LEGLEAN    TRULEAN    FATMASS     BMC     BMD 
 
    1   9237     12201      26798       7173      18274      25032      22603     3018    1.262 
    2   9370     11931      26790       7362      18589      23808      21672     3143    1.288 
    3   7410     10555      21604       4873      14736      21728      35920     2869    1.241 
    4   7675     10810      22579       4721      15131      22015      36500     2928    1.254 
    5   9603     11931      26771       6713      19521      24036      38881     3630    1.308 
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  Obs  ID  GENDER AGE HEIGHT MODE  TRAINING  RMR VO2PEAKA VO2PEAKR BRUCTIME BODYWT BODYMASS 
 
    6 GB3    M     39  73.0  Water   POST   1432   3550     37.50     647    209.0   95.000 
    7 RR5    F     42  64.5  Water   PRE    1317   1891     24.90     432    169.0   76.800 
    8 RR5    F     42  64.5  Water   POST   1104   2175     28.74     491    166.5   75.700 
    9 DD7    F     58  63.0  Land    PRE    1252   2150     28.10     397    169.0   76.800 
   10 DD7    F     58  64.0  Land    POST   1382   2360     31.60     544    164.5   74.800 
 
  Obs CHEST AXILLA TRICEP SUBSCAP ABDOM SUPRAIL THIGH  SUM  BODYDENS   BMI   PERCFTSK WAIST 
 
    6  40.5  35.5   36.5    35.0   37.5   34.5   51.5 271.0  0.98300 27.6300  50.6900  41.5 
    7  34.5  45.5   43.0    42.5   46.0   31.5   58.0 301.0  0.95000 28.6200  66.6500  36.5 
    8  39.5  43.5   35.5    37.5   41.5   33.5   52.0 283.0  0.95900 28.2000  62.4200  35.5 
    9  29.5  34.5   30.0    28.5   37.0   24.5   49.0 233.0  0.98000 30.0000  52.0100  35.0 
   10  38.0  35.0   31.5    32.0   34.5   20.0   41.5 232.5  0.98000 28.3000  51.9000  32.5 
 
  Obs  HIP WHRATIO PERCFTDX ANDROID GYNOID AGRATIO  LBM  LAPERFAT LLPERFAT LTRPRFAT LTOPRFAT 
 
    6 46.0   0.90    41.2     49.9   44.5    1.12  53541   28.2     39.6     47.2     41.3 
    7 41.0   0.89    45.6     49.5   50.8    0.97  39988   44.9     46.3     47.6     45.4 
    8 40.5   0.88    44.0     49.4   50.2    0.98  40484   44.1     45.6     45.4     44.0 
    9 43.5   0.80    45.8     47.8   51.0    0.94  39449   36.6     48.3     47.9     46.0 
   10 41.0   0.79    44.6     47.1   51.7    0.91  39339   40.3     47.6     45.8     44.6 
 
  Obs RAPERFAT RLPERFAT RTRPRFAT RTOPRFAT ARMPRFAT LEGPRFAT TRUPRFAT LAFAT LLFAT LTRFAT LTOFAT 
 
    6   28.1     39.6     47.1     41.1     28.2     39.6     47.1    1332  6327  10828  18937 
    7   44.9     46.3     47.6     45.7     44.9     46.3     47.6    1844  5910   8697  16974 
    8   44.1     45.6     45.4     44.0     44.1     45.6     45.4    1801  5398   8451  16080 
    9   36.5     48.3     47.9     45.6     36.6     48.3     47.9    1039  6289   8887  16582 
   10   40.3     47.6     45.8     44.5     40.3     47.6     45.8    1431  5533   8462  15823 
 
  Obs RAFAT RLFAT RTRFAT RTOFAT ARMFAT LEGFAT TRUFAT LALEAN LLLEAN LTRLEAN LTOLEAN RALEAN 
 
    6  1311  6591  10179  18548  2643   12919  21007  3392    9669  12134   26915   3348 
    7  1802  5451   8866  16530  3646   11361  17563  2259    6863   9587   20373   2209 
    8  1814  5144   8332  15731  3615   10542  16783  2282    6450  10184   20436   2299 
    9  1054  6228   8975  16752  2093   12517  17862  1803    6729   9676   19471   1831 
   10  1477  5673   8221  15811  2908   11206  16683  2116    6090  10025   19618   2187 
 
  Obs RLLEAN    RTRLEAN    RTOLEAN    ARMLEAN    LEGLEAN    TRULEAN    FATMASS     BMC     BMD 
 
    6  10069     11432      26626       6739      19739      23566      37485     3688    1.282 
    7   6329      9759      19615       4468      13192      19346      33503     2836    1.232 
    8   6147     10035      20048       4581      12598      20219      31811     2652    1.216 
    9   6659      9776      19978       3633      13389      19452      33334     2817    1.205 
   10   6245      9739      19720       4304      12335      19763      31634     2740    1.200 
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                                          The SAS System            12:25 Sunday, May 30, 2010  31 
 
  Obs  ID  GENDER AGE HEIGHT MODE  TRAINING  RMR VO2PEAKA VO2PEAKR BRUCTIME BODYWT BODYMASS 
 
   11 BB8    M     49  70.0  Water   PRE    1761   3110     31.30     585    219.5   99.800 
   12 BB8    M     50  69.0  Water   POST   1649   3200     32.30     645    219.0   99.500 
   13 JC9    M     35  75.0  Water   PRE    1394   3440     26.70     481    284.0  129.100 
   14 JC9    M     35  75.0  Water   POST   2093   3840     29.90     570    282.0  128.200 
   15 SD11   F     59  62.0  Land    PRE       .   1565     23.40     429    147.5   67.000 
 
  Obs CHEST AXILLA TRICEP SUBSCAP ABDOM SUPRAIL THIGH  SUM  BODYDENS   BMI   PERCFTSK WAIST 
 
   11  47.5  46.0   34.5    47.5   41.5   19.5   55.0 291.5  0.97100 31.5600  56.3300  42.5 
   12  26.5  30.5   22.0    36.5   30.0   20.5   33.0 199.0  1.01100 32.4100  37.7700  42.0 
   13  52.0  50.0   41.5    42.0   57.0   28.0   57.5 328.0  0.95900 35.5700  62.1300  48.5 
   14    .     .      .       .      .      .      .     .    .        .        .        . 
   15  25.5  37.0   30.0    26.5   35.5   38.5   52.5 245.5  0.97400 27.0300  54.8800  31.0 
 
  Obs  HIP WHRATIO PERCFTDX ANDROID GYNOID AGRATIO  LBM  LAPERFAT LLPERFAT LTRPRFAT LTOPRFAT 
 
   11 43.0   0.99    38.2     49.7   39.7    1.25  59031   31.5     32.0     45.1     38.0 
   12 44.0   0.95    38.7     49.6   40.1    1.24  58292   29.1     32.2     46.2     38.7 
   13 48.0   1.01    42.5     53.2   41.1    1.29  69817   31.1     36.8     49.5     42.7 
   14   .     .      40.9     52.5   37.7    1.39  71605   30.2     34.8     48.4     41.0 
   15 41.0   0.76    38.4     34.1   48.0    0.71  39583   43.1     47.2     32.9     38.4 
 
  Obs RAPERFAT RLPERFAT RTRPRFAT RTOPRFAT ARMPRFAT LEGPRFAT TRUPRFAT LAFAT LLFAT LTRFAT LTOFAT 
 
   11   31.5     32.0     45.2     38.4     31.5     32.0     45.1    1729  4847  11162  18294 
   12   29.0     32.2     46.2     38.7     29.1     32.2     46.2    1481  4757  11711  18450 
   13   30.9     36.8     49.5     42.3     31.0     36.8     49.5    1849  6870  16809  26053 
   14   30.0     34.8     48.4     40.7     30.1     34.8     48.4    2011  6774  15714  24985 
   15   43.1     47.2     32.8     38.4     43.1     47.2     32.9    1443  5639   4909  12373 
 
  Obs RAFAT RLFAT RTRFAT RTOFAT ARMFAT LEGFAT TRUFAT LALEAN LLLEAN LTRLEAN LTOLEAN RALEAN 
 
   11  1727  4728  11296  18166  3456    9575  22458  3758   10287  13585   29860   3748 
   12  1518  4746  11648  18388  2998    9503  23358  3612   10003  13643   29192   3708 
   13  2078  7223  15831  25555  3927   14093  32640  4106   11787  17144   35026   4642 
   14  2133  6991  14962  24524  4143   13765  30675  4657   12671  16721   35940   4971 
   15  1431  5545   4975  12305  2874   11184   9884  1909    6302  10025   19840   1890 
 
  Obs RLLEAN    RTRLEAN    RTOLEAN    ARMLEAN    LEGLEAN    TRULEAN    FATMASS     BMC     BMD 
 
   11  10026     13717      29172       7506      20313      27302      36460     3843    1.346 
   12   9973     13579      29100       7320      19976      27222      36838     3954    1.412 
   13  12385     16165      34791       8747      24172      33309      51608     3930    1.331 
   14  13070     15920      35665       9627      25741      32640      49509     4112    1.343 
   15   6195     10171      19743       3798      12497      20196      24678     2090    1.059 
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  Obs  ID  GENDER AGE HEIGHT MODE  TRAINING  RMR VO2PEAKA VO2PEAKR BRUCTIME BODYWT BODYMASS 
 
   16 SD11   F     59  62.0  Land    POST      .   1709     26.00     478    145.0   65.900 
   17 KN12   M     29  71.0  Land    PRE    1791   2680     22.60     449    261.0  118.600 
   18 KN12   M     30  71.0  Land    POST   2168   3020     25.60     526    260.0  118.200 
   19 TS16   M     37  72.5  Land    PRE       .   3020     30.20     548    220.0  100.000 
   20 TS16   M     37  72.5  Land    POST      .   3820     39.00     662    216.0   98.200 
 
  Obs CHEST AXILLA TRICEP SUBSCAP ABDOM SUPRAIL THIGH  SUM  BODYDENS   BMI   PERCFTSK WAIST 
 
   16  20.5  16.5   27.5    26.0   24.5   16.5   35.0 166.5  1.01100 26.5800  37.6900  32.0 
   17  39.5  41.5   41.5    56.0   41.0   34.5   50.0 304.0  0.97200 36.4800  56.1700  50.0 
   18  34.5  34.0   31.5    40.5   35.0   23.5   39.5 238.5  1.00000 36.3400  42.9200  50.0 
   19  26.5  19.5   15.5    23.5   19.0   15.5   36.5 156.0  1.03400 29.4900  27.9600  44.0 
   20    .     .      .       .      .      .      .     .    .        .        .        . 
 
  Obs  HIP WHRATIO PERCFTDX ANDROID GYNOID AGRATIO  LBM  LAPERFAT LLPERFAT LTRPRFAT LTOPRFAT 
 
   16 41.0   0.78    40.0     36.6   49.2    0.74  37849   41.1     48.0     36.4     40.0 
   17 47.0   1.06    47.4     58.4   46.6    1.25  59313   41.8     41.4     53.9     47.3 
   18 46.0   1.09    30.0     58.1   47.6    1.22  58878   41.0     43.6     53.3     47.7 
   19 44.0   1.00    37.6     31.0   37.7    0.82  65254   27.9     36.1     31.6     32.3 
   20   .     .      37.8     29.5   34.7    0.85  65653   25.3     33.9     31.0     31.0 
 
  Obs RAPERFAT RLPERFAT RTRPRFAT RTOPRFAT ARMPRFAT LEGPRFAT TRUPRFAT LAFAT LLFAT LTRFAT LTOFAT 
 
   16   41.1     47.9     36.4     40.0     41.1     48.0     36.4    1389  5341   5696  12768 
   17   41.8     41.4     53.9     47.6     41.8     41.4     53.9    2287  7353  16514  26834 
   18   41.0     43.6     53.3     47.7     41.0     43.6     53.3    2515  7357  16587  27094 
   19   27.9     36.1     31.7     32.5     27.9     36.1     31.6    1304  6489   7350  15532 
   20   25.2     33.9     31.0     30.9     25.3     33.9     31.0    1204  6005   7214  14732 
 
  Obs RAFAT RLFAT RTRFAT RTOFAT ARMFAT LEGFAT TRUFAT LALEAN LLLEAN LTRLEAN LTOLEAN RALEAN 
 
   16  1364  5386   5307  12470  2753   10727  11003  1989    5791   9964   19113   1951 
   17  2519  7111  16505  26673  4806   14464  33019  3182   10403  14150   29896   3513 
   18  2561  7358  16062  26603  5076   14715  32649  3618    9515  14511   29660   3679 
   19  1385  6812   7202  15737  2689   13301  14552  3367   11471  15881   32516   3577 
   20  1292  6154   6863  14656  2496   12159  14076  3549   11712  16063   32842   3835 
 
  Obs RLLEAN    RTRLEAN    RTOLEAN    ARMLEAN    LEGLEAN    TRULEAN    FATMASS     BMC     BMD 
 
   16   5847      9268      18735       3940      11638      19231      25238     2192    1.065 
   17  10067     14113      29416       6696      20470      28264      53506     3530    1.418 
   18   9510     14071      29218       7297      19025      28582      53698     3747    1.403 
   19  12041     15548      32739       6944      23513      31428      31270     3330    1.163 
   20  12001     15270      32811       7384      23713      31333      29388     3311    1.168 
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  Obs  ID  GENDER AGE HEIGHT MODE  TRAINING  RMR VO2PEAKA VO2PEAKR BRUCTIME BODYWT BODYMASS 
 
   21 CM19   M     35  65.0  Land    PRE    1864   2363     22.50     417    231.0  105.000 
   22 CM19   M     35  65.0  Land    POST   1888   2596     25.10     465    228.0  103.600 
   23 GJ20   M     51  68.0  Land    PRE    1579   3017     29.60     500    187.0   85.000 
   24 GJ20   M     52  68.0  Land    POST   1363   3349     40.10     662    184.0   83.600 
   25 MP22   F     51  67.0  Water   PRE    1711   1990     15.90     289    276.0  125.500 
 
  Obs CHEST AXILLA TRICEP SUBSCAP ABDOM SUPRAIL THIGH  SUM  BODYDENS   BMI   PERCFTSK WAIST 
 
   21  45.5  35.5   41.5    42.5   40.0   45.0   49.5 299.5  0.97200 38.5200  56.0600  49.0 
   22  33.5  32.5   31.5    35.0   32.5   34.0   41.5 240.5  0.99700 38.0200  43.9800  47.0 
   23  40.5  23.5   30.5    27.5   42.5   22.5   40.5 227.5  0.99800 28.4900  43.5000  38.0 
   24  31.0  23.0   26.5    24.0   33.0   13.0   35.0 185.5  1.01642 28.0400  35.4200  37.0 
   25  38.5  51.5   36.5    49.0   41.0   37.5   54.5 308.5  0.94600 43.3200  69.0300  48.5 
 
  Obs  HIP WHRATIO PERCFTDX ANDROID GYNOID AGRATIO  LBM  LAPERFAT LLPERFAT LTRPRFAT LTOPRFAT 
 
   21 48.0   1.02    42.6     56.4   47.2    1.20  56775   39.5     43.9     46.1     43.6 
   22 46.0   1.02    47.4     57.4   47.0    1.22  52239   39.3     43.9     52.7     47.6 
   23 42.0   0.90    32.2     42.1   34.2    1.23  54542   24.3     26.9     38.9     32.3 
   24 41.0   0.90    30.4     41.2   32.5    1.27  55417   21.6     25.6     36.9     30.4 
   25 52.5   0.92    46.9     54.2   46.4    1.17  64087   49.0     45.8     49.0     46.8 
 
  Obs RAPERFAT RLPERFAT RTRPRFAT RTOPRFAT ARMPRFAT LEGPRFAT TRUPRFAT LAFAT LLFAT LTRFAT LTOFAT 
 
   21   39.4     43.9     46.1     43.6     39.5     43.9     46.1    2044  6910  12228  21658 
   22   39.3     43.9     52.7     47.2     39.3     43.9     52.7    1839  6698  14300  23309 
   23   24.3     26.9     38.8     32.2     24.3     26.9     38.9    1023  3465   8136  13032 
   24   21.6     25.6     36.9     30.4     21.6     25.6     36.9     981  3165   7860  12453 
   25   49.0     45.8     49.0     47.0     49.0     45.8     49.0    3016  8956  16464  29099 
 
  Obs RAFAT RLFAT RTRFAT RTOFAT ARMFAT LEGFAT TRUFAT LALEAN LLLEAN LTRLEAN LTOLEAN RALEAN 
 
   21  2185  7054  12493  22241  4229   13964  24721  3132    8843  14284   27967   3355 
   22  2022  6964  14141  23747  3861   13663  28441  2839    8555  12845   25639   3126 
   23  1124  3459   7954  12914  2147    6923  16089  3181    9396  12801   27342   3503 
   24  1000  3246   7226  11770  1982    6412  15087  3562    9189  13459   28477   3641 
   25  2756  8849  15460  27565  5772   17805  31924  3142   10614  17108   33034   2873 
 
  Obs RLLEAN    RTRLEAN    RTOLEAN    ARMLEAN    LEGLEAN    TRULEAN    FATMASS     BMC     BMD 
 
   21   9026     14592      28808       6487      17869      28875      43899     2286    1.311 
   22   8898     12708      26600       5965      17454      25553      47056     2762    1.249 
   23   9375     12519      27200       6684      18771      25230      25946     3498    1.262 
   24   9424     12383      26940       7203      18613      25842      24223     3480    1.257 
   25  10485     16059      31054       6014      21099      33167      56664     2764    1.354 
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  Obs  ID  GENDER AGE HEIGHT MODE  TRAINING  RMR VO2PEAKA VO2PEAKR BRUCTIME BODYWT BODYMASS 
 
   26 MP22   F     52  67.0  Water   POST   1593   2439     21.10     382    254.5  115.700 
   27 GA24   M     49  69.5  Land    PRE    1864   2970     30.10     508    217.5   98.900 
   28 GA24   M     49  69.5  Land    POST   1479   2830     30.50     599    204.5   93.000 
   29 HW14   F      .    .   Land    PRE       .   2170     22.52       .    212.0   96.364 
   30 HW14   F      .    .   Land    POST      .      .       .         .       .      . 
 
  Obs CHEST AXILLA TRICEP SUBSCAP ABDOM SUPRAIL THIGH  SUM  BODYDENS   BMI   PERCFTSK WAIST 
 
   26  30.5  35.5   32.0    40.0   32.5   20.5   40.5 231.5  0.98172 39.9437  51.3089  46.0 
   27  41.5  43.5   33.5    42.5   42.0   17.5   50.5 271.0  0.98000 31.7200  52.0600  42.5 
   28  28.5  21.5   13.0    33.0   34.0   18.0   15.0 163.0  1.02706 29.8286  30.7587  39.0 
   29    .     .      .       .      .      .      .     .    .        .        .        . 
   30    .     .      .       .      .      .      .     .    .        .        .        . 
 
  Obs  HIP WHRATIO PERCFTDX ANDROID GYNOID AGRATIO  LBM  LAPERFAT LLPERFAT LTRPRFAT LTOPRFAT 
 
   26 50.0   0.92    46.4     54.0   46.6    1.16  59715   47.1     46.4     48.1     46.2 
   27 44.5   0.96    30.2     43.1   31.0    1.39  66394   21.6     22.1     39.6     30.0 
   28 41.5   0.94    28.0     41.9   27.9    1.50  64288   21.9     19.6     36.1     27.9 
   29   .     .        .        .      .      .        .     .        .        .        . 
   30   .     .        .        .      .      .        .     .        .        .        . 
 
  Obs RAPERFAT RLPERFAT RTRPRFAT RTOPRFAT ARMPRFAT LEGPRFAT TRUPRFAT LAFAT LLFAT LTRFAT LTOFAT 
 
   26   47.1     46.4     48.1     46.6     47.1     46.4     48.1    2652  8276  14772  26364 
   27   21.5     22.1     39.6     30.4     21.6     22.1     39.6    1200  3671   8752  13957 
   28   21.7     19.7     36.1     28.0     21.8     19.6     36.1    1155  2840   8224  12588 
   29     .        .        .        .        .        .        .        .     .      .      . 
   30     .        .        .        .        .        .        .        .     .      .      . 
 
  Obs RAFAT RLFAT RTRFAT RTOFAT ARMFAT LEGFAT TRUFAT LALEAN LLLEAN LTRLEAN LTOLEAN RALEAN 
 
   26  2903  7933  14018  25307  5555   16209  28790  2974    9550  15963   30684   3257 
   27  1247  3502   9619  14793  2446    7172  18371  4343   12947  13365   32507   4544 
   28  1167  2780   8082  12354  2322    5620  16308  4131   11649  14539   32513   4199 
   29     .     .      .      .     .       .      .     .       .      .       .      . 
   30     .     .      .      .     .       .      .     .       .      .       .      . 
 
  Obs RLLEAN    RTRLEAN    RTOLEAN    ARMLEAN    LEGLEAN    TRULEAN    FATMASS     BMC     BMD 
 
   26   9155     15140      29031       6231      18705      31103      51671     2816    1.350 
   27  12311     14652      33887       8887      25258      28017      28750     3738    1.271 
   28  11348     14286      31775       8330      22997      28825      24942     3620    1.288 
   29      .         .          .          .          .          .          .        .     . 
   30      .         .          .          .          .          .          .        .     . 
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  Obs  ID  GENDER AGE HEIGHT MODE  TRAINING  RMR VO2PEAKA VO2PEAKR BRUCTIME BODYWT BODYMASS 
 
   31 PR15   F      .    .   Water   PRE       .   2222     14.92       .    327.6  148.909 
   32 PR15   F      .    .   Water   POST      .      .       .         .       .      . 
   33 KE23   F      .    .   Land    PRE       .   1980     18.15       .    240.0  109.091 
   34 KE23   F      .    .   Land    POST      .      .       .         .       .      . 
   35 CR21   M      .    .   Water   PRE       .   2540     18.55       .    301.2  136.900 
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                                                      R      A 
                                       T       A      E      C 
                                       R       C      C      T 
              G          H             A       T      T      T           T 
              E          E             I       I      O      O           O 
              N          I      M      N       V      T      T           T     M    P 
   O          D    A     G      O      I       I      C      C     C     F     O    O    S    P 
   b    I     E    G     H      D      N       T      A      A     H     A     N    L    A    R 
   s    D     R    E     T      E      G       Y      L      L     O     T     O    Y    T    O 
 
   1   JG1    M   40   68.0   Water   PRE    2527   2906   2540   327    86   22   12   27   102 
   2   JG1    M   40   68.0   Water   POST   2891   2696   1551   220    51   15    6   18    60 
   3   RK2    F   51   64.5   Water   PRE    2905   2295   1594   224    52   14    7   20    65 
   4   RK2    F   51   64.5   Water   POST   2826   2350   2593   306   114   22   13   42    92 
   5   GB3    M   39   73.0   Water   PRE    3115   3110   2313   312    82   12    3   32    93 
   6   GB3    M   39   73.0   Water   POST   3083   3030   3235   554    84    7    4   26    78 
   7   LG4    F   34   65.5   Water   PRE    2623   2452   2040   264    67   13    8   26   102 
   8   LG4    F   34   65.0   Water   POST   2588   2406   1434   155    64   16    8   25    70 
   9   RR5    F   42   64.5   Water   PRE    2472   2304   1419   186    53   10    5   20    56 
  10   RR5    F   42   64.5   Water   POST   2453   2258   1535   165    76   11    4   36    49 
  11   DD7    F   58   63.0   Land    PRE    2684   2149   1770   141    99   14    2   34    82 
  12   DD7    F   58   64.0   Land    POST   2627   2131    972   103    34    5    2   11    62 
  13   BB8    M   49   70.0   Water   PRE    3345   2950   2069   227    94   28   10   28    91 
  14   BB8    M   50   69.0   Water   POST   3242   2921   2072   250    75   17    6   31   102 
  15   JC9    M   35   75.0   Water   PRE    4426   3590   3870   479   153   48   12   50   157 
  16   JC9    M   35   75.0   Water   POST   4185   3388   3065   367   145    7    3   31    78 
  17   SD11   F   59   62.0   Land    PRE    2292   1997   3270   362   149   14    7   49   100 
  18   SD11   F   59   62.0   Land    POST   2414   1991   2364   304   108   34   28   21    66 
  19   KN12   M   29   71.0   Land    PRE    4021   3450   2893   420   104   31   11   35    88 
  20   KN12   M   30   71.0   Land    POST   3864   3479   1285   181    41    8    2   15    60 
  21   TS16   M   37   72.5   Land    PRE    3407   3095   2449   331    82   22    7   35   107 
  22   TS16   M   37   72.5   Land    POST   3294   3086   3918   476   150   28   14   50   135 
  23   CM19   M   35   65.0   Land    PRE    3611   3110   2515   397    78    7    5   22    70 
  24   CM19   M   35   65.0   Land    POST   3439   3088   2533   332   115   16   14   31    58 
  25   GJ20   M   51   68.0   Land    PRE    2972   2698   2834   349    94   23   15   45    63 
  26   GJ20   M   52   68.0   Land    POST   2952   2653   2028   218    70   13    5   22    59 
  27   GA24   M   49   69.5   Land    PRE    3304   2918   2863   310   117   35   16   32   148 
  28   GA24   M   49   69.5   Land    POST   3287   2860   2766   246   129   48   29   35   130 
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APPENDIX J 
 
SAMPLE STATISTICAL CODE AND RAW DATA FOR CHAPTER IV 
 
 
Variable Definitions: 
Independent Variables 
 Animal Number animal 
Treatment Group group 
Phenotype (Lean vs obese) phenotype 
Gel for Western blot analysis gel 
Exercise condition (RE vs SED) exercise 
 
 
Dependent Variables 
 Muscle Protein Expression (Relative 
Abundance) 
 F1 ATPase (ATP Synthase) F1ATPASE 
FAT/CD36 CD36 
p38 MAPK p38 
CPT-I CPT-I 
p38γ MAPK p38gamma 
PPARδ ppard 
PGC-1α PGC1a 
AMPKα AMPK 
AMPK phosphorylation (Thr 172) pAMPK 
AMPK relative phosphorylation pAMPKTOTAL 
Cytochrome C Oxidase-IV COX 
PPARδ PPARd 
LKB1 phosphorylation (Ser 428) pLKB1 
  Blood Lipids and Lipoproteins 
 NEFA (post RE3) threeNEFA  
NEFA (post RE4) fourNEFA  
Total cholesterol (Post RE3) threeTC 
Total cholesterol (Post RE4) fourTC 
LDL-cholesterol (Post RE3) threeLDL 
LDL-cholesterol (Post RE4) fourLDL 
HDL-cholesterol (Post RE3) threeHDL 
HDL-cholesterol (Post RE4) fourHDL 
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ANOVA 
Data were analyzed using the Statistical Analysis System (SAS) version 9.2.  SAS 
process for data analysis used was PROC MIXED to determine change in content of the 
above listed proteins and concentration of blood lipids and lipoproteins due to the 
exercise intervention and differences between lean and obese phenotypes.  By use of 
PROC MIXED we are able to place a repeated measure on ―gel‖ to statistically account 
for differences between Western blot membranes in normalizing the data.  Sample code: 
 
PROC MIXED DATA = WORK.SORTTempTableSorted 
 METHOD=REML; 
 CLASS animal phenotype exercise gel ; 
 MODEL AMPK= phenotype exercise phenotype*exercise 
  / HTYPE=3; 
REPEATED gel / SUBJECT=animal*gel TYPE=UN; 
LSMEANS phenotype*exercise / PDIFF=ALL ADJUST=TUKEY ; 
RUN; 
QUIT; 
 
The above code allows for the analysis of any main or interactive effects of the exercise 
intervention or phenotype.  The statement ―REPEATED‖ allows for the system to model 
the statistic based on the repeated-measures variables indicated, for this analysis: ―gel‖.  
This repeat allowed the statistical system to adjust for differences in Western blot gels of 
intensity of densitometry.  The statement TYPE on this line of code provides a place to 
input methods of modeling for the covariance matrix of the repeated variables.  The 
following two lines set up post hoc analysis across all conditions in the MODEL 
statement.  Differences here are determined across all levels (PDIFF=ALL) using the 
Tukey-Kramer method.  Fisher‘s LSD is also automatically printed with the output. 
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Correlations 
For the assessment of correlation of PPARδ, PGC-1α, and AMPKα to blood lipid and 
lipoprotein variables the PROC CORR process was used.  This process enabled the 
assessment of Pearson‘s Product-Moment correlations on all variables of interest.  
Sample Code: 
 
PROC SORT; 
BY Phenotype; 
 
PROC CORR;  
BY Phenotype; 
    VAR  F1 CD36 p38 CPTI p38g COXIV pAMPK
 PPARd AMPKa PGC1a pAMPKTOTAL; 
 
    WITH   threeNEFA  fourNEFA  threeTC fourTC thretwoTC
 fourtwoTC LDLHDLthree1 LDLHDLfourone threeLDL
 fourLDL threeHDL fourHDL F1 CD36 p38 CPTI p38g
 COXIV pAMPK PPARd AMPKa PGC1a
 pAMPKTOTAL; 
To assess correlations it was first necessary to sort data by variable Phenotype or 
exercise.  Therefore, prior to running PROC CORR, PROC SORT was run for either or 
both of these variables.  This was followed by PROC CORR which allowed the 
assessment of correlations at each level of phenotype, exercise or phenotype*exercise 
for protein variables of interest with all protein and blood variables. 
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                                          three     four                     thretwo  fourtwo 
  Obs  Animal  Phenotype  Exercise  gel    NEFA     NEFA   threeTC   fourTC     TC       TC 
 
    1   121      Lean       EX       1   1.15203  0.39287   86.082   82.077   98.273  101.838 
    2   122      Lean       EX       1   0.83007  0.48628  114.272   99.164  120.427  107.540 
    3   123      Lean       EX       2   0.88933  0.61057   90.322   96.200  101.128  105.436 
    4   124      Lean       EX       2   0.66925  0.71897  119.499   95.053  143.428  109.595 
    5   125      Lean       EX       3   0.87102  0.48780   84.109  128.629   67.950   83.482 
    6   126      Lean       EX       3   0.88067  0.40905   95.029  116.290   79.028   73.693 
    7   127      Lean       EX       4   0.95176  0.33558   73.192   88.521   62.126   55.619 
    8   128      Lean       EX       4   1.11366  0.30385  133.044  142.955  112.750  126.811 
    9   111      Lean       SED      1   0.70484  0.40577  106.093   95.126  123.753  123.126 
   10   112      Lean       SED      1   0.76385  0.31125  101.243   92.284  103.164  106.834 
   11   113      Lean       SED      2   1.08266  0.43738  110.138  101.679  120.398  126.539 
   12   114      Lean       SED      2   0.82065  0.49156   70.426  114.857   90.915  103.559 
   13   115      Lean       SED      3   0.66372  0.59202   84.985   74.882   77.405   63.117 
 
                                       three               three 
  Obs  LDLHDLthree1   LDLHDLfourone     LDL     fourLDL     HDL     fourHDL      F1       CD36 
 
    1     133.409         80.875      54.0394    42.217    79.370    38.657    .         . 
    2     186.555        147.026      75.6939    65.085   110.861    81.941   4.40964   2.55734 
    3     122.771        117.299      23.9266    57.579    98.844    59.720   4.19853   2.49735 
    4     195.696        122.025      63.4846    52.803   132.212    69.222   6.79412   2.71958 
    5     108.987        111.261      51.2949    60.254    57.692    51.007   4.13616   1.99625 
    6     118.703        102.734      54.7750    51.342    63.928    51.392   6.54920   2.96629 
    7      93.828         85.304      41.1947    47.652    52.634    37.652   5.71111   1.90909 
    8     177.671        149.397      59.3783    77.269   118.293    72.128   5.60000   2.98182 
    9     144.225        140.339      43.9038    57.217   100.321    83.123   6.43373   2.20926 
   10     153.536        109.371      60.4888    57.068    93.048    52.303    .         . 
   11     183.331        157.690      65.7393    72.866   117.592    84.824   5.17647   1.25397 
   12     104.754        120.520      49.3855    60.249    55.369    60.271   4.08088   2.87302 
   13     119.521         99.019      45.3965    41.166    74.124    57.852   5.40618   1.71536 
 
                                                                                           p 
  Obs    p38       CPTI      p38g     COXIV     pAMPK     PPARd     AMPKa     PGC1a    AMPKTOTAL 
 
    1   .         .         .         .         .         .        0.71186   0.76032     . 
    2  1.98649   1.95918   4.38158   1.72973   1.34043   1.65813   1.27119   0.73878    1.05447 
    3  1.63478   1.45789   6.96774    .        0.29091   0.53149   2.00000   1.31906    0.14545 
    4  2.01739   1.11579   5.74194    .        0.69091   1.01385   0.57143   0.83564    1.20909 
    5  1.84211   1.38265   6.03846   1.08475   0.88095   1.19477   0.84932   0.60403    1.03725 
    6  2.42105   1.18878   5.07692   1.18644   1.56349   1.75294   1.00685   1.87752    1.55286 
    7   .        2.88462   5.96154   1.43561   0.49116   0.70446    .        1.56842     . 
    8   .         .        7.50000   0.57955   0.41768   0.63507    .        1.24211     . 
    9  1.91892   1.37415   4.32895   1.45946   0.54255   0.81938   1.20339   1.05117    0.45085 
   10   .         .         .         .         .         .        1.18644   1.22980     . 
   11  1.53913   1.47368   8.61290    .        0.36364   0.57431   1.57143   1.48343    0.23140 
   12  1.66957   1.42105   5.06452    .        1.69091   1.57683   1.07143   1.49586    1.57818 
   13  2.10526   1.03061   6.34615   1.79661   0.57937   0.58954   1.19863   0.59899    0.48336 
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                                          three     four                     thretwo  fourtwo 
  Obs  Animal  Phenotype  Exercise  gel    NEFA     NEFA   threeTC   fourTC     TC       TC 
 
   14   116      Lean       SED      3   0.83519  0.24670  118.116  140.955  103.270  133.687 
   15   117      Lean       SED      4   0.85498  0.38560  142.701  177.799  124.081  117.366 
   16   118      Lean       SED      4   0.43117  0.42848   84.747  132.783     .      87.593 
   17   131      Obese      EX       3   1.84693  0.69153  216.079  129.357  153.800   85.307 
   18   141      Obese      EX       1   1.47261  0.63710  243.844  189.734  355.079  243.582 
   19   142      Obese      EX       1   1.29213  0.45319  248.298  284.012  319.626  287.397 
   20   143      Obese      EX       2   1.64293  0.62011  848.843  446.602  993.374  546.148 
   21   144      Obese      EX       2   1.13893  1.11825  183.681  170.734  283.528  208.843 
   22   145      Obese      EX       3   1.46648  1.01544  462.663  331.172  428.452  245.778 
   23   147      Obese      EX       4   1.40664  0.24899  258.532   27.769  267.239   17.480 
   24   148      Obese      EX       4   1.19484  1.08833  231.510  219.935  255.268  211.954 
   25   132      Obese      SED      1   2.06117  0.35486  411.109  156.763  578.199  187.845 
   26   133      Obese      SED      2   0.90366  0.57445  208.622   94.284  263.196  129.593 
 
                                       three               three 
  Obs  LDLHDLthree1   LDLHDLfourone     LDL     fourLDL     HDL     fourHDL      F1       CD36 
 
   14     165.220        122.005      76.4037    73.434    88.817    48.571   7.63043   2.42322 
   15     168.419        170.319      49.3236    87.679   119.096    82.640   6.73333   1.67273 
   16      93.932        116.381      51.7786    66.247    42.154    50.134   6.68889   2.18182 
   17     194.523        107.252      80.7472    54.747   113.775    52.505   7.90847   2.70037 
   18     319.427        300.343      55.8708   101.445   263.557   198.898   8.31024   1.09256 
   19     384.891        255.273      87.3759   138.113   297.515   117.161   5.97289   1.99598 
   20     912.499        489.943      68.5886   186.032   843.910   303.910   6.34559   1.41270 
   21     232.309        231.658      31.5265    60.075   200.782   171.583   7.16176   2.23810 
   22     608.699        300.094      48.9484   116.169   559.751   183.925   4.02632   1.69288 
   23     263.991         22.271      46.0823    14.620   217.908     7.651   4.77778   1.61818 
   24     286.847        229.895      44.3064    81.922   242.540   147.972   6.37778   1.74545 
   25     537.614        190.122      22.3226    84.299   515.292   105.823    .         . 
   26     362.990        130.111      94.1479    57.688   268.842    72.424   4.12500   2.51323 
 
                                                                                           p 
  Obs    p38       CPTI      p38g     COXIV     pAMPK     PPARd     AMPKa     PGC1a    AMPKTOTAL 
 
   14  2.63158   0.81122   5.76923   0.98305   1.23810   1.29412   0.75342   1.71141    1.64329 
   15   .        1.61538   7.88462   0.69318   0.23978   0.44734    .        1.10000     . 
   16   .        3.03846   8.84615   1.16288   0.47182   0.74845    .        1.61579     . 
   17  2.15789   0.84694   6.42308   1.16949   1.42063   1.54118   0.66438   2.15940    2.13828 
   18  2.06757   1.01361   4.43421   3.17838   0.51064   0.66688   1.00000   0.92101    0.51064 
   19  2.31081   1.65306   3.88158   1.28649   0.75532   0.80250   1.18644   2.13824    0.63663 
   20  2.27826   1.36316   5.90323    .        0.85455   0.81864   1.57143   1.60083    0.54380 
   21  1.84348   1.03684   5.06452    .        0.87273   0.88917   1.00000   1.51796    0.87273 
   22  2.47368   1.08163   5.53846   0.64407   0.58730   0.71242   1.15068   0.75000    0.51039 
   23   .        1.92308   4.03846   1.56061   0.52597   0.74783    .        0.75263     . 
   24   .        1.19231   6.53846   1.06439   0.33260   0.58984    .        1.22632     . 
   25   .         .         .         .         .         .        0.93220   1.16427     . 
   26  1.82609   1.48947   4.03226    .        0.65455   0.66373   1.50000   1.11464    0.43636 
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                                          three     four                     thretwo  fourtwo 
  Obs  Animal  Phenotype  Exercise  gel    NEFA     NEFA   threeTC   fourTC     TC       TC 
 
   27   135      Obese      SED      2   1.62182  0.77967  339.827  296.455  343.527  254.936 
   28   136      Obese      SED      3   1.70763  0.42553  200.056   41.156  235.202   25.072 
   29   137      Obese      SED      3   1.63015  0.65486  414.320  118.890  368.268   90.017 
   30   146      Obese      SED      1   1.19159  0.36551  203.127  183.549  273.815  199.358 
 
                                       three               three 
  Obs  LDLHDLthree1   LDLHDLfourone     LDL     fourLDL     HDL     fourHDL      F1       CD36 
 
   27     366.567        318.191      38.8255    94.545   327.742   223.646   6.46324   2.49206 
   28     206.219         30.428      37.6769    18.019   168.542    12.410   4.01945   1.65918 
   29     402.701        156.442      55.0584    85.947   347.642    70.495   6.35698   2.00749 
   30     251.911        261.776      42.1617    86.863   209.749   174.913   4.77711   1.34004 
 
                                                                                           p 
  Obs    p38       CPTI      p38g     COXIV     pAMPK     PPARd     AMPKa     PGC1a    AMPKTOTAL 
 
   27  1.73913   0.87895   5.61290    .        0.12727   0.27330   0.85714   1.44337    0.14848 
   28  1.94737   1.16327   6.34615   3.28814   0.46825   0.49673   1.23973   1.33389    0.37771 
   29  1.57895   0.88776   6.19231   2.13559   0.70635   1.13595   0.50685   1.44463    1.39361 
   30  2.10811   1.02041   4.57895   1.29730   0.50000   0.25625   0.88136   0.77648    0.56731  
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